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ABSTRACT 
 
The thesis is in two main sections. 
In the first section, studies on methylarginine processing enzymes are presented. 
Dimethyalrginine dimethylaminohydrolase (DDAH) is a class of enzymes involved in 
the metabolism of methylarginines ADMA and L-NMMA, which indirectly regulate 
physiological nitric oxide levels. It is desirable to inhibit excess NO in pathological 
situations, and the arginine mimetic L-257 is a DDAH inhibitor which reduces levels of 
NO. Synthesis of ester analogues of L-257 proved to be troublesome with a low 
yielding key guanidine forming reaction. However, amide analogues were readily 
synthesised, and testing for DDAH inhibition showed the dimethylamide analogue 
possessed similar activity to L-257. Further design and synthesis of a 7-membered 
cyclic analogue, based on the crystal structure of huDDAH1 with L-257, provided a 
novel analogue with no significant inhibition for rat kidney DDAH. Purified and 
isolated huDDAH2 protein showed activity after incubation with substrate L-NMMA. 
 
In the second part studies on aldehyde auto-oxidation are presented. 
Aldehydes autoxidise to their acids, via an acyl radical, which can undergo addition 
reactions with electron-deficient acceptors in a radical hydroacylation reaction. An α-
iodo and α-chloro hexanal failed to autoxidise, however 7-hydroxycitronellal readily 
autoxidised and added to pentafluorophenyl(PFP)-vinyl sulfonate. Further studies on 
hydroacylation of butanal with PFP-vinyl sulfonate led to functionalised β-keto-
sulfonates which undergo elimination to form an enone and can then undergo further 
conjugate addition in situ by nucleophiles. Conjugate addition was carried out using 
carbon, nitrogen, oxygen and phosphorus nucleophiles, providing a method of obtaining 
products which are challenging to make via hydroacylation of electron-rich alkenes. 
Decarbonylation of pivaldehyde to the t-butyl radical, via auto-oxidation, was optimised 
and the alkyl radical captured by a number of electron-deficient acceptors, providing a 
complementary method to current methods of t-butyl addition using metal reagents.  
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Evaluation of Novel Arginine Based Inhibitors of DDAH 
 
Chapter 1: Introduction  
 
1.1 Nitric oxide and its effects 
Nitric oxide (NO) is a key biological mediator involved in the physiology of the human 
body.1 Its in vivo effects have led the scientific community to spend considerable effort 
on its modulation.2 NO is a highly reactive gaseous molecule formed in the body from 
L-arginine by the nitric oxide synthase (NOS) family of enzymes. There are three 
isoforms of NOS: endothelial NOS (eNOS) constitutively expressed in endothelial cells, 
neuronal NOS (nNOS) constitutively expressed in the nervous system, and inducible 
form of NOS (iNOS). In the endothelial system NO has a vital role regulating vascular 
homeostasis by relaxing smooth muscle cells in blood vessels thereby controlling blood 
pressure, and preventing platelet aggregation.3  In the central nervous system NO 
produced acts as a neurotransmitter.4 NO produced from iNOS is involved in 
inflammatory responses by attacking invading organisms.  
 
The NOS enzymes function as dimers around a central zinc atom, and contain a 
reductase domain that binds the cofactors flavin mononucleotide (FMN), flavin adenine 
dinucleotide (FAD) and NADPH, and an oxygenase domain which binds 
tetrahydrobiopterin (BH4) and haem.5 Molecular oxygen is required for the oxidation of 
L-arginine 1 to L-citrulline 2 and NO. eNOS and nNOS activity is dependent on 
calmodulin binding (CAL) which in turn is dependent on a intracellular calcium 
concentration controlled by receptor-mediated calcium channels. Contrastingly, iNOS 
already has tightly bound Ca+/calmodulin and is regulated on the transcriptional level. 
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Figure 1: Conversion of L-arginine to citrulline by the NOS enzymes.2 
In endothelial cells, increase in NO leads to vasodilatation by the following  mechanism 
(Figure 2):6 NO synthesis is triggered by a rise in Ca2+ concentration due to receptor 
activation on the cell membrane by various chemical signals. When it is formed it 
diffuses across the plasma membranes of neighbouring smooth muscle cells, where it 
activates the enzyme guanylate cyclase, converting guanosine monophosphate (GTP)  
into cyclic guanosine monophospate (cGMP). Increase in cGMP then leads to relaxation 
of the smooth muscle and eventual vasodilatation, which plays an important role in 
regulating blood pressure. 
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Figure 2: Mechanism of smooth muscle relaxation.  
Although NO is an important molecule required for various functions, excess levels of 
NO have been implicated in many disease states. The harmful effects of excess NO 
induced by nNOS is implicated in migraine, stroke and neurodegenerative diseases such 
as Alzheimers disease. NO induced by iNOS is implicated in septic shock, ischeamia 
and cerebral inflammation, and NO induced by eNOS has an effect on diabetes and 
inflammation.7 More recently it has been found that low levels of NO are found in 
malignant human breast, neuronal, gastric, cervical and ovarian cancers, but not in the 
surrounding benign tissues.8 It is therefore clinically desirable to modulate levels of NO 
in certain disease states. The most obvious target is to inhibit the NOS enzymes, but to 
date no clinically useful inhibitors have been discovered, as there are issues of 
selectivity of a single NOS isoform. Examples of NOS inhibitors include the 
endogenous inhibitor monomethylated L-arginine (L-NMMA 3, Figure 3). L-NMMA 
has been evaluated in phase III clinical trials to treat septic shock patients but a poor 
survival rate impeded its further development. A substrate based inhibitor 1400W 
showed considerable selectivity for iNOS over the other isoforms, ~10,000 fold 
selectivity for iNOS over eNOS and ~30 fold selectivity for iNOS over nNOS (Figure 
3). However, toxicity problems in humans hindered its development. Other selective 
iNOS inhibitors with toxicity problems preventing their development include 
GW273629 5, L-NIL 6, and the isothiourea 1,4-PBITU 7. Another class of NOS 
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inihibitors are dimerization inhibitors such as Miconazole 8. However, dimerization 
inhibitors show poor selectivity of one NOS isoform over another, and are not viable 
candidates for development for clinical use.2  
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Figure 3: NOS inhibitors. 
To date there have been no NOS inhibitors developed for widespread clinical use for the 
control of excess NO production. Since most NOS inhibitors show poor isoform 
selectivity or are associated with toxicity problems, developing NOS inhibitors for the 
control of excess NO does not show promise. However, control of the metabolism of 
endogenous NOS inhibitors offers an alternative approach. 
 
1.2 The ADMA/DDAH pathway 
L-Arginine 1 is converted to nitric oxide by NOS, which can be inhibited by the 
methylarginines asymmetric dimethylarginine (ADMA) 9 and L-NMMA 3 (Scheme 1). 
These methylarginines are metabolised to citrulline and the corresponding alkylamine 
by the dimethylarginine dimethylaminohydrolase (DDAH) enzymes. Inhibiting DDAH 
would increase the concentrations of ADMA and L-NMMA which would lead to the 
inhibition of NOS and therefore reduce levels of NO in pathological situations where 
NO is overproduced (Scheme 1).9 Both L-NMMA and ADMA are formed via protein 
methylation on the terminal nitrogen of arginine residues. The protein methylation here 
is accomplished by a post translational modification by protein-arginine 
methyltransferases (PRMTs). Using S-adenosyl methionine (SAM) as methyl group 
donors type I PRMTs produce ADMA and L-NMMA, whilst type II produce L-NMMA 
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and symmetric dimethylarginine (SDMA) 10 which does not inhibit NOS. After 
methylation of arginine residues in proteins, free methylarginines are generated by 
proteolysis and are present in the cytosol.  
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Scheme 1: The ADMA/DDAH pathway. 
DDAH dysfunction leads to accumulation of ADMA which acts as a marker of various 
disease states of the vascular system,10 as well as for diabetes and  renal failure.11’12  In a 
recent study by Vallance et al. it was found in ddah1 knock out mice that ADMA 
accumulates in endothelial cells and there is a reduction in NO signalling.13 This in 
turns leads to increased blood pressure, endothelial dysfunction and systemic vascular 
resistance. It is proposed that the vascular dysfunction associated with sepsis can be 
improved by inhibition of DDAH. In a study by Konishi et al. it was found that DDAH 
can promote endothelial repair after vascular injury; hence vascular dysfunction can 
perhaps be improved by targeting DDAH.14 
Although NO levels can be regulated by targeting NOS or DDAH, NO itself can self-
regulate to some extent in a potential homeostatic mechanism, when present at high 
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levels. Vallance et al. showed that DDAH enzyme activity is regulated by S-
nitrosylation.15 Recombinant PaDDAH is reversibly inhibited after incubation with NO 
donors in vitro, and mammalian DDAH in cytosolic extracts is reversibly inhibited the 
NO donor DEA-NONOate. This effect was reversed 92% by incubating with the 
reducing agent DTT. In cultured endothelial cells, cytokine induced iNOS expression of 
NO, S-nitrosylates human DDAH II. However, the significance of this regulatory 
mechanism is yet to be determined. 
 
1.3 Function and structure of DDAH  
DDAH exists as two isoforms: DDAH1 and DDAH2.16 The isoforms share 62% 
homology in their amino acid sequence and have a conserved active site sequence, but 
have low sequence homology with the bacterial Pseudomonas aeruginosa DDAH 
(PaDDAH). DDAH1 and DDAH2 also differ in their locality. DDAH1 is widely 
expressed especially in the brain, liver, skeletal muscle, macrophages and pancreas and 
is roughly co-localised with nNOS. DDAH2 is generally co-localised with eNOS; it has 
a wider distribution but is most densely expressed in the heart, placenta and the 
endothelium. DDAH2 is also expressed in the immune tissues that express iNOS and 
both of the enzymes are densely expressed in the kidneys.17  
 
The first crystal structure of DDAH was solved by Vallance et al.18 This was the DDAH 
crystal structure from the PaDDAH complexed with L-Citrulline. PaDDAH is 245 
amino acids long and its structure is a barrel comprised of five repeats of a ββαβ 
structural motif (Figure 4, A and B). Structure A shows a bird's eye view and structure 
B shows a side view of the crystal structure of PaDDAH. The N and C terminus project 
out of one side of the barrel (‘bottom side’) and the ‘top’ side consists of a protruding 
loop region (magenta) acting as a lid to the active site. The active site is formed from a 
central channel closed in the middle by a salt bridge, which acts as the bottom of the 
active site; and the other side of a channel is a water filled pore. The crystal structure 
showed a catalytic triad present at the active site involving a cysteine residue: Cys249, 
His162 and Glu114. The crystal structure also showed homology with Arginine 
Deiminase (ADI) and Arginine:Glycine Amidinotransferase which also share a common 
catalytic triad and catalyse similar reactions. Hence, DDAH is part of a superfamily of 
arginine modifying enzymes.  
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A DDAH1 structure of the mammalian bovine brain was later solved by Grütter et al. 
who showed, that like the PaDDAH1, Bovine DDAH1 is also comprised of five repeats 
of a ββαβ structural motif (Figure 4, C and D).19 L-Citrulline is bound in the active site 
of bovineDDAH1 as a space-filling model with yellow carbon atoms, blue nitrogen 
atoms and red oxygen atoms. The magenta loop is the ‘lid’ to the active site and the 
bottom of the active site is closed by a salt bridge between Glu77 and Lys174 shown in 
structure D. The water channel pore is thought to exist to reload molecules of water 
needed for the hydrolysis mechanism.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4 A: bird’s eye view of PaDDAH; B: side on view of PaDDAH; C: bovine 
DDAH1 complexed with citrulline; D: bovine DDAH1 showing a salt bridge between a 
glutamic acid and a lysine residue.18 
The crystal structure of L-Citrulline bound bovine DDAH in the closed lid conformation 
shows that the Cα-carboxyl group forms three salts bridges: two with the guanidine 
C 
A B 
D 
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group of Arg144 and one with the guanidine group of Arg97 (Figure 5). The Cα-amino 
group forms two H-bonds with the main chain carbonyls of Val267 and Leu29 and a 
salt bridge to Asp72. The terminal hydrogens of the ureido moiety are held in place in 
the active site by hydrogen bonding to Asp78 and Glu77. Phe75 and Leu171 shield the 
middle alkyl chain on both sides in a small hydrophobic pocket. The positions in the 
catalytic triad of bovineDDAH differ from those of PaDDAH, and they are Cys273, 
His172 and Asp126.  
 
Figure 5: Binding of citrulline in DDAH active site. 
1.4 Mechanistic studies  
Vallance et al. proposed the hydrolysis mechanism of substrates such as ADMA in the 
active site of PaDDAH goes via an imine hydrolysis, whereby the dimethylated 
nitrogen is protonated by the active site His162.18  This imine is then attacked by the 
thiolate of Cys249, which they propose is deprotonated by His162, suggesting that Cys-
249 and His162 form an ion pair. However, Fast et al. argue against this proposing that 
the deprotonation of the cysteine thiolate is substrate assisted as crystal structures show 
that Cys246 and His162 are too far away from each other to form an ion pair.8 The 
authors propose the Cys249 in the resting enzyme is only deprotonated when bound to 
cationic substrates, lysine and metals (Scheme 2). Binding of the substrate L-NMMA 
with a positively charged guanidine residue is thought to induce the deprotonation of the 
thiol. It is not known whether this proton is lost to the solvent or to an unknown base. 
The thiolate attacks at the guanidinium carbon of the substrate (state A) and expels 
20 
 
methylamine leading to the formation of a covalent thiouronium intermediate (state B). 
The methylamine leaving group picks up a proton from the protonated histidine. 
Subsequent deprotonation of water by the His162, for the hydrolysis of the thiouronium 
species, leads to the formation of citrulline, and regeneration of the protonated thiol of 
Cys249 and protonated His162 (state C).  
 
 
Scheme 2: Hydrolysis mechanism at the active site of PaDDAH.  
 
1.5  DDAH inhibitors 
1.5.1  Endogenous Inhibitors 
Endogenous inhibitors of DDAH include Zn2+, L-homocysteine 11, S-nitroso-L-
homocysteine (HcyNO) 12 and 4-hydroxynonenal (4-HNE) 13 (Figure 6). 
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Figure 6: Endogenous inhibitors of DDAH. 
Knipp et al. describe the inhibition of bovine DDAH1 by S-nitroso-L-homocysteine by 
its covalent attachment to the active site of the enzyme.20 They propose the mechanism 
goes through the attack of the active site Cys249 thiolate on HcyNO 12 (Scheme 3). 
The covalently attached molecule is a dead-end complex 14 (Scheme 3) and the authors 
propose that this compound may help in the design of covalently attached inhibitors for 
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DDAH and the structurally and mechanistically related enzyme, arginine deiminase, 
ADI. 
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Scheme 3: Reaction of HcyNO at DDAH active site. 
DDAH does not have any cofactor requirements for its catalytic activity, but exists as an 
inactive enzyme bound to a single Zn2+ ion. Removal of the Zn2+ ion from the enzyme 
by phosphate or imidazole increases its activity. Hence, it appears that Zn2+ has a 
stabilising and regulatory role in the activation of the DDAH enzymes.21 The crystal 
structure of DDAH1 from bovine brain shows it is a monomeric enzyme with a 
molecular mass of 31.2 kDa. Although the structure of  bovine brain DDAH1 showed it 
to have bound zinc, a more recent paper disclosing the crystal structure of human 
DDAH1 did not show any bound zinc.13 Hence, the exact role of zinc in the regulation 
of DDAH activity seems uncertain. 
 
4-HNE 13 is a reactive aldehyde and is the product of oxidative degradation of 
polyunsaturated fatty acids. It is produced in pathological situations of oxidative stress 
especially in cardiovascular diseases. It was shown by Cardounel et al. that exposure in 
pathological situations of 4-HNE to huDDAH1 leads to a dose dependent inhibition of 
the enzyme by forming an adduct at the histidine residues (His15 and His173) of 
huDDAH1.22 This leads to inhibition of DDAH and hence leads to lowering of NO 
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levels. It is thought that this mechanism plays a critical role in mediating endothelial 
dysfunction seen in disease states involving oxidative stress. 
 
1.5.2  Structurally distinct inhibitors 
Inhibitors which are structurally different to the natural substrate include the 
pentafluorophenylsulfonates 15 and 16, chloroacetamidine 17, and the 
indolylthiobarbiturates 18 and 19 (Figure 7). Prompted by the work of Roush et al. on 
sulfonates and sulfonamides as cysteine protease inhibitors, Vallance et al. have 
reported pentafluorophenyl (PFP) sulfonates and their activity against DDAH and 
ADI.23, 24 The sulfonates 15 and 16 showed significant activity against DDAH and ADI, 
with IC50 values of 16 µM of 15 against PaDDAH, and 74 µM of 16 against ADI 
(Figure 7). These compounds represent the first structurally different inhibitors of 
DDAH, and the first exogenous small molecules to inhibit ADI. 
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Figure 7: DDAH inhibitors. 
Chloroacetamidine 17 (Figure 7) is an irreversible time-dependent inhibitor which 
targets the active site Cys249. 25 It also inhibits peptidyl argininedeiminase (PAD4) and 
is a widely applicable inhibitor for the superfamily of arginine modifying enzymes. The 
authors suggest incorporation of additional functional groups may lead to the design of 
future therapeutics.  
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Selwood et al. more recently took a different approach for the discovery of DDAH 
inhibitors.26 They used in silico virtual screening and hit analysis, which does not 
require high throughput screening and has additional advantages of lower cost, higher 
speed and lower resource requirements. Filtering of physicochemical parameters from a 
308,000 compound library and biological screening identified the barbituric acids 18 
and 19 (Figure 7) as active PaDDAH inhibitors. Compound 18 was the most active 
compound identified IC50(PaDDAH) = 2 µM and represents the most active PaDDAH 
inhibitor to date. However, in a more recent study Clement et al. reported no activity for 
18 against huDDAH1.27 Although the active site is highly conserved in both PaDDAH 
and huDDAH1, sequence similarity is only ~25% and the work of Clement highlights 
the limitations of using PaDDAH as a model for mammalian DDAH.  
 
1.5.3  Substrate based inhibitors 
 
One of the first exogenous molecules found to inhibit DDAH was a chain shortened 
analogue of L-NMMA, 4124W 21 (Figure 8), a weak inhibitor with activity at 
millimolar concentrations and poor selectivity.28 Based on the structure of 4124W 
Rossiter et al. have developed structural analogues of 4124W to improve DDAH 
inhibition and enhance selectivity for DDAH over NOS.29 Modifications of 4124W 
made include changing the number of carbon atoms in the middle alkyl chain and 
changing the R groups on the guanidine moiety of 20 (Figure 8).  
 
From a library of 4124W analogues it was found that guanidine 23 (Figure 8) bearing a 
2-methoxyethyl group on the guanidine moiety, and a benzyl ester on the acid, was the 
most potent (IC50 = 27 µM) out of a series of analogues with a two carbon length alkyl 
chain. Analogues with amide groups in place of the ester moiety were not as effective at 
inhibiting DDAH. One carbon chain extension of 23 to give free acid L-257 22 (IC50 = 
22 µM) and methyl ester L-291 24 (IC50 = 20 µM) exhibited higher activity for DDAH, 
without any significant effect on NOSs. Treatment of rats with L-257 22 and L-291 24 
led to an increase in ADMA concentrations as compared with control animals,  
[ADMA] ~ 1.2 µM, vs ~ 0.8 µM in controls. Hence, compounds L-257 22 and L-291 24 
show potential as DDAH inhibitors and for exploring the significance of the DDAH 
enzymes. 
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Figure 8: Substrate based DDAH inhibitors. 
Vallance et al. recently disclosed the first crystal structure of huDDAH1 complexed 
with citrulline and the DDAH inhibitor L-257 (Figure 9).13 The residues in the catalytic 
triad in huDDAH1 consist of Cys273, His172 and Asp126 which differ from the 
catalytic triad residues in PaDDAH (Cys249, His162 and Glu114). Crystal structure A 
shows the electron density of L-257 in the active site of DDAH (DDAH carbon atoms 
in green) with a closely bound water molecule near the active site cysteine Cys273.  
This is needed for the hydrolysis of the thiouronium species (Scheme 2, B). Crystal 
structure B shows a comparison of L-257 (carbon atoms in cyan, oxygen atoms in red) 
and L-citrulline (in yellow) bound in the active site. Both molecules are anchored to the 
active site by H-bonding to Asp78. Binding of L-257 induces changes in the active site. 
Movement of His172 creates a pocket for the 2-methoxyethyl moiety of the L-257 to fit 
in, and increase its affinity for the active site, and hence impede the hydrolysis 
mechanism of DDAH. Whereas the carboxyl end of citrulline is bonded to Arg144 
(Figure 5), L-257 induces a large change in the position of Arg144 away from the 
carboxyl end of the inhibitor, and creates a large pocket. This pocket can potentially be 
filled by a functional group at the acid end of L-257. 
 
 
 
 
25 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: A Crystal structures of huDDAH1 bound with inhibitor L-257; B Comparison 
of bound L-257 and citrulline. 
A more recent investigation into the binding pocket of the guanidine moiety by 
screening substituted guanidines, amidines and isothioureas was carried out by Clement 
et al.27 Replacing the guanidine moiety of ornithine with amidine as a bioisostere 
showed improvement in activity of inhibitors 25. The alkenyl amidine 26 (Table 1, 
entry 1) showed 97% inhibition at 1 mM with an IC50 value of 13 µM and a Ki of 2 µM 
when assayed against huDDAH1 and 26 is the most potent huDDAH1 inhibitor to date. 
Compounds 27 and 28 (entry 2 and 3 respectively) also showed modest activity with 
78% and 73% inhibition at 1 mM respectively. The authors suggest that having a double 
bond in the side chain increases potency as is evident when compound 26 (entry 1) is 
compared to 27 (entry 2). Nω-Substituted L-arginines 29 and 30 (entries 4 and 5) were 
also investigated where groups with π-systems, alkenyl and alkynyl, were added but 
none of the synthesised compounds showed anymore potency than the amidines.  
  
A B 
26 
 
Entry Compound 
COOH
NH2
N
H
NH
R
25  
Inhibition at 1 
mM (%) 
IC50 (µM) Ki (µM) 
 
1 COOH
NH2
N
H
NH
26  
 
97 ± 3 
 
13 ± 3 
 
2 ± 1 
 
2 COOH
NH2
N
H
NH
27  
 
78 ± 7 
 
70 ± 21 
 
32 ± 6 
 
3 COOH
NH2
N
H
NH
28  
 
73 ± 8 
 
79 ± 25 
 
36 ± 3 
 
4 COOH
NH2
N
H
N
H
NH
29  
 
71 ± 3 
 
189 ± 10 
 
57 ± 9 
 
5 COOH
NH2
N
H
N
H
NH
30  
 
83 ± 7 
 
55 ± 8 
 
17 ± 5 
Table 1: Alkenyl amidine inhibitors and guanidine inhibitors 
Fast et al. recently surveyed a range of DDAH and NOS inhibitors as dual targeted NO 
inhibitors, as inhibiting both DDAH and NOS would lead to a decrease in levels of 
NO.30 They found that the amidino group was a promising scaffold to build a dual-
targeted inhibitor. Extending the alkyl chain on the amidines 31, 32 and 33 (Figure 10) 
from the iminoethyl through to the iminopentyl side chains, increased the inhibition of 
huDDAH1 (990, 52, 7.5 µM Ki values respectively) and decreases the inhibition for 
nNOS (1.7, 3.0, 20 µM Ki). Further extension to the iminohexyl side chain on 
compound 34 led to a decrease in inhibition (100 µM Ki), but an increase in selectivity 
for DDAH. Similar length compound L275 also showed selectivity for DDAH over 
NOS, and this suggests a smaller binding pocket at the active site of NOS compared to 
that of DDAH. 
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Figure 10: Amidine inhibitors. 
Further studies on N5-(1-iminopropyl)-L-ornithine (L-IPO) 32 revealed that this 
compound is a competitive nonhydrolyzable substrate analogue. A crystal structure of 
this compound in the active site huDDAH1 shows it to adopt a similar conformation to 
that of L-257 in the active site, the only difference being continous electron density 
between the active site cysteine thiol and the Cζ of L-IPO, suggesting a tetrahedral 
intermediate is formed (Figure 11). This covalent adduct is thought to be in rapid 
equilibrium with the parent compound and enzyme and hence, has not been detected via 
mass spectrometry. 
 
 
Figure 11: Binding of L-IPO at DDAH active site. 
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1.6  Synthesis of guanidines 
 
Key to the synthesis of L-arginine derivatives is the synthesis of guanidines. The ability 
of the guanidinium moiety to form H-bond, charge-pair, and cation π-interactions makes 
it a vital amino acid involved in many proteins and their active sites.  Many isolated 
natural products contain the guanidine motif and their synthesis and biological activities 
have been well investigated.31 One such natural product is Batzelladine A 38 (Figure 
12) which contains three guanidine moieties. Guanidine groups are also important in the 
pharmaceutical industry forming parts of various drug molecules, including those used 
for diabetes, cardiovascular drugs, antihistamines, anti-inflammatory agents, 
antibacterial and antifungal agents.32  Metformin 35 is an anti-diabetic for type II 
diabetes, Amiloride 36 is a potassium-conserving drug used to manage hypertension, 
and Cimetidine 37 is a H2-receptor antagonist which was previously used for the 
treatment of heartburn and peptic ulcers (Figure 12). Guanidine acts as a strong base, 
with a pKaH of 12.5, hence many organic transformations are carried out with 
guanidines and substituted guanidines.33 One example is 1,1,3,3-tetramethylguanidine 
(TMG) 39 which catalyses alkylation of carboxylic acids.34 
 
 
 
Figure 12: Drugs and natural products containing the guanidine moiety.  
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There are numerous ways to synthesise guanidines and not all the methods can be 
covered in the scope of this introduction, but these have been extensively reviewed in 
the literature.31-33 Many of these methods have also been adapted to solid-phase 
synthesis.32 The most common ways to synthesise guanidines include synthesis from 
thioureas, isothioureas, pyrazoles and isothiocyanates. Less common syntheses include 
the use of cyanamides and triflyl guanidines. All of these will be examined briefly in 
this introduction. 
 
1.6.1  Guanidines from thioureas and isothioureas 
Many of the examples in the literature for the synthesis of guanidines employ 
isothioureas, especially methylisothiourea, which are converted to guanidines using 
guanylating reagents. Some of the reagents used for this purpose include Mukaiyama’s 
reagent, thiophiles such as HgCl2, HgO, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDCI) and 1-fluoro-2,4-dinitrobenzene (Sanger’s reagent).32  
 
The substitution pattern of the resulting guanidine can be modified to afford tri- and 
tetra- substituted guanidines by starting with di-substituted guanidines and primary or 
secondary amines. Isothioureas are easy to prepare from thioureas, and subsequent 
reaction with an amine with concomitant loss of a thiol affords guanidines. For 
example, treatment of thiourea 40 with methyl iodide in methanol yields the 
methylisothiouronium salt 41, which when treated with morpholine, forms the di-
substituted guanidine 42 (Scheme 4).35 
H2N NH
S
Ph
40
MeI, MeOH
17 h, 94% H2N N
S
Ph.HI
MeCN, reflux, 
24 h, 63%
HN
O
H2N N
N
Ph
.HI
O
41 42  
Scheme 4: Synthesis of a 1,2-disubstituted guanidine using an isothiourea. 
Long reaction times were observed for the formation of the isothiouronium salt 41 as 
well as for the formation of the guanidine 42. The guanidine forming reaction can be 
accelerated by using HgCl2, as shown by Guo et al. Treatment of commercially 
available N,N’-bis-Boc-S-methylisothiourea 43 with HgCl2 and amines lead to the 
formation of bis-Boc-guanidines (up to 3.5 h, Scheme 5).36 Sterically hindered amines 
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such as disopropyl amine work well affording 44 in 77% yield in 3.5 h, as well as 
aromatic amines such as aniline. One of the disadvantages to using methylisothioureas 
in guanidine synthesis is the formation of the malodorous by-product methanethiol. 
 
BocN NHBoc
S
HgCl2, DMF, Et3N
0 oC, 3.5 h, 77%
N
H
BocN NHBoc
N
43 44  
Scheme 5: Synthesis of a guanidine from an isothiourea. 
The addition of HgCl2 to thioureas aids desulfurization leading to the formation of an 
intermediate carbodiimide. This is then attacked by amine nucleophiles to form a 
guanidine. For example, treatment of bis-Boc protected thiourea 45, HgCl2, Et3N and 
proline 46 as the amine nucleophile in DMF leads to the quick formation of the bis-Boc-
protected guanidine 47 (Scheme 6).37 This is a fast reaction and other amine 
nucleophiles diisopropylamine and o-chloroaniline also reacted in 0.5 h and 2 h 
respectively, to give good yields of their corresponding guanidines. Hence, it can be 
seen that the rate of guanidine formation is enhanced by using HgCl2. However, 
purification of the guanidine from the mercury waste presents a drawback in using this 
reagent. 
N
H
N
H
S
Boc Boc
N
H
CO2Bn+
HgCl2, NEt3, DMF
20 min, 0oC, 90% yield N N
H
N
Boc Boc
CO2Bn
45 46 47  
Scheme 6: Synthesis of a guanidine from a thiourea. 
Isothiocyanates are often used to form thioureas which are subsequently converted to 
guanidines. Hamilton et al. describe the reaction of carbamoyl isothiocyanate 48 with 
benzylamine to form thiourea 49.38 This is subsequently converted to a guanidine via 
treatment of an amine and EDCI as the coupling agent. For example, reaction of 
thiourea 49 with the hindered tert-butyl amine furnished the guanidine 50 in near 
quantitative yield (Scheme 7). This protocol was used to synthesise 1,3-disubstituted 
guanidines using a range of amines with varying reactivities in high yields by 
condensation with the thiourea 49 (Table 2).  
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Scheme 7: Synthesis of a guanidine from an isothiocyanate. 
Entry Amine (RNH2) Guanidine yield (%) 
1 t-butyl amine 99 
2 Morpholine 95 
3 Diisoproplyamine 76 
4 4-methoxyaniline 82 
 
Table 2: Amines used in synthesis of guanidines from an isothiocyanate. 
The carbamoyl moiety acts as a protecting group for the isothiocyanate and offers the 
advantages of increasing its reactivity, and makes the purification of the polar guanidine 
compounds easier.  
 
Thioureas can also be oxidised to sulfonic acids to convert the sulfur into an enhanced 
leaving group, and hence promote nucleophilic displacement by an amine to form a 
guanidine. The treatment of thiourea 51 with hydrogen peroxide and acetic acid by 
Miller et al. lead to the oxidation of thiourea to sulfonic acid 52. This can be easily 
displaced by glycine to form guanidino acid 53 (Scheme 8).39 Reaction of 52 with 
amino acids DL-methionine, L-phenylalanine, DL-serine and DL-valine gave lower yields 
(60, 45, 50 and 55% respectively). An advantage of this method is the easy isolation and 
purification, whereby the products precipitated out and could be purified by 
recrystallization. However, reaction of sulfonic acid 52 with DL-alanine, L-isoleucine 
and L-leucine led to products which were soluble in the reaction mixture and therefore 
difficult to isolate. 1,2-Disubstituted and 1,2,3-trisubstituted guanidino acids can also be 
formed via functionalisation of the starting thiourea. Miller et al. oxidised 
diphenylthiourea 54 to the sulfonic acid and condensed it with glycine to form a 1,2,3-
trisubstituted guanidino acid 55 but with a lower yield of 35% (Scheme 8). It can be 
concluded that substituted guanidines are formed in low yields using this protocol. 
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Scheme 8: Synthesis of a guanidines from sulfonic acids. 
1.6.2  Guanidines from isocyanates 
Isocyanates are also used in guanidine synthesis and can be readily converted to their 
corresponding carbodiimides. For example, Molina et al. have reacted the aromatic 
isocyanate 56 with N-aryliminophosphorane 57 to afford carbodiimide 58.40 This was 
treated with an aromatic amine in the presence of tetrabutylammonium fluoride 
(TBAF), to form the desired guanidine 59 (Scheme 9). This method is highly efficient 
in synthesising 1,2,3-trisubstituted guanidines in good yields. 
N PPh3
N
C
O
N
C
NBr
Br
N
H
NH
N
58
Br
H2N
THF, rt TBAF, THF, rt
73%
56 59
57
 
Scheme 9: Synthesis of a guanidine from an isocyanate. 
1.6.3  Guanidines from cyanamides 
Cyanamides are widely used in the synthesis of guanidines. They can be formed from 
amine condensation on cyanogen bromide, where further treatment with a nitrogen 
nucleophile forms a guanidine. For example, Wang et al. treated the primary amine 60 
with cyanogen bromide to form the cyanamide 61, which on further treatment with 
hydroxylamine hydrochloride furnished the hydroxyguanidine 62 (Scheme 10).41 The 
authors also report producing cyanamide from a range of alkyl and aryl amines. Mono- 
and 1,2-disubstituted guanidines are reported to have been made using this method, but 
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this is the limit of the substitution that can be achieved. Another useful cyanamide 
employed in the synthesis of monosubstituted guanidines is hydrogen cyanamide. 
Reaction of an amine with hydrogen cyanamide leads to a monosubstituted terminal 
guanidine. For example, Paul et al. converted amine 63 into guanidine 64 using 
hydrochloric acid and hydrogen cyanamide (Scheme 10).42 
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Scheme 10: Synthesis of guanidines from cyanamides. 
1.6.4  Guanidines from triflyl guanidines 
Recently the use of triflyl guanidines for the synthesis of monosubstituted guanidines 
has been reported by Goodman et al.43 These can be prepared from guanidine 
hydrochloride 65 via reaction with Boc-anhydride to yield the Boc-protected guanidine 
66, or CBzCl to form the CBz protected analogue (Scheme 11). Further treatment with 
triflic anhydride converts the diprotected guanidine into the triflyl guanidine 67. The 
triflyl amine is a very good leaving group and can be displaced with amine 
nucleophiles. For example, Fmoc-protected L-ornithine can be condensed with triflyl 
guanidine 67 to furnish Boc-protected arginine 68 in a high yield.  
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Scheme 11: Synthesis of triflyl guanidine and its use in guanidine formation. 
 
1.6.5 Guanidines from Pyrazoles 
N,N’-bis-tert-butoxycarbonylpyrazole-1-carboxamidine 69 (Scheme 12) can be reacted 
with a variety of amines and amino acids to form protected guanidines.44 For example, 
Drake et al. treated CBz- protected ornithine 70 with pyrazole 69 to form the Boc-
protected guanidine 71 in 70% yield. Employment of simple amines butylamine, tert-
butylamine and benzylamine in this reaction yielded the corresponding guanidines in 
yields in excess of 90% yields in 1-3 h. Reaction with secondary amine proline took 16 
h at room temperature and yielded its corresponding guanidino acid in 73%. Hence, 
both primary and secondary amines yield mono-substituted guanidines in good yields. 
Disubstituted guanidines can also be produced by modification of the pyrazole 69 via 
the Mitsunobu reaction, whereby alkylating at the disubstituted nitrogen of 69 and 
reaction with an amine leads to the formation of 1,2-disubstituted guanidines (see 
section 1.7). 
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Scheme 12: Synthesis of a guanidino acid from a pyrazole. 
1.7  Previous syntheses of arginine based DDAH inhibitors 
Rossiter et al. used pyrazole 69 to synthesise disubstituted guanidines in the synthesis of 
analogues of 4124W in the search for more potent inhibitors of DDAH.29 The alkylation 
of pyrazole 69 was achieved via Mitsunobu reaction with an alcohol. The 
carboxamidine 72 was then reacted with the amine 73 to displace the pyrazole and yield 
the protected guanidine amino acid 74. This could be deprotected in 4 M HCl in 
dioxane to give the monosubstituted guanidine 75 where R1 = H, and 1,2-disubstituted 
guanidine where R1 = alkyl group (Scheme 13). 
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Scheme 13: Synthetic route to analogues of 4124W. 
1,2,2-Trisubstituted guanidines were also synthesised via the following synthetic route 
(Scheme 14): A Mitsonobu reaction was performed, to attach the amino acid 76 onto 
pyrazole 69. Displacement of the pyrazole group on 77 using a secondary amine, led to 
the formation of guanidine 78. The Boc groups were removed with HCl to yield the 
1,2,2-trisubstituted guanidino acid 79. Rossiter et al. also made some ester analogues of 
these compounds by reacting them with thionyl chloride and an alcohol to form esters 
80.29  
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Scheme 14: Synthetic route to ester analogues. 
 
Amide analogues were also synthesised (Scheme 15); the amide groups were formed on 
the carboxylic acid of amino acid 81 to form the amides 82. The Fmoc groups were 
removed using piperidine, and the amino group thus revealed was used to displace the 
pyrazole from compound 69 to yield the protected amides 83. These were then 
deprotected to furnish 1,2-disubstituted guanidine amide analogues 84 of arginine. 
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Scheme 15: Synthetic route to amide analogues. 
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Chapter 2:  Results and discussion 
2.1  Aims 
Analogues of 85 have been synthesised by Rossiter et al. where R = H, and OMe 
(Figure 13).29 The aim of this project is to synthesise further ester analogues of 22 where 
R = allyl and substituted aromatic groups. 
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Figure 13: Ester analogues. 
A route similar to that taken by Rossiter et al. will be adopted (Scheme 16). Ester 
analogues will be synthesised on amino acid 86. Fmoc-deprotection of 87 and reaction 
with pyrazole 88 to give Boc-protected guanidines 89 can be deprotected using HCl to 
give guanidines 85. 
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Scheme 16: Proposed synthetic strategy. 
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This synthetic strategy will also be tested on the chain shortened analogue 75.  Substrate 
based design will further be investigated by attaching  amide groups on the carboxyl 
end, using the strategy empolyed by Rossiter et al. for amide analogues (Scheme 15).29 
Drug design will also be carried out using the crystal structure of DDAH to design 
possible inhibitors, and it is foreseen that drug design based on the crystal structure of 
huDDAH1 with the inhibitor L-257 in the active site (Figure 9) will give rise to 
conformational structures that could be synthetically mimicked. This approach would 
potentially give DDAH1 specific inhibitors which could be useful as DDAH1 is roughly 
colocalised with nNOS (Section 1.3). Crystal structures of DDAH2 have not been 
elucidated to date and biological work on the extraction and purification of the DDAH2 
enzyme will be attempted. If successful then the DDAH2 enzyme will be subjected to 
crystal structure studies and drug design specific to DDAH2. 
 
2.2  Synthesis of ester analogues of L-257 
The initial aim of the project was to synthesise esters of L-257 22, namely the methyl 
and benzyl ester, and hence validate the synthetic route for the synthesis of further ester 
analogues (Figure 14).  
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Figure 14: Ester analogues of L-257. 
Initial efforts were concentrated on synthesising the methyl ester 24 (L-291) and the 
benzyl ester 90 starting from Boc-Orn(Fmoc)-OH 86 (Scheme 17). The methyl ester 91 
and benzyl ester 92 were synthesised in 95% and 91% yields respectively. The Fmoc 
groups were then cleaved using piperidine, and subsequent treatment with the N,N’-bis-
Bocpyrazole-1-carboxamidine 88 failed to form the products 93 and 94.45,29 
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Scheme 17: Attempted synthesis of esters 93 and 94. 
The failure of the guanidine forming reaction, coupled with the expense of the pyrazole 
88, led us to consider the use of a cheaper alternative guanylating agent. The 
Bocthiourea 45 was readily synthesised starting from thiourea 51 (Scheme 18). 
Conversion of the Bocthiourea 45 to the Bocmethylisothiourea 43 was readily achieved 
with methyl iodide in 84% yield, and subsequent treatment of the urea with 2-
methoxyethanol, under Mitsunobu reaction conditions, furnished the methylisothiourea 
95 in 94% yield.46,47,48,49 This guanylating agent served as a cheaper alternative to the 
pyrazole 88. It was necessary to attach the 2-methoxyethyl group on the 
methylisothiourea 43, for selective N-alkylation as treatment of thiourea with base and 
1-bromo-2-methoxyethane leads to S-alkylation despite literature precedence.   
 
41 
 
BocHN
S
NHBoc
Boc2O, NaH
THF, 0 oC   21 oC
2 h, 45%
O OH
DEAD, PPh3, THF
MeI, K2CO3
MeCN, 60 oC
1 h, 84%
0 oC, 30 min
21 oC, 24 h, 94%
51 45 43
95
BocN
S
N
Boc
O
H2N
S
NH2 BocN
S
NHBoc
 
Scheme 18: Synthesis of guanylating agent 95. 
It was previously established that formation of guanidine 97 using the methylisothiourea 
95, with para-methoxybenzylamine 96 could be easily achieved in 96% yield (Scheme 
19).45 Deprotection of the Fmoc group of ester 92, and treatment of the subsequent crude 
reaction mixture, under the same reaction conditions under reflux, led to a complex 
reaction mixture with no isolable products. At this point it became clear that Fmoc-
deprotection from ester 92 would liberate an amine, which could easily undergo 
cyclisation, to form a six membered cyclic lactam. This was indeed observed when 
reaction of the ester with piperidine in DMF for 1 h led to the formation of the lactam 
98, isolated in a quantitative yield.  
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Scheme 19: Guanidine formation using methylisothiourea 95. 
The design of the synthetic approach to ester analogues of L-257 was flawed. To 
circumvent the cyclisation problem, the ester moiety would have to be installed on the 
acid 99 (Scheme 20) after guanidine formation, by coupling Boc-Orn-OH with 
methylisothiourea 95. The subsequent acid 100 could also be used to make a range of 
esters and amides.  
BocN N
Boc
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H2N
NHBoc
O
OH
O
N
Boc
N
H
NBoc
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O
NHBoc99 100
95
 
Scheme 20: Synthesis of acid 100. 
Two different conditions were initially employed for the coupling of Boc-Orn-OH to 
methylisothiourea 95; 1. THF, Et3N, reflux and, 2. HgCl2, Et3N, DMF (Scheme 21). 
Neither reaction went to completion which made it extremely difficult to purify the 
product acid 100 from Boc-Orn-OH, as they were both very polar products, and had 
similar retention factors on silica gel. Nevertheless, semi purification of the reaction 
mixture generated in THF, via flash chromatography, gave a mixture of the two polar 
compounds which were treated with MeI and Et3N to furnish the methyl ester 93 in 5% 
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yield over the two steps. Similarly, the semi purified acid 100 from reaction conditions 
(2), and further treatment with benzyl bromide and Et3N, gave the benzyl ester 94 in 
24% yield over two steps. The extremely low yields achieved over two steps for esters 
93 and 94 were thought to have occurred due to the incomplete reaction of Boc-Orn-OH 
with methylisothiourea 95 to form acid 100, as opposed to the ester formation step. 
Esters 93 and 94 were then deprotected in 4 M HCl to yield the hydrochloride salts of 
the arginine esters, 24 and 90, in 99 and 60% yields respectively. 
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Scheme 21: Synthesis of methyl and benzyl ester analogues of L-257. 
2.3  Optimisation of guanidine formation 
Boc-protected guanidine 100 formation with 95 using HgCl2 was carried out at 80 °C 
for 48 h, and monitoring by tlc showed the reaction did not reach completion. However, 
due to biological systems being sensitive to any mercuric residue left after purification, 
optimisation of this reaction without the use of mercury was pursued. Several reaction 
conditions were employed to try and optimise guanidine formation (Table 3). Coupling 
agent EDCI was employed using conditions used by Hamilton et al., but the reaction 
failed to proceed (Table 3, entry 1).38 Guanidine formation was also attempted using 
water as a polar solvent in the first instance, for two days at 21 °C, and thence at 80 °C 
for two days. Unfortunately, in both cases no reaction was observed with only 
methylisothiourea 95 recovered in 90% (Table 3, entry 2). Reactions in DMF with Et3N 
led to an incomplete reaction, but with DBU led to decomposition of 95 with no product 
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formation. Further reactions in the microwave, also led to incomplete reactions with 
90% starting material recovered each time (Table 3, entries 5-7). 
 
H2N
NHBoc
O
OH N
H NHBoc
O
OH
NBoc
N
Boc
O
10099
HgCl2, Et3N, DMF
80oC, 48 h
BocN N
Boc
S
O
95
 
Entry  1 
(eq.) 
 
Boc-Orn-
OH (eq.) 
 
 Reaction conditions 
 
Observation 
1 1 1.5 DIPEA (2eq), EDCI (3eq), 
DMF, RT, 5days 50 
No reaction 
2 1 1.5 Et3N, H2O, RT, 2 days,  80°C, 2 
days 
~ 90% 95 recovered 
3 1 2 Et3N, DMF, 80 °C, 6 days 77% starting material 
recovered 
4 1 2 DBU (2 eq), DMF, 80°C,  48 h,  Complete decomposition of 95 
5 1 2 NMP, MW, 90oC, 100oC, 110oC, 
(30min at each temp.) 
~ 90% starting material 95 
recovered 
6 1 2 NMP, MW, Et3N (2 eq), 100oC, 
110oC, (30min at each temp.) 
~ 90% starting material 95 
recovered 
7 1 2 DMF, MW, Et3N (2 eq), 90oC, 
100oC, 110oC, (30 min at each 
temp.) 
~ 90% starting material 95 
recovered 
 
Table 3: Optimisation conditions for guanidine formation. 
A number of reasons may be attributed to the prevention of guanidine formation. The 
Boc groups on methylisothiourea 95 may have been sterically hindering the carbon at 
which the amine was supposed to attack; the free acid was perhaps hindering the 
reaction; or the methanethiol was not a good enough leaving group. The latter seemed 
unlikely as the reaction worked well with amine 96 (Scheme 19). 
 
2.4  Synthesis of mono-Boc guanylating agent 103 
In order to establish whether the two large Boc groups were sterically hindering the 
reaction, mono-Boc analogue 103 was synthesised to see if this improved the guanidine 
formation. A different synthetic route had to be used for the synthesis of the mono-Boc 
protected substrate 103 (Scheme 22). The 2-methoxy ethyl group was attached via 
treatment of 2-methoxyethyl amine 101 with thiophosgene, which furnished the 
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isothiocyanate 102 in 61% yield. This was then treated with sodium hydride and t-butyl 
carbamate, to yield the mono-Boc protected thiourea 103 in 48% yield.51 Reaction with 
methyliodide to give the methylisothiouronium salt, and subsequent treatment with 
benzylamine, led to the formation of the guanidine 104 in quantitative yield. Hence, the 
mono-Boc protected thiourea 103 seemed to be a promising substrate for the formation 
of a guanidine, and it was thought that this reduction in steric bulk, around the carbon 
atom to be attacked, might aid nucleophilic attack by the amine of Boc-Orn-OH. 
O NH2 CH2Cl2, H2O
CSCl2, K2CO3
O N C
S
3 h, 61%
O
NH2O
0o  C      21 oC
BocHN
S
N
H
O
 reflux, 5 h
PhH2N
NEt3, THF, 21 oC
N
H
Ph
NH
N
H
O
1. MeI, MeCN
NaH, THF
4 h, 48%
101 102
103
2.
48 h, >99%
104  
Scheme 22: Synthesis of guanidine using mono-Boc thiourea 103. 
However, treatment of the thiourea 103 with methyliodide, and then Boc-Orn-OH, led 
to the formation of the desired guanidine but with a low yield, 19% (Scheme 23). 
Purification of the product guanidine 105 was also difficult, as the product was 
extremely polar. The yield of this synthetic route was deemed insufficient for the 
synthesis of a larger library of arginine mimetics.  
NEt3, THF, 21 oC
BocHN
S
N
H
O
1. MeI, MeCN
O
N
H
N
H
OH
O
NHBoc
NBoc
2. Boc-Orn-OH
48 h, 19%
105103
reflux, 5 h
 
Scheme 23: Synthesis of guanidine 105. 
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2.5  Guanidine formation using Boc-Orn-O-tBu  
An ester stable to cyclization is the t-butyl ester formed on the carboxyl end of Boc-
Orn-OH. The t-butyl ester 106 is commercially available and was employed in the 
guanylating reaction with the methylisothiourea 95, which pleasingly underwent smooth 
conversion to the guanidine 107 in 70% yield after three days (Scheme 24). Moreover, 
the isolation of this compound was readily achieved by flash chromatography. This 
suggested that protecting the acid improved the guanidine forming reaction and hence, 
that the free acid in Boc-Orn-OH was hindering product formation.  
Et3N, DMAP, 95, THF, N2
 21 oC, 3 days, 70%
O
O
NHBoc
H2N
106
O
O
N
H
N
Boc
NBoc
O
NHBoc107  
Scheme 24: Protecting groups for the acid of Boc-Orn-OH. 
Following the ester formation example by Rossiter et al. (Section 1.7, Scheme 14) the t-
butyl ester 107 was deprotected along with all the Boc groups, using 4 M HCl in 
dioxane to reveal arginine analogue 22 (Scheme 25).29 On treatment of this compound 
with thionyl chloride and with 4-fluorobenzyl alcohol as the solvent, the reaction 
seemed to yield the desired product 108 but impurities in the compound, as well as the 
high boiling point of 4-fluorobenzyl alcohol, meant that the 4-fluorobenzyl alcohol 
could not be evaporated in vacuo as reported by Rossiter et al. Numerous attempts and 
failure at purification of this compound led us to conclude this esterification procedure 
was unsuitable to be carried out on arginine analogue 22. Hence, synthesis of ester 
analogues required a different approach with easier purification of end products. 
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Scheme 25: Synthesis of impure fluorobenzyl analogue 108. 
Since, the synthesis of the t-butyl ester 107 proceeded with a relatively high yield, it 
was perceived that selective t-butyl ester deprotection in the presence of the carbamate 
groups, could lead to the desired guanidino acid 100 (Table 3). Yadav et al. describe a 
mild and efficient cleavage of t-butyl esters in the presence of Boc groups using 
molecular iodine in water.52 For example, the t-butyl ester 109 was cleaved to the acid 
110 using 30 mol% molecular iodine and water, 92% yield (Scheme 26). 
 
N
Boc
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O
N
Boc
OH
O
I2, (0.3 eq), H2O
CH3CN, reflux, 5 h, 92%
109 110  
Scheme 26: Selective cleavage of t-butyl ester in presence of carbamate. 
The t-butyl ester 107 was subjected to the same conditions with 30 mol% iodine in 
water and acetonitrile under reflux for 5 h (Scheme 27). This yielded a small amount of 
a compound containing signals consistent with two t-butyl groups in the 1H NMR 
spectrum. However, infra red analysis failed to show an acid peak, hence, these 
conditions failed to cleave the t-butyl ester and gain access to the acid 100, suggesting 
instead that compound 111 was formed. Analysis by mass spectrometry also supported 
this as it showed a molecular ion at 389, which suggests that two Boc groups were 
cleaved leaving one Boc group and the t-butyl ester intact. This suggests that the Boc 
groups on the guanidine moiety are extremely labile in these mildly acidic conditions, 
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where a small amount of hydroiodic acid is thought to be produced. Deprotection of 
these Boc groups also lead to compounds with such high polarity, it makes purification 
extremely difficult. 
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Scheme 247: Selective cleavage of t-butyl ester. 
2.5.1  Synthesis of the chain shortened analogue of L-257 
Synthesis of the chain shortened analogue of L-257, 22, was carried out by treating the 
methylisothiourea 95 with the deprotected Boc-Dab(Fmoc)-OH 81,  which was thought 
to yield the guanidine 112 in 51% yield (Scheme 28). However, the NMR spectrum of 
this compound was not easy to interpret because of the presence of Boc groups which 
broaden all the other proton peaks in the 1H NMR. In order to improve this situation, the 
compound was deprotected using 4 M HCl in dioxane, which yielded a compound that 
had similar peaks to that of 113, but contained an unknown impurity which could not be 
separated from the desired product. Hence, the synthesis of the chain shortened 
analogue 113 was carried out by the method of Rossiter et al. using the t-butyl ester 
114.45 This was treated with the methylisothiourea 95 and after 48 h at 21 °C furnished 
the guanidine 115 in 83% yield. The Boc groups and t-butyl ester were then cleaved by 
4 M HCl, to reveal the chain shortened analogue 113 in 85% yield.  
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Scheme 28: Synthesis of the chain shortened analogue 113. 
2.6  Synthesis of amide analogues 
Crystallization conditions led to the hydrolysis of the ester moieties of the methyl ester 
24 and benzyl ester 90 (Scheme 21).53 It was therefore envisaged that the more stable 
amide analogues of arginine should be synthesised for crystal structure studies, as well 
as testing for biological activity. 
 
Amides were synthesised via the route outlined in Scheme 15 (section 1.6.6), using the 
methylisothiourea 95 instead of pyrazole 88.29 Amide formation on Boc-Orn(Fmoc)-OH 
via an EDCI and HOBT coupling reaction gave moderate yields of the amides 117a-d, 
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(Scheme 29, Table 4).54,55 These amides were then treated with piperidine to cleave the 
Fmoc groups, and subsequent reaction with methylisothiourea 95, furnished the 
guanidines 118b-d. The guanidine forming reactions were low yielding, the 
benzylamide 118c was furnished in 70% yield, however the methylbenzyl amide 118d 
was only achieved in 24% yield. The dimethyl amide 118b could not be isolated in pure 
form, even after attempted purification by flash chromatography, and was therefore 
used impure in the next step. The amide 117a failed to form the guanidine 118a; the 
primary amide is not expected to be as nucleophilic as the primary amine formed from 
Fmoc cleavage, for nucleophilic attack at the thiourea. However, the presence of a 
primary amide seemed to have hindered the reaction. The Boc protected guanidines 
118b-d were then deprotected to yield the amide analogues 119b-d.  
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Scheme 29: Synthesis of amide analogues. 
R1 R2 Amide Yield 
(%) 
Guanidine  Yield 
(%) 
Deprotected 
guanidine 
Yield 
(%) 
H H 117a 89 118a - 119a - 
Me Me 117b 46 118b 8 119b 3 
H Bn 117c 70 118c 70 119c 62 
Me Bn 117d 92 118d 24 119d 71 
 
Table 4: Yields in the synthesis of amide analogues. 
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2.7  Biological results  
2.7.1  Biological results for DDAH synthesised DDAH inhibitors 
In order to determine the inhibitory activity of the esters 24 and 90, and of the amides 
119b, 119c and 119d, they were tested on rat kidney lysates which contained both 
DDAH1 and DDAH2. The assay measured the conversion of [14C]-L-NMMA to [14C]-
citrulline. Inhibitors were added to the lysate and incubated at 37 C, and 14C Citrulline 
formation was measured by scintillation counting, and the IC50 values were calculated 
using Graphpad Prism software. 
 
The results in table 5 show that the benzyl ester 90 was not as active as the methyl ester 
in competitively inhibiting the activity of DDAH. The methyl ester was not as active as 
the literature compound L-291(IC50 = 20 µM).29,56 This may be attributed to errors in 
measuring out small concentrations of the inhibitor, as well as the DDAH enzymes in 
the kidney lysate loosing activity. The benzyl amide 119c and the methyl benzyl amide 
119d did not show significant inhibition at 500 µM, with the benzyl amide being a 
better inhibitor than the methyl benzyl amide. However, the dimethyl amide 119b 
seemed to have similar inhibition to L-257 and the methyl ester L-291, with an IC50 
value of 23 µM. These results indicate that smaller R groups give better inhibition of 
DDAH, with the amide 119b showing increased inhibition than the larger amides 119c 
and 119d, and the larger benzyl ester being a weaker inhibitor than the methyl ester. 
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Inhibition at 500 
µM 
 
 
IC50 (µM) 
22 –OH – 20 ± 2 29 
24 –OMe – 37 ± 4 
90 –OBn – 78 ± 3 
119c –NHBn 65% 300 ± 7 
119d –NMeBn 29% – 
119b –NMe2 – 23 ± 3 
 
Table 5: Biological results of synthesised analogues. 
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2.7.2  Studies on DDAH2 
The crystal structure of DDAH2 has not been solved to date and it was thought we 
could express and purify DDAH2, for this purpose. Myc-DDAH1 and Myc-DDAH2 
were overexpressed in sEND cells and then purified using an immunoprecipitation 
technique using a Myc-antibody. Ten T75 flasks of the cells had to be grown in order to 
obtain 1mL of the cell lysate containing the Myc-DDAH protein. The aim was to purify 
enough DDAH2, ~1 mg, for crystallisation studies. In previous purifications in the 
group, western blots showed that DDAH1 and DDAH2 were present in the purified 
protein solution from three T75 flasks. However, once the DDAH2 was purified, a 
standard protein assay could not detect any protein in the lysate, as the concentration of 
the protein was too small. To purify larger amounts of DDAH2, it would have required 
many more T75 flasks of cells than is possible. Hence, purification of DDAH2 via the 
immunoprecipitation method was not a viable method to get enough protein for crystal 
structure studies. 
 
The purified protein was nevertheless incubated with [14C]-L-Citrulline overnight at 4 
ºC as a control, and at 37 ºC to check for activity of the protein. The graph below shows 
a difference in the radiocounts between the two reactions, for both purified DDAH1 and 
DDAH2 (Graph 1). Purified DDAH1 showed a difference of 2935 cpm between the 4 
ºC and the 37 ºC reaction. The difference in counts was higher with the purified 
DDAH2. These results showed that DDAH1 and DDAH2 remain active after 
purification, and this purified DDAH2 can perhaps be developed into a DDAH2 specific 
assay for development of DDAH2 specific inhibitors. This result however could not be 
repeated as subsequent purification of DDAH2 using immunoprecipitation, and activity 
assay failed to show any activity in the purified enzyme. 
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Graph 1: Activity of purified DDAH1 and DDAH2. 
2.8  Inhibitor design from huDDAH1 crystal structure 
Publication of the crystal structure of huDDAH1 complexed with the inhibitor L-257 by 
Leiper et al. showed the 2-methoxy ethyl chain of L-257 sat in a 7-membered ring via a 
hydrogen bond between the hydrogen of the guanidine and the oxygen of the 2-
methoxyethyl chain (Figure 15 22, Figure 16).56 This suggested that constraining the 
guanidine group up into a 7-membered ring i.e. analogue 120, may lead to a more 
potent inhibitor (Figure 16). 
 
Figure 15: Crystal structure of L-257 in huDDAH1. 
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Figure 16: Conformation of L-257 in huDDAH1 and proposed 7-membered analogue. 
Although cyclic analogues have been synthesised previously and didn’t exhibit 
significant activity, cyclic analogue 120 had not been evaluated. The 7-membered cyclic 
thiourea 122 was synthesised starting from carbon disulphide with 1,4-diaminobutane. 
Condensation of thiourea 122 with Boc2O furnished bright yellow thiourea 123 in 87% 
yield (Scheme 30). Subsequent treatment of this thiourea with methyl iodide, and then 
refluxing with Boc-Orn-OH for 48 h, furnished the Boc protected cyclic guanidine 124 
in 11% yield, and the bisBoc protected guanidine 125 in 28% yield. Presumably, the 
refluxing conditions lead to the loss of the additional Boc group of guanidine 125.  The 
Boc groups were then deprotected using 4 M HCl in dioxane to yield the cyclic 
analogue 120. The inhibitory activity of this compound was assayed against rat kidney 
DDAH and was found to have 92% activity at 500 µM, but disappointingly displayed 
no inhibition at 100 µM. It seems plausible that the large 7-membered ring may restrict 
the ability of 120 to dock into the active site of the DDAH1. 
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Scheme 30: Synthesis of 7-membered cyclic analogue 120. 
2.9  Summary 
Our investigations into the synthesis of ester analogues on the carboxyl end of L-257 
proved to be troublesome. Initial synthesis of the methyl and benzyl ester, 24 and 90 
respectively, were extremely low yielding. This was due to the key guanidine forming 
reaction being difficult to effect with high yields. Different conditions using mercury 
and EDCI as a coupling agent, and differing solvents, temperature and reaction times 
did not seem to have any significant effect on increasing the small yield of the 
guanidine formed (Table 3). The high polarity of the intermediates also resulted in 
purification problems. The key problem in the guanidine forming reaction was proved 
to be the free acid on Boc-Orn-OH used in the coupling reaction as the t-Butyl ester 
protected Ornithine 106 underwent smooth conversion to the guanidine in high yields 
(Scheme 24). These difficulties with the synthesis of esters led us to attempt synthesis 
of other functional groups on the carboxyl end of L-257. A number of amide analogues 
were synthesised on Boc-Orn-OH which underwent good conversion to their 
corresponding guanidines (Scheme 29, Table 4). However, the amide analogues 
prevented a drawback as testing for inhibition of DDAH showed that apart from the 
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dimethylamide analogue which showed similar activity to L-257 and L-291, larger 
amide analogues did not possess any significant activity.  
 
As substrate based inhibitor design did not prove fruitful, a crystal structure approach to 
designing an inhibitor was adopted. This was prompted by the publication of the crystal 
structure of huDDAH1 with L-257 at the active site. This allowed for the design of a 7-
membered cyclic analogue, by mimicking the conformation taken by the 2-
methoxyethyl chain of L-257. The synthesis of this compound was relatively facile. 
However, subsequent biological evaluation showed disappointing inhibition of rat 
kidney DDAH with no activity at 100 µM. It is anticipated that further analogues based 
on the crystal structure of L-257 in huDDAH1 will lead to more promising inhibitors of 
DDAH. 
 
Alongside the chemical synthesis of inhibitors of DDAH, some biological investigations 
into DDAH2 was also carried out. The crystal structures of bacterial and mammalian 
DDAH1 had been solved but the crystal structure of DDAH2 is unresolved thus far. 
Hence, an attempt was made to purify huDDAH2 for crystal structure studies via an 
immunoprecipitation technique. This failed to produce enough protein for 
characterisation of its crystal structure. However, purification of DDAH2 and 
incubation with substrate L-NMMA showed some activity. This result however, could 
not be further reproduced.  
It is envisaged that the search for DDAH inhibitors will be carried out in the future via 
crystal structure based design. Indeed, there are many more conformations of L-257 in 
the active site of huDDAH1 that could potentially be mimicked, or another useful way 
is by attaching a group onto L-257 to displace the closely bound water molecule needed 
for hydrolysis seen in Figure 9, A. Development of inhibitors with high potency could 
lead to clinically useful drugs for NO reduction in pathological situations such as 
ischemia, migraine and septic shock.  
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Investigations into Radical Hydroacylation of Vinyl Sulfonates 
 
Chapter 3: Introduction 
 
3.1  Hydroacylation  
Hydroacylation reactions can be carried out using a number of methods. These methods 
include the Stetter reaction, transition metal catalysed and radical mediated 
hydroacylation. The Stetter reaction employs an aldehyde, an α,β-unsaturated ketone 
with a thiazolium catalyst which leads to the formation of a 1,4 dicarbonyl via an 
umpolung mechanism. For example, the aldehyde 126 was treated with methylvinyl 
ketone 127 and the thiazolium catalyst 128 to yield 1,4 dione 129 as the intermediate in 
the synthesis of dihydrojasmone by Stetter et al. (Scheme 31).57 Transition metals, in 
particular rhodium, have been used, to catalyse hydroacylation reactions. For example, 
treating pentenal 130 with Wilkinson’s catalyst leads to the formation of 
cyclopentenone 131 (Scheme 31).58 The use of other transition metal catalysed 
hydroacylation reactions has been reviewed by Willis.59 
H
O
O
HO
S
N
Ph
Et3N, EtOH, 80 oC, 16 h, 75%
O
O
H
O
Cl-
126 127
128
129
ORhCl(PPh3)3 (10 mol%)
CHCl3, C2H4, rt, 88h, 72%
+
130 131  
Scheme 31: Stetter reaction and rhodium catalysed hydroacylation. 
Hence, there are a number of distinct mechanisms for hydroacylation of alkenes and 
these include a free radical pathway involving acyl radicals. 
  
59 
 
3.2  Radical Chemistry 
Radicals are atoms, molecules or ions with an unpaired electron and are formed from 
the homolysis of a two electron bond. They are generally highly reactive as the unpaired 
electron can readily ‘pair’ with another electron to form a more stable species, and 
hence they are reactive intermediates. Radical intermediates are found in many naturally 
occurring processes, for example in the human body the formation of OH radical leads 
to indiscriminate destruction of enzymes, fats and DNA. Molecular oxygen, which 
exists as a stable biradical is involved in autoxidation processes such as drying of paints 
and deterioration of foods. 
To form a radical, a relatively weak covalent bond must be broken, with the supply of 
energy to overcome bond dissociation coming from heating (thermolysis) or UV light 
(photolysis). Once initiated, radicals can react with other non-radical species such as 
alkenes, to form another radical (propagation). The reaction of a radical with another 
radical leads to a stable unreactive species which terminates the radical chain reaction 
(Scheme 32). 
R H
X X X
X + RX H
R R R R+
+
Initiation
Propagation
Termination  
Scheme 32: Steps in a radical reaction. 
In synthetic chemistry radicals are formed from molecules containing relatively weak 
bonds i.e. bond energies of 125-165 kJ mol-1. These bonds include heteroatom-
heteroatom, heteroatom-carbon and metal-metal bonds, and can be homolysed at 
relatively low temperatures. One of the most common examples is the single O-O bond 
in peroxides. Diacyl peroxides, in particular benzoyl peroxide (BPO) 132 and lauroyl 
peroxide 133 have low bond energies (~125 kJ mol-1). BPO has a half life of 1 h at 92 
°C and 1 min at 131 °C, and lauroyl peroxide has a half life of 1 h at 80 °C and 1 min at 
120 °C (Figure 17).60 Other common radical initiators include the azobisnitrile 
azobisisobutyronitrile (AIBN) 134 and organometallics such as (SnBu3)2 and (SePh)2. 
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Irradiation by visible and UV light of certain wavelengths can also promote homolysis 
of peroxides and nitriles.  
N
N
CN
CN
benzoyl peroxide 132
O
O (CH2)9CH3
O
H3C(H2C)9
O
lauroyl peroxide 133
O
O
Ph
O
Ph
O
AIBN 134  
Figure 17: Common radical initiators. 
3.3  Organotin in radical reactions  
Chain reactions using organotin hydrides are the most common application of radical 
chemistry in organic synthesis, the most common reagent being tributyltin hydride 
(Bu3SnH). These are used in radical reduction, addition, cyclisation and elimination 
reactions, with initiation of the radical chain by AIBN. The reduction of an alkyl halide 
such as an alkyl bromide, using Bu3SnH proceeds via abstraction of the bromine atom 
by a tributyltin radical (Scheme 33).61  This reaction proceeds to form a strong tin-
halide bond which provides a driving force for the reaction. The radical adduct R  can 
then abstract a hydrogen from the Bu3SnH, forming a stable C-H bond and producing a 
Bu3Sn  radical which further propagates the chain reaction. 
Bu3Sn + R Br R Bu3SnBr
R Bu3SnH R H Bu3Sn+ +
+
Bu3SnH
initiation
 
Scheme 33: Radical reduction by Bu3SnH. 
Intramolecular radical addition reactions are synthetically useful for the formation of 
cyclic structures. In the cyclisation of the alkene 135 (Scheme 34), the radical generated 
from abstraction of the bromine atom leads to radical 136, which can either cyclise to 
form 137 or reduce to 139. The rate of cyclisation (kcyc) must be higher than the rate of 
reduction (kred) for cyclisation to take place. This is achieved by maintenance of a low 
concentration of Bu3SnH which can be achieved by its slow addition over the course of 
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the reaction. In this way it can be possible to maximise the cyclisation pathway and 
minimise the undesired reduction.  
Br
Bu3SnH, AIBN
H SnBu3
Bu3SnBr
H SnBu3
H
135
136 137
138
139
kcyc
kred
SnBu3
 
Scheme 34: Intramolecular radical addition. 
Radicals are frequently used in synthesis due to the advantages they offer over ionic 
reactions. They are unsolvated and this can create more sterically hindered systems than 
ionic species; they are compatible with functional groups (protecting groups are not 
needed for NH or OH), less prone to rearrangement, and their ambiphilic nature allows 
them to react with both electrophilic and nucleophilic reagents. An area of organic 
chemistry where radicals are widely used is in hydroacylation of alkenes for the 
formation of ketones. 
 
3.4  Radical hydroacylation 
One of the first reports of radical hydroacylation was by Kharasch et al. in 1949 
whereby addition of aldehyde 140, to alkene 141, (6:1 respectively) led to the formation 
of ketone 142 (Scheme 35).62 Small amounts of a double addition product 143, the 
alkane 144 derived from decarbonylation of the acyl radical, and carbon monoxide were 
also formed.  
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R1 H
O
R2
R1
O
R2 R1
O
R2
R2
R1H CO
hv or peroxide
+ + + +
140 141 142 143 144  
Scheme 35: Kharasch’s hydroacylation of alkenes. 
The reaction occurs via the following sequence (Scheme 36):  
(a)  An initiator abstracts the aldehydic hydrogen from the aldehyde 140 to form an 
acyl radical 145.  
(b) The acyl radical 145 adds to an alkene forming radical adduct 146.  
(c) Abstraction of an aldehydic hydrogen from another molecule of aldehyde by 
adduct 146 generates the ketone 142 and another acyl radical.  
It has now widely established that ketones can be synthesized from acyl radicals which 
are nucleophilic and add to electron poor alkenes.63 Addition of the acyl radical to 
neutral or electron rich alkenes i.e. if R2 = alkyl is sluggish (Scheme 36).  This is 
because the nucleophilic adduct 146 is not efficient in abstracting the aldehydic 
hydrogen. However, hydroacylation is relatively fast when R2 is an electron-
withdrawing group. When the rate of reaction is slow due to the inefficiency of the 
abstracting radical adduct 146, additional chain carriers can be used. For example, 
Roberts et al. used a thiol as a chain carrier and found that thiol catalysis was effective 
for hydroacylation of electron-rich, -neutral and -deficient alkenes, in particular for 
addition to electron-rich double bonds.64 The thiol acts as a polarity-reversal catalyst, 
whereby the adduct radical 146 abstracts a hydrogen from the thiol 147 to form the 
ketone 142, and the thiyl radical 148 thus formed is polarity matched to abstract the 
aldehydic hydrogen to form an acyl radical and regenerate itself (Scheme 36). 
63 
 
R1
O
R2
146
R1
O
R2
H
142
R'-SH R'-S
R1 H
O
140
R1
O
145
R2
141
147 148
Inititiator or 146  
Scheme 36: Hydroacylation reaction mechanism (black), and thiol catalysis (blue). 
An example using butanal 149 (2 eq.) and isopropenyl acetate 150, with di-tert-butyl 
hyponitrite TBHN as the initiator and methylthioglycolate 151 as the thiol chain carrier, 
gave the ketone 152 in 80% yield (Scheme 37), whereas reaction without a thiol catalyst 
gave only 8% yield, indicating the effectiveness of the thiol chain carrier.  
H
O
O
O
+
tBuON=NOtBu (5 mol%)
dioxane, 60 oC, 4 h,  80%
O
O
HS
O
O
O
149 150 152(10 mol%)
151
 
Scheme 37: Hydroacylation of an electron-rich alkene using methylglycolate. 
Another such chain carrier used by Ishii et al. is N-hydroxyphthalimide (NHPI). This 
molecule also acts as a polarity reversal catalyst.65 In a similar manner to the thiol 
catalyst protocol, adduct radical 146 (Scheme 36) abstracts a hydrogen from the NHPI 
to form the ketone and the phthalimide N-oxyl (PINO) radical. This radical can then 
abstract an aldehydic hydrogen to form an acyl radical and regenerate the NHPI. The 
example below shows the hydroacylation of propanal with 1-hexene 154. Catalytic 
amounts of NHPI and BPO were used to give the ketone 155 in 73% yield (Scheme 38). 
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H
O O
NHPI (10 mol%)
chlorobenzene
90 oC, under Ar, 73%
+
153 154 155
BPO (10 mol%)
 
Scheme 38: Hydroacylation using polarity-reversal catalyst NHPI. 
Although most of the hydroacylations of alkenes involve electron poor acceptors via 
what is thought to be a nucleophilic acyl radical, it was recently shown that acyl radicals 
add to imines solely via reaction on the nitrogen. Ryu et al. showed that the acyl radical 
is N-philic and reacts exclusively at the nitrogen of imines (Scheme 39).66 For example, 
treatment of the alkyl bromide 156 with Bu3SnH and carbonylation to form an acyl 
radical, led to cyclisation at the more electron rich end of the C=N π-bond, yielding the 
lactam 157.  
Br N
Bu3SnH, CO (80 atm)
AIBN, benzene
N
O
156 157  
Scheme 39: Cyclisation of N-philic acyl radical. 
3.5  Generation of acyl radicals 
Chatgilialoglu et al. broadly classify the generation of acyl radicals into three routes: i) 
from the homolysis of a C-X bond; ii) carbonylation of alkyl radicals; and iii) homolysis 
of an R-R’ bond.63  
 
3.5.1  Acyl radical generation via homolysis of R-X where X = H  
Acyl radical formation directly from aldehydes can occur via homolysis of the 
aldehydic C-H bond. Homolysis of this bond requires activators, such as peroxide 
reagents and Bu3SnH. Kharasch used the peroxide initiator diacetyl peroxide (Scheme 
35). Marko et al. reported the reaction of aldehydes with AIBN and N-
bromosuccinimide (NBS) to afford acid bromide 158 (Table 6).67 Heptanal, 
cyclohexanal and trimethyl acetaldehyde were converted to their acid bromides in 10-15 
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min in good yields (Table 6). This is a synthetically useful reaction as the acid bromides 
can be further converted to amides upon addition of amines. 
R H
O AIBN (0.02 eq), NBS (1.2 eq)
R Br
O
158CCl4, 95 
oC, 10-15 min
 
Entry Substrate Product 
yield 
1 
C6H13 H
O
 
78% 
2 
H
O
 
83% 
3 
t-Bu H
O
 
85% 
 
Table 6: Acid bromide formation. 
Recently it was shown that tetrabutylammonium decatungstate (TBADT) acts as an 
efficient activator of the aldehydic hydrogen in photocatalyzed hydroacylation of 
electron poor alkenes.68 The process is thought to be initiated by excited TBADT (P*) 
which abstracts the aldehydic hydrogen of aldehyde 140, leading to the formation of the 
acyl radical 145 (Scheme 40). The acyl radical is captured by the electron-poor alkene 
159 to form adduct 160. Hydrogen atom transfer by PH completes the cycle forming 
ketone 161. Hydroacylation using primary, secondary and tertiary aldehydes were 
successful in the reaction as well as using a variety of different activated alkenes. 
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R H
O
140
R
O
EWG
159
145
P*
PHP
EWG
O
R
EWG
O
R 160161
hv
 
Scheme 40: Hydroacylation using TBADT. 
Decarbonylation of trimethylacetaldehyde 162 led to the alkyl addition product 164 in 
70% yield at room temperature (Scheme 41). Predominance in the acyl addition product 
165 over the alkyl addition was achieved by lowering the temperature of the reaction 
to  ̵ 20 °C, which reduced decarbonylation, to give a ratio of 3:1.   
(nBu4N)4[W10O32]
MeCN, hv
O
H CO2MeMeO2C
CO2Me
CO2Me
CO2Me
CO2Me
O
162 163 164 165
+ +
 
Scheme 41: TBADT mediated hydroacylation of pivaldehyde. 
Equimolar amounts of aldehyde and alkene were used, with only 2 mol% of the 
TBADT present. Foul smelling auxiliaries such as thiols were also not needed and 
hence the authors suggest these properties qualify the synthetic method as ‘green’. This 
approach mediated by TBADT was recently used to attach acyl groups to 
[60]fullerene.69  
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3.5.2  Acyl radical generation via homolysis of R-X where X ≠ H 
Acyl radicals can be formed from acyl chlorides as demonstrated by a number of 
groups.63 Chatgilialoglu showed that reduction of an acid chloride 166 with Bu3SnH is 
plagued by the formation of an ester by-product 167 (Scheme 42).70  
R Cl
O
Bu3SnH
R H
O
Bu3SnCl
R Cl
O
2 Bu3SnH2
R O
O
R
2 Bu3SnCl
+ +
+ +
166
167  
Scheme 42: Reduction of acid chlorides with Bu3SnH. 
Treating acid chlorides with tris(trimethylsilyl)silane ((CH3Si)3SiH) and AIBN leads to 
the reduction of acid chlorides to the aldehyde or decarbonylated alkane, and reduces 
ester by-product formation. For example, Chatgilialoglu et al. showed that nonanoyl 
chloride could be reduced to the corresponding aldehyde and decarbonylated product, 
RH, in 37 and 63% yields respectively with only a small amount of ester formation 
(Table 7, entry 1).71 However, reaction of cyclohexanecarbonyl chloride (entry 2) and 
pivaloyl chloride (entry 3) led to almost exclusive formation of their decarbonylated 
products via the acyl radical pathway. 
 R Cl
O
R H
O
R O
O
R
+ +RH
(CH3Si)3SiH(1.2 eq)
toluene, 80 oC
AIBN (0.1 eq)
 
Entry RCOCl Time (min) RCHO 
yield 
RH 
yield 
Ester 
yield 
1 CH3(CH2)8COCl 30 37 63 Unquantified 
small amounts 
2 c-C6H11COCl 40 <1 99 - 
3 (CH3)3COCl 30 - 98 - 
 
Table 7: Acid chloride reduction using (CH3Si)3SiH. 
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Thioesters can also be employed as acyl radical precursors. Grunwell et al. reported the 
photolysis of aromatic thiol esters using a 254 nm light source to generate the 
corresponding thiyl radical and an acyl radical.72 For example, photolysis of 4’-tolyl 
thiol-4-phenylbutyrate 168 gave, primarily disulfide 169 and aldehyde 170, presumably 
via generation of an acyl radical and a thiyl radical (Scheme 43). Minor amounts of 
other products were also formed including propylbenzene 171, and sulfide 174, 
presumably from decarbonylation of the acyl radical, and recombination of the thiyl 
radical and the decarbonylated acyl radical respectively. 
S
O
Ph
hv
C6H12
O
H
S
S
SH
168 169 75% 170 36%
171 6% 172 7% 173 9%
S Ph
174 2%
+
+ + +
+
 
Scheme 43: Acyl radical generation by photolysis of a thioester. 
Simple thioesters such as S-phenyl thioesters show a lack of reactivity towards stannane 
mediated chain reactions. Boger et al. showed that treatment of the thiol ester 175 with 
AIBN and Bu3SnH led to no reaction; however, treatment of the corresponding seleno 
ester under the same conditions led to the formation of the cyclised product 176 in 84% 
yield (Scheme 44).73 Selenoesters are more useful for this purpose than thioesters as the 
RCO-SeR’ bond is weak and reacts readily with stannyl radicals.  
COX
O
X = SPh                                                    no product
X = SePh                                                    84%
AIBN (0.05 eq)
Bu3SnH (1.2 eq)
C6H6, reflux,  2.5-3 h
175 176
 
Scheme 44: Cyclisation of acyl radicals generated from thioester and selenoester. 
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Boger et al. also showed that a range of phenyl selenide acyl precursors underwent 
hydroacylation to a range of alkenes without decarbonylation.74 Se-Phenyl 
benzenecarboselenoate 177 and methyl acrylate 178 underwent hydroacylation to give 
ketone 179 in 58% yield under standard radical conditions using AIBN and Bu3SnH 
(Scheme 45). 
SePh
O
O
O
+
O
O
O
AIBN, Bu3SnH
benzene, 80 oC, 1.5 h
177 178 17958%  
Scheme 45: Phenylselenide as an acyl radical precursor. 
Telluroesters are also commonly used and acyl radicals from telluroesters can be 
generated via white light photolysis. For example, telluroester 180 is reduced to 
aldehyde 181 by treatment with thiophenol under white light (Scheme 46).75 
Te-1-naphth
O
PhSH, hv, 8 oC
80%
H
O
180 181  
Scheme 46: Telluroester as an acyl radical precursor. 
Pattenden et al. showed that white light photolysis of aryl and acetyl cobalt salophens 
yield acyl radicals, and that these can undergo decarbonylation to alkyl radicals, and can 
then be trapped by various electrophiles including phenyldisulphides in moderate to 
good yields.76 For example, cobalt-salophen 182 was converted to the phenylsulfide 183 
in 63% (Scheme 47).  
PhSSPh, hv
182 183
CH2Cl2, 42 h, 56%
O
O
N
N
Co
O
O
O
SPh
 
Scheme 47: Cobalt salophen as an acyl radical precursor. 
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There are many more examples of acyl radical precursors in the literature, including 
those from metal carbene complexes and acylphosphine oxides. The phosphine oxide 
(2,4,6-trimethylbenzoyl)diphenylphosphine oxide 184 is a commercial photoinitiator 
used in polymerization processes (Scheme 48).77 This molecule forms benzoyl 185 and 
phosphonyl 186 radicals with initiation by UV light of 355 nm wavelength.78 
P
O
Ph
O
Ph  hv (355 nm)
O
P Ph
O
Ph
heptane
184 185 186
+
 
Scheme 48: Acyl radical generation from a phosphine oxide. 
More recently acyl hydrazines and hydrazides have been employed as acyl radical 
precursors. Braslau et al. employed acyl hydrazines in cyclisation reactions whereby the 
hydrazine 187 was treated with lead oxide (PbO2) to form the acyl radical which was 
then trapped by 2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPO).79 This yielded the 
acyloxyamine 189, and the α,β-unsaturated system 188 formed via elimination of the 5-
exo-cyclisation product 190 (Scheme 49). Zard et al. also used acyl hydrazide analogues 
to carry out cyclisation reactions. 80 In this case the acyl radicals were trapped by phenyl 
selenide, and this seemed to give improved yields over hydrazines. For example, the 
hydrazide 191 was treated with diphenyl diselenide and phenylseleninic anhydride to 
yield the cyclised and trapped product 192 in 74% yield. 
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O
S S
O
SePh
PhSeSePh (0.2 eq)
PhSeO2H (0.5 eq)
PhMe, reflux, 4 h, 74%
191 192  
Scheme 49: Acyl hydrazine and acyl hydrazides as acyl radical precursors. 
3.5.3  Acyl radical generation via carbonylation 
Alkyl and aryl radicals can be carbonylated with CO usually under high pressure, to 
generate acyl radicals. Ryu et al. showed that alkyl radicals, generated from alkyl 
halides such as 1-bromoctane 193, could be carbonylated under CO pressures of 70-90 
atm (Scheme 50).81  Dehalogenation by Bu3Sn• led to the formation of the alkyl radical 
194 which carbonylated to form an acyl radical 195. Abstraction of a hydrogen from 
Bu3SnH furnished the aldehyde 196 in 61% yield.  
AIBN, Bu3SnH
benzene, CO
Br
O
O
H
CO
193 196
194 195
Bu3SnHBu3Sn
 
Scheme 50: Acyl radical formed via carbonylation. 
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Further development of this reaction by substituting tris(trimethylsilylsilane) 
(TMS)3SiH for Bu3SnH reduced the need for the high CO pressure, instead requiring 15 
atm of CO to produce a similar yield of product (65%). 
 
3.5.4 Acyl radical generation through fragmentation of C-C bonds 
Fragmentation of ketones and diketones by a Norrish type I photocleavage mechanism 
leads to the formation of acyl radicals (Scheme 51). The carbonyl group of the ketone 
can be excited to the singlet state S1 198 by accepting a photon.  It can then reach the 
triplet state 199 through intersystem crossing (ICS) and cleave forming two radical 
fragments 145 and 200. The acyl radical can undergo decarbonylation to form an alkyl 
radical R , and then recombine with another alkyl radical to form 201, or recombine to 
form the original ketone 197. 
R R
O hv
R R
O
S1
R R
O
T1
ISC
R
O
R+
197 198 199
145 200
-CO
R R+ R R
201
 
Scheme 51: Acyl radical formation via Norrish type 1. 
3.6 Acyl radical generation using air 
Although it seems from the literature precedence that an added initiator is needed for the 
activation of the C-H bond of aldehydes to form the acyl radical for addition to olefins, 
a discovery made by Caddick et al. provides evidence for the C-H activation of 
aldehydes without the need of this additive.82  This reaction was detected when an 
aldehyde was reacted with a vinyl sulfonate in the presence of air which led to the 
formation of an unexpected unsymmetrical ketone. The initial reaction used 2 
equivalents of butanal and one equivalent of trichlorophenyl(TCP)-vinyl sulfonate in 
dioxane at room temperature. This furnished the corresponding unsymmetrical ketone 
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203 in a 40% yield, with a small amount of the double addition product 204 (Scheme 
52).  
H
O O
SO3R
O
SO3R
SO3R
SO3R
1,4-dioxane, air
        21 oC 203 R = TCP 204 R = TCP150
+
202
205 R = PFP  
Scheme 52: Hydroacylation using TCP-vinyl sulfonate as acceptor. 
Further investigations into the reaction parameters revealed higher concentrations and a 
high ratio of aldehyde to alkene (5:1 respectively) increased the yield of the product 203 
to 74% after 24 h. A much smaller reaction time was needed for the reaction of butanal 
with pentafluorophenyl(PFP)-vinyl sulfonate as the acceptor, yielding the ketone 205 in 
65% after just 1 h. This can be attributed to the strong electron withdrawing nature of 
the PFP moiety. The generality of the reaction with respect to aldehydes was also 
investigated, and it was found that primary and secondary aldehydes underwent 
conversion to their corresponding ketones in good yields with TCP-vinyl sulfonate, and 
in lower yields but faster reaction times with PFP-vinyl sulfonate as the acceptor. 
Further optimisation of the reaction with PFP-vinylsulfonate in water at room 
temperature led to an increase in yield for a range of aldehydes employed in the 
reaction. The butanal reaction with PFP-vinyl sulfonate in these conditions increased 
the yield of 205 to 78%.83  
Evidence for a radical mechanism in this reaction comes from the complete inhibition of 
this reaction, when the radical inhibitor 2,6-di-tert-butyl-4-methylphenol (BHT 1%) is 
added. In addition, reaction of the pivaldehyde led to the formation of 206 and the 
decarbonylated product (207, Figure 18) which is indicative of radical decarbonylation 
and addition. 
O
SO3TCP
206
SO3TCP
207  
Figure 18: Reaction products of pivaldehyde. 
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The authors postulate that the reaction proceeds though a radical mechanism (Scheme 
53). The acyl radical 145 is formed by autoxidation of the aldehyde 140 by molecular 
oxygen in air. The radical 145 adds to the vinylsulfonate 208 to form the radical adduct 
209. This then abstracts the aldehydic hydrogen to form ketone 210. The acyl radical 
formed via autoxidation of the aldehyde, can also react further with molecular oxygen 
resulting in the formation of the carboxylic acid 211.  
R H
O
R
O
R OH
O
SO3PFP
R
O
SO3PFP
R
O
SO3PFP
H
R H
O
140
209
210
211
145
208O2
steps
 
Scheme 53: Postulated mechanism by Caddick et al. 
 
3.7 Autoxidation 
It is known that aldehydes autoxidise to their corresponding acids via aerobic oxidation 
involving acyl radicals. Melville and Cooper have shown that n-decanal autoxidises to a 
peroxy radical by reacting with molecular oxygen. 84,85 Formation of peroxyradicals 212 
occurs via reaction of an acyl radical 145 with molecular oxygen (Scheme 54). The 
peroxyradical 212 abstracts the aldehydic hydrogen from a molecule of aldehyde 
leading to the formation of the acyl radical and a peroxy acid 213. The peroxyacid then 
reacts with a molecule of aldehyde forming an α-hydroxyperester 214 which 
decomposes to 2 molecules of carboxylic acid 211. This overall pathway represents the 
autoxidation of aldehydes to their respective acids. 
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Scheme 54: Autoxidation of aldehydes. 
The α-hydroxyperoxyacid 214 can also break down to give a formate 215 and an acid, 
as shown by Lehtinan et al. through a Bayer-Villiger mechanism if the aldehyde is α-
branched.86 The α-branched aldehyde 2-ethyl hexanal reacts to give a mixture of the 
corresponding acid and formate in a ratio of 1:0.43 (acid: formate) (Scheme 55).  
O
O O
O H
214
R2
R1
R2
R1
H
R2
R1
OH
O
O
O H
R1
R2+
211 215  
Scheme 55: Alternative degredation pathway of the α-hydroxyperester 
Autoxidation studies of simple aldehydes were carried out by Caddick et al., by mixing  
aldehyde in air for 2 h, examining the ratio of the unreacted aldehyde to the acid formed 
(Table 8) and comparing them with hydroacylation reaction rates.83 For the same 
aldehyde, it can be seen that the hydroacylation reaction rates depend on the 
autoxidation rate of the aldehyde, which in turn depends on the length of the aldehyde 
i.e. for the longer aldehydes decanal and hexanal, autoxidation rates were slower and 
therefore reaction rates were slower. However, too fast a rate of autoxidation leads to a 
smaller yield of addition product, as can be seen with isobutaraldehyde (Table 8, entry 
1).  
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R H
O
140
R OH
O
211
Air
 
Entry R = Ratio of 140 : 
211 after 
autoxidation 
(2h) 
Reaction time (h) 
of hydroacylation 
to PFP-vinyl 
sulfonate in water 
Yield of 
hydroacylation 
product  210 (Scheme 
53) (%) 
1 –CH(CH3)2 1:5.11 3h 40 
2 –CH(C2H5)(CH2)3CH3 1: 2.16 3h 83 
3 –CH2CH(CH3)2 1:1.20 3h 74 
4 –(CH2)2CH3 1:1.08 3h 78 
5 –cC6H11 1:0.66 3h 74 
6 –(CH2)4CH3 1:0.37 6h 75 
7 –(CH2)8CH3 1.0.04 6h 62 
 
Table 8: Comparison of aldehyde autoxidation rates with hydroacylation reaction times.  
Aerobic oxidation of aldehydes to their respective acyl radicals and subsequent reaction 
to give acids has been used synthetically by many researchers, including Shapiro et 
al.87,88,89 They used the autoxidation of aldehydes to carry out the Passerini reaction on 
water. The hydroacylation of aldehydes to vinyl sulfonates discovered by Caddick et al. 
exploits the inherent tendency of aldehydes to be autoxidised by molecular oxygen in 
air.82 Compared to radical hydroacylation reactions being carried out in which various 
reagents for acyl radical formation are needed (section 3.4), this reaction represents a 
‘green’ reaction using only air as the oxidant for the formation of an acyl radical. 
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Chapter 4: Results and discussion 
 
4.1  Aims 
Caddick et al. have reported the hydroacylation of aldehydes to vinylsulfonates, via 
autoxidation of aldehydes in air.82 The scope of aldehydes employed thus far is 
extremely limited, with no reports of the use of aldehydes bearing functional groups 
such as halides, esters, alcohol etc. The focus of this work is to investigate the tolerance 
of the aerobic hydroacylation of vinyl sulfonates to a range of functional groups, hence 
expanding the utility of this method. Functional groups that will be examined include 
halides, alcohols, alkene and alkynes, nitriles, esters and ketones (Scheme 56).  
H
O
X
n
+ SO3R
1,4-dioxane
rt, air
O
X
n SO3R
X = Cl, Br, I
OEt
O
O
N
R = TCP
PFPOH
 
Scheme 56: Use of functionalised aldehydes in hydroacylation.  
 
Hydroacylation of nucleophilic alkenes is sluggishand difficult to carry out (Section 
3.3). 63,90  Another method of gaining entry to ketone 234 is via hydroacylation of 
vinylsulfonates 202, followed by base catalysed elimination and conjugate addition 
(Scheme 57). This is a new method of gaining entry to such compounds and the scope 
of the nucleophile will be investigated using oxygen, nitrogen, sulphur and phosphorus 
nucleophiles. 
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Caddick et al. also report that the reaction of pivaldehyde led to the formation of 206 
and the decarbonylated product (207, Figure 18) which is indicative of radical 
decarbonylation via aldehyde autoxidation, and addition to an acceptor. This 
autoxidation of aldehydes will be further investigated to gain entry to alkyl radicals via 
decarbonylation. Further capture of the alkyl radical by electron-deficient alkenes will 
be examined.   
79 
 
4.2  Functional group compatibility in hydroacylation 
4.2.1 Functional group compatibility tests 
With the limited functional groups used in the hydroacylation reaction by Caddick et al. 
it was envisaged that functional group compatibility of aldehydes could be expanded.82 
Hence, PFP-vinyl sulfonate 208 was synthesised from 216 by the method of Caddick et 
al. in 87% yield (Scheme 56), and evaluated in hydroacylation with butanal, in order to 
rapidly evaluate functional group tolerance by simply doping the hydroacylation 
reaction with molecules containing potentially sensitive functional groups. A single 
equivalent of dopant was added, and conversion of PFP-vinyl sulfonate and yield of 
ketone 205 measured by 1H NMR using pentachlorobenzene as an internal standard 
(Scheme 59, Table 9). 
Cl
S
Cl
O O
-78       21oC, 1 h, 87%
SO3PFP
216
Et3N, PFPOH, CH2Cl2,
208  
Scheme 58: Synthesis of PFP-vinyl sulfonate. 
3-Chlorobutan-2-one and benzyl bromide had no effect on the reaction, whereas 
cyclohexyliodide inhibited the reaction (Table 9, entries 1-3). If the iodide from 
cyclohexyl iodide was abstracted under free-radical conditions then; cyclohexane 
should have formed and it would be of interest to isolate this by-product. However, 
because of its volatility it can be difficult to detect and hence another experiment using 
a less volatile species, menthyl iodide, was carried out and this appeared to slow the 
reaction down (Table 9, entry 4).91 An alternative iodide, 1-(2-iodoethyl)-4-
methylbenzene, also seemed to inhibit the reaction (Table 9, entry 5), and the iodides 
used seem to present no obvious pattern to inhibition of the reaction. Thus we are 
unable to make a definitive conclusion on the compatibility of the reaction to iodides. 
3-Methylbutan-1-ol, (E)-hex-3-ene and hex-3-yne seemed to have no effect on the 
reaction, whereas a terminal acetylene, oct-1-yne, seemed to hinder the reaction (Table 
9, entries 6-9). Ester, nitrile and epoxide functionalities also had no effect on the 
reaction (Table 9, entries 10-12). Incorporation of these functional groups on aldehydes 
with subsequent hydroacylation, would validate these doping experiments. 
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Scheme 59: Hydroacylation of butanal with PFP-vinyl sulfonate. 
Entry Dopant PFP-vinyl sulfonate 
conversion (%) 
Product yield (%)* 
1 
 
100 95 
2 
 
100 79 
3 
 
0 0 
4 I
 
48 39 
5 
 
15 0 
6 
 
100 88 
7  91 78 
8  100 71 
9  75 28 
10 
 
100 91 
11 
 
100 92 
12 
 
100 82 
*   1H NMR yields using pentachlorobenzene as internal standard 
Table 9: Functional group compatibility testing. 
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4.2.2  Synthesis of functionalised aldehydes 
A strategy to functionalised aldehydes was via diol monoprotection, oxidation of the 
alcohol to the aldehyde and deprotection of the alcohol to reveal a hydroxy substituted 
aldehyde. Diol 217 monoprotection using TBDPS-Cl gave the protected alcohol 218 in 
54% yield (Scheme 60). The alcohol 218 was oxidised to the aldehyde 219 using a 
Swern oxidation, in 94% yield. Subsequent deprotection of the silyl group with 
tetrabutyl ammonium fluoride failed to furnish the desired alcohol substituted aldehyde 
220.  
HO OH HO OTBDPS O OTBDPS
NEt3, CH2Cl2
0 oC       21 oC
(COCl)2, DMSO
NEt3, CH2Cl2
0 oC         21 oC
TBDPSCl
218 219
Bu4NF, THF
217
O OH
1 h, 94%
220
21 oC, 3 h
24 h, 54%
 
Scheme 60: Synthesis of an alcohol substituted aldehyde. 
With the success of the Swern oxidation it was perceived that alcohols containing 
functional groups could simply be oxidised to their corresponding aldehydes. Oxidation 
of 3-chloro-1-propanol 221 furnished the product aldehyde 222 in a disappointing 2% 
yield (Scheme 61).92 However, the instability of the aldehyde led to its decomposition, 
most probably via an elimination to acrolein. The keto-alcohol 3-acetyl-1-propanol 223 
was also oxidised via the Swern oxidation to the corresponding aldehyde 224. However, 
this aldehyde was also extremely sensitive and decomposed when the solvent was being 
evaporated in vacuo after purification by flash chromatography. Hence, this synthetic 
approach was not successful and an alternative was sought.  
Another method for generation of an α-hydroxy aldehyde was by reduction of a lactone 
to a lactol.93 Hence, γ-butyrolactone 225 was reduced to the lactol using DIBAL to give 
tetrahydrofuran-2-ol 226 in a disappointing 4% yield (Scheme 61).  
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Scheme 61: Synthesis of functionalised aldehydes by oxidation and reduction. 
Enamine alkylation has been adopted by many chemists for the synthesis of chiral 
functionalised aldehydes. Macmillan et al. have carried out extensive research on 
enamine and iminium catalysis to form products resulting from α-halogenation, α-
oxyamination, α-vinylation and others.94,95,96 For example, organocatalytic α-
chlorination of aldehydes was carried out using N-chlorosuccinimide (NCS) as the 
chlorinating agent.97  
Using proline, NCS and hexanal 227, an α-chlorinating reaction was carried out 
(Scheme 62). This reaction had to be carried out under carefully controlled conditions at 
-30 °C, and due to the sensitivity of the aldehyde the products had to be maintained at 
low temperature and solvents had to be evaporated ice-cold, to give α-chlorohexanal 
228 in 63% yield. α-Chlorohexanal could further be converted to α-iodo-hexanal 229 on 
treatment with NaI, in 37 % yield. 
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Scheme 62: Synthesis of α-chloro and α-iodo hexanal by method of MacMillan et al. 
 
4.2.3  Hydroacylation of functionalised aldehydes 
Synthesis of functionalised aldehydes proved quite difficult as aldehydes can be 
difficult to handle, and prone to self condensation or decomposition. The functionalised 
aldehydes 219, 226, 228, 229 and the commercially available aldehyde 231 were treated 
with PFP-vinyl sulfonate in dioxane (Scheme 63 and 65). Treatment of the silyl-
protected aldehyde 219 in dioxane with PFP-vinyl sulfonate at 21 °C showed no product 
formation after 3 days, and subsequent heating at 60 °C led to its decomposition. 
Reaction of the lactol 226 with PFP-vinyl sulfonate led to no reaction even after mixing 
for 5 days at 21 °C and reflux for 24 h.  
R H
O
210
R
O
SO3PFP
SO3PFP
Dioxane, 21 oC
24 h
 R =
ICl
HOTBDPSO
229228226219  
Scheme 63: Functionalised aldehydes tested in the radical reaction. 
α-Chlorohexanal 228 was evaluated in the hydroacylation reaction with stirring for two 
days at 21 °C, then at 40 °C for two days, and then at reflux for 1 h. No product 
formation was observed. Crude 1H NMR of the reaction mixtures suggested that 
elimination of HCl from aldehyde 228 had taken place. Doping the reaction with 3-
chlorobutan-2-one (Table 9, entry 1) showed that the chlorinated molecule had no effect 
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on hydroacylation, and treatment of hexanal in dioxane with PFP-vinyl sulfonate 
resulted in the formation of the addition product 230 in 74% after 6 h (Scheme 63), 
suggesting that the reaction with the α-chloroaldehyde should occur, hence having a 
chlorine at the α-position has an inhibitory effect on the autoxidation of the aldehyde.  
Similarly, α-iodoaldehyde 229 failed to autoxidise and react with PFP-vinyl sulfonate in 
dioxane. The crude NMR did not show any change after 5 days at 21 °C. This suggests 
the iodide prevents autoxidation of aldehyde 229, and hence addition to PFP-vinyl 
sulfonate. This was indeed indicated by the doping experiments with iodide molecules, 
which predicted that hydroacylation will be inhibited. 
H
O SO3PFP O
SO3PFPdioxane, 21 oC
6 h, 74%
230
 
Scheme 64: Hydroacylation of hexanal. 
The commercially available 7-hydroxycitronellal 231 underwent the addition leading to 
product 232 in 78% yield after 16 h (Scheme 65). This showed that the presence of an 
alcohol functionality can be tolerated and appears not to hinder the autoxidation of the 
aldehyde, or its subsequent addition to PFP-vinyl sulfonate. This is consistent with the 
doping experiments, which showed that the alcohol functional group is tolerated in 
radical hydroacylation.  
231
H
O
HO
232
O
SO3PFPHO
SO3PFP
Dioxane, 21 oC
16 h, 78%  
Scheme 65: Hydroacylation of 7-hydroxycitronellal. 
 
4.3  In situ elimination and conjugate addition of ketosulfonate 205 
Acyl radicals, which are nucleophilic, add readily to electron poor alkenes but addition 
to neutral or electron rich alkenes 233 for the formation of ketone 234, is sluggish and 
difficult to carry out (Section 3.3). 63,98  Another method of gaining entry to ketone 234 
is via hydroacylation of vinylsulfonates 202, followed by base catalysed elimination and 
conjugate addition (Scheme 66). This potentially circumvents the difficulty associated 
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with hydroacylation of electron rich alkenes, and can produce molecules which would 
otherwise be difficult to access. 
R
O
Nu
R H
O
SO3Ar
1)
2) base, Nu-
R H
O Nu
140 234 202
233
 
Scheme 66: Formation of ketone 234. 
 
Caddick et al. showed that an aldehyde could be converted to an enone via 
hydroacylation and elimination.83 Treatment of hydroacylation product 205 with DBU 
led to the formation of enone 235 which could be trapped in situ by thiols, to form β-
keto sulfides 236 (Scheme 67). Enone synthesis from aldehydes usually requires 
oxidising conditions or metal reagents,99,100 and hence this is a clean method of enone 
generation, where the subsequent enone can potentially undergo a wide range of 
conjugate addition reactions.101  
O
SO3PFP
O
SR
O
RSHDBU
CH2Cl2205 235 236  
Scheme 67: Elimination and in situ conjugate addition. 
Caddick et al. have carried this out with thiols, and it was envisaged that the set of 
nucleophiles could be utilised for conjugate addition to enone 235, formed in situ via 
elimination of ketone 205.83 Nucleophiles that could be used for conjugate addition 
include nitrogen, oxygen, carbon, and phosphorus nucleophiles and an initial attempt 
with hexane thiol worked smoothly to furnish 243 in quanititative yield (Table 10, entry 
1). 
Treatment of ketone 205 with DBU and dimethyl malonate failed to produce any new 
spots by tlc after 24 h, and enone peaks were not visible in the crude 1H NMR. Hence, 
DBU may not have been a suitable base to deprotonate the acidic proton from the 
malonate, or the enone may have polymerised before addition of malonate occurred. 
Other bases were hence tried; K2CO3 is used by Gervais et al. as a base for the addition 
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of malonate to enones at room temperature.102 This base was used in methanol to 
promote the elimination and malonate deprotonation steps, furnishing conjugate 
addition product 244 in 23% yield after 3 h (Table 10, entry 2). However, use of NaH as 
the base resulted in no product formation, and the use of NaOEt in ethanol, led to the 
displacement of methyl esters to form product 245 in 11% yield (Table 10, entry 4). 
Campana et al. used sodium tetramethoxyborate to catalyse Michael reactions at room 
temperature.103 Sodium tetramethoxyborate was readily synthesised by refluxing 
sodium borohydride in methanol and used in the conjugate addition of malonate to 
enone 205, which furnished the product 244 in 63% yield over 24 h (Table 10, entry 3).  
Two nitrogen nucleophiles were evaluated, a good nitrogen nucleophile, morpholine, 
and a weaker nucleophile, aniline. Reaction with morpholine yielded an impure addition 
product after 1 h, which could not be purified to homogeneity by flash chromatography, 
the impurity was presumed to be the sulfonamide 237 arising from the attack of the 
morpholine of the PFP-sulfonate moiety (Figure19). Hence, to circumvent sulfonamide 
formation, DBU and ketone 205 were first stirred for 20 minutes before the addition of 
morpholine, and this led to the clean formation of 246 in 80% yield after 1 h (Table 10, 
entry 5). Conjugate addition with aniline did not go to completion after 24 h. The 
absence of enone peaks in the crude NMR, suggested that the enone may have 
polymerised before the aniline could add, hence the conjugate addition product 247 was 
isolated in 38% yield (Table 10, entry 6).  
237
O
S
N
O
OO
 
Figure 19: Possible sulfonamide from attack of morpholine on PFP-sulfonate. 
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Triethylphosphite was used in an Arbuzov-type reaction. Treatment of ketone 205 with 
DBU in triethylphosphite in methanol heated at 100 °C under microwave heating 
conditions, gave 77% of a mixture of products 238, 239 and 240 (Scheme 68). Hence 
carrying the reaction out in ethanol led to the clean formation of product 239 in 90% 
yield (Table 10, entry 8).  
O
SO3PFP
DBU, CH3OH
P(OEt)3, MW,
O
P
205 238 239
240
+
+
100 oC, 1 h
OMe
O
OMe O
P OEt
O
OEt
O
P OEt
O
OMe
 
Scheme 68: Mixture of product from reaction in methanol. 
Peroxide can act as an oxygen nucleophile and adds to conjugated systems to form 
peroxides. For example, Antczak et al. reacted 3-butenone with hydrogen peroxide and 
NaOH to get the epoxy-ketone 241 in 60% yield (Scheme 69).104 However, treatment of 
ketone 205 with DBU, with H2O2 and NaOH did not succeed in forming the epoxy-
ketone product. 
O
H2O2 (30 mol%), NaOH,
0 oC    22 oC, 2 h, 60%
O
O
235 241
MeOH
 
Scheme 69: Epoxide formation via conjugate addition. 
We also considered sodium ethoxide as an alternative oxygen nucleophile which might 
add to enone 235. Treatment of ketone 205 with DBU and NaOEt in ethanol led to the 
formation of the addition product 248 in 41% by NMR. However, the product could not 
be isolated as the product seemed to decompose on silica (Table 10, entry 7). 
Hence, these reactions show carbon, nitrogen, phosphorus and oxygen nucleophiles are 
successful in conjugate addition reactions of enone 235, generated in situ from the 
sulfonate 205. Only a limited number of hydroacylations of vinyl phosphonates and 
enamides have been carried out successfully. For example, treatment of butanal with 
benzoyl peroxide and diethylvinyl phosphonate by Rakhimov et al., led to the formation 
88 
 
of the hydroacylation product in 54% yield after 8 h of heating.105 Hence, the present 
approach utilising, the elimination and conjugate addition approach by 
triethylphosphate, seems a much faster and higher yielding reaction as compared to the 
hydroacylation of electron rich vinyl phosphonate. Roberts et al. used a thiol catalyst 
methylthioglycolate for hydroacylation of butanal with enamides N-vinylpyrrolidin-2-
one and N-vinylphthalimide in 62% and 50% yields repectively.106 Hence, conjugate 
addition to enone 235 with nitrogen nucleophiles is a complimentary method to existing 
methods based on direct hydroacylation reaction of electron rich enamides. The results 
with triethylphosphite and morpholine and aniline, show that this method can be used 
for the formation of products that would otherwise be difficult to generate by direct 
hydroacylation of electron-rich alkenes. 
  
89 
 
O
SO3PFP
base, CH2Cl2
21 o C, Nu-
O
Nu
242205  
Entry Nucleophile Base  Solvent Time 
(h) 
Product yield (%) yield 
1 C6H13SH DBU DCM 1 O
SC6H13
243  
>99 
2 Dimethyl 
malonate 
 K2CO3 MeOH 3 O
CO2Me
CO2Me244  
23 
3 Dimethyl 
malonate 
 DBU, 
NaB(OMe)4 
MeCN 24 244 63 
4 Dimethyl 
malonate 
NaOEt  EtOH, 48 O
CO2Et
CO2Et245  
11 
5 Morpholine DBU DCM 1.2 O
N
O246  
80 
6 PhNH2 DBU DCM 24 O
N
H247  
38 
7 NaOEt in 
EtOH 
DBU EtOH 1 O
O
248  
381 
8 P(OEt)3  DBU EtOH 12 
239
O
P OEt
O
OEt
 
90 
1Based on internal standard pentachlorobenzene  2Heated in MW at 100 °C 
Table 10: Elimination and conjugate addition by different nucleophiles. 
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4.4 Pivaldehyde decarbonylation 
 
4.4.1  Decarbonylation of acyl radicals 
One of the difficulties associated with the synthetic utility of acyl radicals is their 
propensity to undergo decarbonylation to generate alkyl radicals. For decarbonylation to 
occur, it must be faster than the rate of acyl radical reduction to the aldehyde, and acyl 
radical addition to an acceptor, and the ease of decarbonylation depends on the stability 
of the newly generated radical. 
Decarbonylation of acid chlorides and selenoesters occur with direct reduction to give 
the corresponding alkane, with tributyl tinhydride or trimethylsilylhydride as reducing 
agents.63 For example, Chatgilialoglu et al. treats acid chlorides 249 and 250 with 
(TMS)3SiH to furnish the secondary and tertiary alkanes cyclohexane and adamantane 
in 92% and 90% yields respectively (Scheme 70).107  
Cl
O
(TMS)3SiH
 AIBN, 80 oC 92%
ClO
(TMS)3SiH
 AIBN, 80 oC 90%
toluene
toluene
249
250  
Scheme 70: Decarbonylation of acid chlorides. 
An example of decarbonylation of a selenoester is demonstrated by Stojanovic et al.  
who show that the α-amino phenyl selenoester 251 can be reduced to the corresponding 
alkane 252 under tributyltin hydride conditions in 90% yield, and the alkyl radical can 
be captured by methyl acrylate to furnish 253 in 50% yield (Scheme 71).108 
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Scheme 71: Decarbonylation of selenoester. 
Although authors have used acyl radical precursors for the formation of acyl radicals 
(Section 3.4) and the subsequent decarbonylation to alkyl radicals, for the formation of 
alkyl compounds, Caddick et al. reported the reaction of pivaldehyde with TCP-vinyl 
sulfonate 254 in air, which resulted in the a 1:8 mixture of alkylated:acylated product 
207 and 206 at 50 °C (Scheme 72).82 Selectivity as high as 1:11 of 206:207 could be 
achieved at 60 °C, and the authors propose that at higher temperatures, the unimolecular 
decarbonylation of the acyl radical would be accelerated. 
O
H SO3TCP
Dioxane

+
162 254
O
SO3TCP
206
SO3TCP
207
+
 
Scheme 72: Pivaldehyde 162 addition to TCP-vinyl sulfonate 254. 
 
4.4.2  Decarbonylation of pivaldehyde 
The aim of this work was to show that it can be possible to use aldehyde autoxidation of 
aldehydes as a route to alkyl radicals via decarbonylation, and initial investigations 
concentrated on attaining a higher selectivity for this reaction via complete 
decarbonylation to the t-butyl radical, and thence capture by PFP-vinyl sufonate. 
Optimisation of this reaction under thermal conditions was carried out in water with two 
equivalents of aldehyde to alkene, and 0.05 mol% peroxide but these conditions failed 
to give complete decarbonylation of pivaldehyde (Table 11, entries 1-3). Selectivity as 
high as 23:1 for the 255:256 product was achieved at 100 °C using 5 equivalents of 
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pivaldehyde to 1 equivalent of PFP-vinyl sulfonate in dioxane, and an isolated yield of 
70% (Table 11, entry 5).  
O
H SO3PFP
Dioxane

+
O
SO3PFP
256
SO3PFP
255
+
 
Entry Temperature (°C) Solvent Initiator  Ratio of 
255:256 
1 75 H2O H2O2 4:1  
2 100 H2O H2O2 7:1 
3 125 H2O H2O2 9:1 
4 75 dioxane – 16:1 
5 100 dioxane – 23:1 
 
Table 11: Optimisation of decarbonylation of pivaldehyde. 
 
4.4.3  Optimisation of reaction in microwave 
When carried out under microwave heating at 100 °C for 3 h, the reaction does not 
proceed to completion due to pressure build-up in the microwave tube (Table 12). 
However, repeated reactions in the microwave for 10 mins x 3, with venting after each 
10 min, led to the complete consumption of the PFP-vinyl sulfonate. This suggested that 
high CO pressure in the reaction vessel from the decarbonylation of the pivaldehyde 
prevented the forward reaction. The reaction was further carried out in the microwave in 
1 min intervals with regular venting. After 7 x 1 min the reaction was complete with a 
65% yield of only the alkylated product 255. 
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Aldehyde 
scale 
Time (h) Temperature 
(°C) 
PFP-vinyl sulfonate 
conversion1 
% Yield2 (255:256) 
 
 
1 mmol  
Scale  
3 h 100 35 – 
1 h 150 40 45% (1:0.04) 
3 x 10 min 100 100 – 
30 min 100 30 – 
10 x 1 min 100 100 61% (1:0) 
7 x 1 min 100 100 65% (1:0) 
 
0.25 mmol  
10 min 100 100 – 
5 min 100 100 – 
2 min 100 100 80% isolated (1:0) 
1 tlc monitoring of  PFP-vinyl sulfonate consumed   2 NMR yields using pentachlorobenzene as an 
internal standard unless otherwise stated. 
Table 12: Optimisation of pivaldehyde deacrbonylation in the microwave. 
Scaling down the reaction to 0.25 mmol of pivaldehyde led to further optimisation of 
the reaction at 2 mins, with an isolated yield of 80% alkylated product. Scaling down 
the amount of pivaldehyde used kept the CO pressure in the microwave tube low 
enough for the reaction to proceed to completion.  
The microwave reactions showed that the reaction needed an open vessel, or a large 
enough vessel to fill the overhead space with the carbon monoxide produced. However, 
in order to produce alkyl radicals from acyl radicals under microwave conditions there 
was a clear requirement for venting the reaction mixture, and despite the reduced 
reaction time and good yield, it was felt that this protocol was not particularly practical. 
Hence, the thermal reaction optimised at 100 °C with 5 equivalents of pivaldehyde and 
one equivalent of PFP-vinyl sulfonate in dioxane, was chosen to investigate t-butyl 
radical addition to different acceptors (Table 11, entry 5). 
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4.4.4 Investigations on the reaction of tert-butyl radical addition reactions using 
pivaldehyde as a precursor 
Addition of the t-butyl radical to electron deficient alkenes was evaluated using the 
aforementioned thermal conditions. The t-butyl radical added to PFP and TCP-vinyl 
sulfonates in relatively good yields, 70% and 64% respectively at 100 °C after 3 h 
(Table 13, entries 1 and 2). The addition to ethyl vinyl sulfone is relatively fast 
compared to all the other alkenes used, proceeding to completion in only 40 min to 
furnish 261 (Table 13, entry 5).  
Addition to maleate and fumarates required longer reaction times of, 6 and 7 h, and 
addition to dimethyl maleate is relatively low yielding furnishing 164 in 46% yield 
(Table 13, entries 6-8). t-Butyl addition to dimethylvinyl phosphonate first led to a 34% 
yield of 264, and took 4 h for 100% conversion of the phosphonate, however 
purification of the compound from its polymer residue led to an increase in yield to 50% 
in 2.5 h (Table 13, entry 10). Addition to dimethyl 2-ethylidenemalonate only 
proceeded with a 10% yield of 263 and needed an increase in temperature and reaction 
time (Table 13, entry 9). This is presumably due to steric hindrance provided by the 
allyl group on the malonate. Further steric bulk on the malonate on compound 265 
(Figure 20), appears to prevent the addition of the t-butyl radical altogether. Addition to 
maleic anhydride 266, and maleimide 267, does not occur, and polymeric residue is 
observed in these reactions presumably due to polymerisation of these compounds. 
O
O
O
O
O
O
O
O
NH
O
O
265 266 267  
Figure 20: Acceptors for t-butyl addition. 
These results are comparable to literature methods for the addition of the t-butyl group 
to vinylsulfones and sulfonates, which include tin-mediated t-butyl iodide addition to 
TCP-vinyl sulfonate in 88% yield, and in a 64% yield under EPHP-BEt3/air mediated 
conditions.109 Addition of t-butyl to vinyl sulfones, sulfonates, and maleate is slightly 
lower than those achieved by Zhao et al. using Zn/Cu reagents and by Esposti et al. who 
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uses decatungstate agent TBADT.68,122  However, considering the only reagent used in 
the reaction is air, these reactions are atom economical and avoid waste production or 
expensive reagents. Hence, although the addition reaction of the t-butyl group derived 
from pivaldehyde are lower yielding, they are advantageous in that they don’t require 
metal reagents, especially tin which is toxic and difficult to get rid of, and hence this 
method of t-butyl addition is complimentary to current methods in the literature. 
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Dioxane
H
O
EWG
EWGair, 100 oC
+
257  
Entry Acceptor Time 
(h) 
Decarbonylated 
product 
yield (%) 
1 SO3PFP  
3 
SO3PFP
258  
70 
2 SO3TCP  
3 
SO3TCP
207  
64 
 
3 SO3Ph  
3 
SO3Ph
259  
76 
4 SO3Et  
4 
SO3Et
260  
54 
5 SO2Et  
0.66 
SO2Et
261  
53 
6 MeO2C CO2Me  
6 
CO2Me
MeO2C
164  
63 
7 MeO2C CO2Me
 
6      164  46 
8 EtO2C CO2Et
 
7 
CO2Et
EtO2C
262  
55 
9 CO2MeMeO2C
 
120 CO2MeMeO2C
263  
10 
11 
P OMe
O
OMe  
2.5 
264
P OMe
O
OMe
 
50 
 
Table 13: Addition of t-butyl radical to electron-deficient alkenes. 
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4.4.5  Secondary aldehydes 
With the success of the decarbonylation of pivaldehyde to the t-butyl radical and its 
subsequent addition to alkenes, it was considered that decarbonylation of secondary 
aldehydes may provide a viable route to secondary alkyl radicals. Three secondary 
aldehydes, cyclohexanecarbaldehyde 269, 2-ethylhexanal 270, and 2-phenyl propanal 
271, were screened for decarbonylation and capture by PFP-vinyl sulfonate at 100 °C 
(Table 14). At 100 °C aldehyde 271 failed to decarbonylate, aldehydes 269 and 270 
showed more promising results with decarbonylated products seen in the crude NMR. 
Addition product from the cyclohexyl radical seemed to decrease with temperature. 
Addition products from the 2-ethyl hexane radical seemed to form both the alkyl and 
acyl addition products without much selectivity. Hence, it was clear that this method 
was not efficient for decarbonylation for secondary aldehydes.  
SO3PFP
R
O
H R
O
SO3PFP
A
R
SO3PFP
B
+dioxane, 3 h
 
R
O
H  
Temperature (°C) A(acyl)* B(alkyl)* 
269  R = c-C6H6 100 0 46 
 130 0 38 
270  R  = C4H9CH(C2H5) 100 3 4 
 130 13 15 
271  R = PhCH(CH3) 100 0 0 
*Percentage isolated 
Table 14: Decarbonylation of secondary aldehydes. 
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4.5  Summary 
Functional group compatibility on the aldehyde in the hydroacylation reaction was 
carried out. In the first instance experiments using small molecule dopants, predicted 
iodo and acetylene functionalities would hinder hydroacylation, and a large number of 
dopants containing alcohol, keto and ester functionalities did not effect hydroacylation 
(Table 9). Synthesis of functionalised aldehydes proved difficult, with decomposition 
observed in short chain aldehydes. However, Swern oxidation of an alcohol provided a 
silyl protected aldehyde 219 and DIBAL reduction provided a lactol 226, unfortunately 
neither of these were successful in autoxidation/ hydroacylation. Enamine alkylation led 
to the synthesis of α-iodo and α-chloro hexanal, which did not seem to autoxidise or add 
to PFP-vinyl sulfonate in dioxane. Commercially available 7-hydroxycitronellal did, 
however add readily to PFP-vinyl sulfonate in a 78% yield demonstrating the feasibility 
of autoxidation of functionalised aldehydes.  
Hydroacylation of pivaldehyde led to two products, the addition of the acyl radical as 
well the addition of the decarbonylated t-butyl radical. Further investigations into 
hydroacylation of pivaldehyde led to the optimisation of the thermal decarbonylation of 
pivaldehyde at 100 °C. Microwave optimisation also led to the optimisation of this 
decarbonylation after just two minutes with an 80% isolated yield when carried out on a 
small scale. However, neither the protocol or scale were practical for synthetic use. 
Hence, thermal conditions were used to add the t-butyl radical to a number of different 
acceptors in relatively good yields. This is a novel and extremely simple method of 
attaching the t-butyl moiety on to a wide range of alkenes including vinyl sulfonates, 
malonates and vinyl phosphonates. These results are as yet unpublished and is 
complementary to literature methods used for the addition of t-butyl species using metal 
reagents.  
The hydroacylation product ketone 205 undergoes elimination in situ and conjugate 
addition by nucleophiles. Conjugate additions were carried out using carbon, nitrogen, 
oxygen and phosphorus nucleophiles, and establishes this approach as an effective 
method for the synthesis of products which are the products derived from formal 
hydroacylation of electron-rich alkenes. 
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Functional group compatibility experiments using small molecule dopants, predicted 
iodo and acetylene functionalities would hinder hydroacylation. Synthesis of 
functionalised aldehydes proved difficult, with decomposition observed in short chain 
aldehydes. However, Swern oxidation of an alcohol provided a silyl protected aldehyde 
and DIBAL reduction provided a lactol, unfortunately neither of these were successful 
in autoxidation/ hydroacylation. Enamine alkylation led to the synthesis of α-iodo and 
α-chloro hexanal, which did not seem to autoxidise or add to PFP-vinyl sulfonate in 
dioxane. Commercially available 7-hydroxycitronellal did, however add readily to PFP-
vinyl sulfonate in a 78% yield demonstrating the feasibility of autoxidation of 
functionalised aldehydes.  
Investigations into hydroacylation of pivaldehyde led to the optimisation of the thermal 
decarbonylation of pivaldehyde at 100 °C. Microwave optimisation also led to the 
optimisation of this decarbonylation but neither the protocol or scale were practical. 
Hence, thermal conditions were used to add the t-butyl radical to a number of different 
acceptors in relatively good yields. This is complementary to literature methods used for 
the addition of t-butyl species using metal reagents.  
The hydroacylation product ketone 205 undergoes elimination in situ and conjugate 
addition by nucleophiles. This was carried out using carbon, nitrogen, oxygen and 
phosphorus nucleophiles, and establishes this approach as an effective method for the 
synthesis of products which are the products derived from formal hydroacylation of 
electron-rich alkenes. 
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Chapter 5: Experimental 
 
5.1  Biology for Chapter 2 
Tissue Culture: DDAH1 and D2M2 cells (Skin Endothelial cells over-expressing Myc-
tagged DDAH1 and Myc-tagged DDAH2, respectively) were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM), supplemented with 1 mM glutamine, 10% FBS 
and penicillin in a humidified incubator at 37 oC with 5% CO2. The cells were divided 
every 2 or 3 days, when they became confluent. 
Immunoprecipitation of DDAH1 and DDAH2: Immunoprecipitation of Myc-DDAH1 
and Myc-DDAH2 was achieved with a ProFound mammalian c-Myc Tag IP/co-IP Kit 
(Pierce Biotechnology, Rockford, IL, USA). The cells from T75 flasks (x 10) were 
collected and lysed in 1 ml of lysis buffer (supplied with the kit). Lysates were then 
incubated with anti-Myc antibody (overnight at 4 C), and then after washes with TBS-
T, the protein was eluted with gentle elution buffer (Pierce Biotechnology, Rockford, 
IL, USA). 
Protein Assay: Six serial dilutions of standard protein were made by dilutions with 
PBS to give a standard curve: 0.5 µM, 0.4 µM, 0.25 µM, 0.20 µM, 0.10 µM, 0.05 µM, 0 
µM. The standard protein and the cell lysate were added to a 96 well plate and 200 µL 
of Bradford Reagent (Biorad, Hemel Hempstead, UK) was added. The absorbance was 
measured at 630 nm using a plate reader and the protein concentration of each sample 
were calculated. 
Preparation of Homogenates: The rat kidneys were homogenised by crushing under 
liquid nitrogen using a mortar and pestle that had been already placed in -80 oC. The 
homogenised tissues were then resuspended in ice-cold PBS with Protease Inhibitor 
(Roche, Hertfordshire, UK). The homogenates were then ultracentrifuged for 40 min, at 
4 oC, >50,000 RPM. After spinning, the fat from the supernatant was removed, and the 
supernatant (protein lysate) removed into a new tube and analysed for DDAH activity. 
CH2Cl2 
DDAH Assay: For DDAH assays, [14C]-L-NMMA was used as a substrate and [14C]-
citrulline was detected as a product. Concentrations of 1 M, 10 M, 30 M, 100 M, 
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300 M and 500 M of the DDAH inhibitors, L291, 22 and 24, were added to 50 L of 
rat kidney tissue lysate or to the purified DDAH1 and DDAH2. The standard assay 
mixture contained 1500 L PBS, 3 µL L-NMMA (100 mM stock) and 1.5 L 14C L-
NMMA. 50 L of the assay mixture was added to all the lysate and PBS samples, and 
then the reaction was initiated by incubation at 37 oC and 4 C for 1 hr. All assays were 
performed in triplicate. The reaction was then terminated by the addition of 500 L of 
cation exchange resin (Dowex 50wx8, pH 7.0). The samples were vortexed and 
centrifuged at 13000 rpm for 3 min. 100 L of the supernatant was then taken and 
mixed with 5 mL of liquid scintillation fluid and the [14C] L-Citrulline content was 
determined by using B-scintillation counting (Hewlett Packard). 
  
102 
 
5.2  Chemistry 
 
5.2.1  General Experimental 
All reagents and solvents were used as received without further purification, unless 
otherwise stated. Reactions were monitored by TLC on Merck SIL G/UV254 plates 
purchased from VWR and were visualised under UV lamp operating at short and long 
wavelength ranges with alkaline potassium permanganate solution. Flash column 
chromatography was carried out with Kieselgel 60M 0.04/0.063nm (230-400 mesh) 
silica gel. All yields quoted are isolated yields. All reactions were carried out at room 
temperature (rt) unless otherwise stated. 
Instrumentation: Microwave reactions were carried out in the CEM Discover™ 
system. 1H NMR spectra were recorded at 300 MHz, 400 MHz, 500 MHz and 600 MHz 
and 13C NMR at 75 MHz, 100 MHz, 125 MHz and 150 MHz on a Bruker AMX300, 
AMX400, AMX500 and AMX600 respectively at ambient temperature unless otherwise 
stated. The chemical shifts () for 1H and 13C are quoted relative to residual signals of 
the solvent on the ppm scale. Coupling constants (J values) are reported in Hertz (Hz). 
Multiplicies for 1H NMR are reported as singlet (s), doublet (d), triplet (t), quartet 
(q), sextet, broad (br) and multiplet (m); or some combination of these. 
Multiplicies for 13C NMR were determined using distortionless enhancement by phase 
transfer (DEPT) spectral editing technique and are reported as singlet (s), doublet (d), 
triplet (t), quartet (q), based on the anticipated multiplicity in a non-decoupled 
spectrum. **For compounds bearing a pentafluorophenyl the 13C NMR signals 
from this group are not reported due to a high degree of C-F coupling. Mass 
spectra were obtained on a VG70-SE mass spectrometer, a MAT 900 XP spectrometer 
or at National Mass Spectrometry Service, Swansea. Infrared spectra were obtained on a 
Shimadzu FTIR-8700 Fourier Transform Infrared Spectrophotometer or Perkin Elmer 
Spectrum 100 FTIR Spectrometer operating in ATR mode. Melting points were 
measured with a Gallenkamp apparatus and are uncorrected. Elemental analysis was 
performed at the Department of Chemistry, University College London. 
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5.2.2  Experimental for Chapter 2 
 
1,3-Bis(tert-butoxycarbonyl) thiourea110 45 
BocHN NHBoc
S
 
 
NaH, 60% in mineral oil (1.94 g, 80.9 mmol, 4.5 eq.) was added to a stirred solution of 
thiourea (1.37 g, 17.9 mmol, 1 eq.) in dry THF (250 mL) under argon at 0 °C. The ice 
bath was removed after 5 min and the reaction mixture was stirred at rt for 10 min. The 
reaction mixture was cooled to 0 °C again, di-tert-butyl dicarbonate (4.35 g, 39.6 mmol, 
2.2 eq.) was added, and the ice bath was removed after 30 min of stirring at that 
temperature. The resulting slurry was stirred for another 2 h at 21 oC and quenched with 
saturated NaHCO3 solution (70 mL). The reaction mixture was poured onto water (350 
ml) and extracted with ethyl acetate (3 x 150 mL). The combined organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo. Purification by column 
chromatography eluting with petrol/Et2O (1/1) gave the title compound as a white solid 
(2.3 g, 45% yield): m.p. 102-106 °C; 1H NMR (300 MHz, CDCl3) δ 9.19 (br s, 2H), 
1.51 (s, 18H);  13C NMR (75 MHz, CDCl3) δ 177.7 (s), 150.3 (s), 84.1 (s), 27.9 ( q); IR 
(neat) 3178, 2983, 1770, 1720 cm-1; LRMS (ES+) 299 (10%, [M+Na]+), 199 (12), 176 
(100), 154 (23).  
 
 
1,3-Bis-(tert-butoxycarbonyl)-S-methyl-thiopseudourea111 43 
BocN NHBoc
S
 
 
Solid K2CO3 (7.9 g, 57 mmol) and MeI (2.2 mL, 36 mmol) was added to a solution of 
1,3-bis(tert-butoxycarbonyl) thiourea 45 (8.0 g, 28 mmol) in dry acetonitrile (250 ml) 
and refluxed at 60 °C for 1 h. The reaction mixture was filtered under vacuum and the 
solvent removed in vacuo. Purification by flash chromatography eluting with 
petrol/Et2O (9/1) gave the title compound as a white solid (6.83 g, 84% yield): m.p. 
126-128 °C; 1H NMR (300 MHz, CDCl3) δ 3.10 (s, 1H), 2.37 (s, 3H), 1.53 (s, 9H), 1.51 
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(s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.4 (s), 160.7 (s), 150.7 (s), 83.2 (s), 80.9 (s), 
28.0 (2 x q), 14.4 (q): IR (neat) 3100, 2983, 1747, 1651 cm-1; LRMS (EI) 290 (19% 
[M]+•), 234 (68), 178 (91), 161 (100), 134 (56). 
 
 
1,3-Bis-(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-isothiourea 95 
BocN N
Boc
S
O
 
 
2-Methoxy ethanol (1.7 mL, 21.7 mmol) and PPh3 (5.4 g, 21.7 mmol) were added to a 
solution of 1,3-bis-(tert-butoxycarbonyl)-S-methyl-thiopseudourea 43 (4.2 g, 14.4 
mmol) in THF (75 mL). The solution was cooled to 0 °C and treated dropwise with 
Diethyl azodicarboxylate (3.4 mL, 21.7 mmol). The reaction was further stirred at 0 °C 
for 30 min and then at 21 oC for 24 h. The solvent was removed in vacuo and 
purification by flash chromatography eluting with petrol/EtOAc (9/1) gave the title 
compound as a colourless oil (7.74 g, 94% yield):  1H NMR (300 MHz, CDCl3) δ 3.74 
(t, J = 6.0 Hz, 2H), 3.55 (t, J = 6.0 Hz, 2H), 3.33 (s, 3H), 2.39 (s, 3H), 1.50 (s, 9H), 1.47 
(s, 9H); 13C NMR (75 MHz, CDCl3) δ 163.4 (s), 158.0 (s), 151.9 (s), 82.5 (s), 81.9 (s), 
70.0 (t), 58.6 (q), 47.8 (t), 28.0 (2 x q), 15.6 (q); IR (neat) 2979, 2931, 1716, 1616 cm-1; 
LRMS (ES+) 349 (100%, [M+H]+), 193 (7), 101 (95); HRMS (ES+) calc. For 
C15H29O5N2S 349.1797 [M+H]+, found 349.1799.    
 
 
 
(S)-Methyl-5-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) 
pentanoate  91 
FmocHN O
O
NHBoc  
 
Triethylamine (0.37 mL, 2.64 mmol) and MeI (0.16 mL, 2.64 mmol) were added to a 
stirred solution of Boc-L-Orn(Fmoc)-OH (400 mg, 0.88 mmol) in CH2Cl2 (5 mL) and 
the reaction was stirred for 24 h. The solvent was removed in vacuo. Purification by 
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flash chromatography eluting with petrol/Et2O (1/2) gave the title compound as a white 
solid (391 mg, 95% yield): m.p. 120-122 °C; 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 
6.0 Hz, 2H), 7.55 (d, J = 9.0 Hz, 2H), 7.42-7.37 (m, 2H), 7.33-2.25 (m, 2H), 5.07 (br s, 
1H), 4.91 (br s, 1H), 4.40 (d, J = 9.0 Hz, 2H), 4.32-4.30 (m, 1H), 4.20 (t, J = 9.0 Hz, 
1H), 3.73 (s, 3H), 3.22-3.12 (m, 2H), 1.82-1.59 (m, 4H), 1.45 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 173.1 (s), 156.5 (s), 155.5 (s), 143.9 (s), 141.3 (s), 127.7 (d), 127.0 (d), 
125.1 (d), 119.9 (d), 80.0 (s), 66.5, (t), 66.0 (t), 52.4 (q), 47.3 (d), 40.5 (t), 30.3 (d), 28.3 
(q), 25.9 (t) ; IR (neat) 3361, 2961, 2925, 1744, 1690 cm-1; LRMS (ES+) 491 (100%, 
[M+Na]+), 435 (94), 391 (89); HRMS (ES+) calc. For C26H32O6N2Na 491.2158 
[M+Na]+, found 491.2169.    
 
 
(S)-Benzyl-5-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) 
pentanoate 92 
FmocHN O
O
NHBoc  
 
Triethylamine (0.18 mL, 1.32 mmol) and benzylbromide (0.16 mL, 1.32 mmol) were 
added to a solution of Boc-L-Orn(Fmoc)-OH (0.2 g, 0.44 mmol) in CH2Cl2 (5 mL) and 
the reaction was stirred for 24 h. The reaction mixture was diluted with CH2Cl2 (5 mL) 
and washed with sat. NaHCO3 (2 x 5 mL). The organic layer was dried over MgSO4, 
filtered, and the solvent evaporated in vacuo. Purification by flash chromatography 
eluting with petrol/Et2O (1/2) gave the title compound as a white solid (0.22 g, 91% 
yield): m.p. 91-93 °C; 1H NMR (300 MHz, CDCl3) δ 7.76 (d, J = 7.0 Hz, 2H), 7.58 ( d, 
J = 7.0 Hz, 2H), 7.42-7.28 (m, 9H), 5.22-5.14 (m, 3H), 4.83 (br s, 1H), 4.40-4.38 (m, 
3H), 4.2 (t, J = 7.0 Hz, 1H), 3.20-3.15 (m, 2H), 1.92-1.82 (m, 1H), 1.65-1.61 (m, 2H), 
1.49-1.46 (m, 1H), 1.44 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 172.4 (s), 156.5 (s), 
155.5 (s), 144.0 (s), 141.4 (s), 135.4 (s), 128.7 (d), 128.6 (d), 128.52 (d) 127.7 (d), 127.1 
(d), 125.1 (d), 120.0 (d), 80.0 (s), 67.1 (t), 66.5 (t), 53.2 (d), 47.3 (d), 40.4 (t), 30.0 (t), 
28.3 (q), 25.8 (t); IR (neat) 3500, 3055, 2985, 1716 cm-1; LRMS (FAB) 545 (10 % 
[M+H]+), 445 (24), 338 (35), 178 (100): HRMS (FAB) calc. for C32H37O6N2 545.2651 
[M+H]+, found 545.2634.    
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(S)-tert-Butyl 2-oxopiperidin-3-ylcarbamate112 98 
 
HN
O H
N
O
O
 
 
Piperidine (1 mL) was added to a stirred solution of (S)-benzyl-5-(((9H-fluoren-9-
yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) pentanoate 92 (145 mg, 0.27 
mmol) in DMF (3 mL) and stirred for 1 h. The solvent was evaporated in vacuo and 
purification by flash chromatography eluting with CHCl3/MeOH (99/1) gave the title 
compound as a clear oil (57 mg, >99% yield): 1H NMR (300 MHz, D2O): δ 3.98 (br s, 
1H), 3.31-3.28 (m, 2H), 2.13-2.06 (m, 1H), 1.97-1.89 (m, 3H), 1.45 (s, 9H); 13C NMR 
(300 MHz, D2O): δ 173.8 (s), 157.8 (s), 82.0 (s), 50.8 (d), 42.0 (t), 28.0 (q), 27.6 (t), 
21.0 (t); IR (neat) 3287, 2974, 1705, 1662 cm-1; LRMS (ES+) 237 (100% [M+Na]+), 176 
(23%); HRMS (ES+) calcd for C10H18N2O3Na [M+Na]+ 237.1215, observed 237.1211. 
 
 
 (S)-Methyl-5-(N', N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl)guanidino)-2-
(tert-butoxycarbonylamino)pentanoate113 93 
 
N
H
O
O
NHBoc
NBoc
N
Boc
O
 
 
Boc-L-Orn-OH (0.51 g, 2.20 mmol) and triethylamine (150 µL, 1.10 mmol) were added 
to a solution of 1,3-bis-(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-isothiourea 
95 (0.38 g, 1.10 mmol) in dry THF (8.0 mL) and refluxed for 48 h. The solvent was 
evaporated in vacuo and a mixture of the product and starting material acid was 
obtained by flash chromatography eluting first with petrol/EtOAc (4/1), then with 
CH2Cl2/MeOH (4/1). The crude product (0.81 g) was dissolved in CH2Cl2 (8 mL) to 
which was added Triethylamine (640 μL, 4.57 mmol) and MeI (280 µL, 4.57 mmol) 
and stirred for 24 h. The solvent was evaporated in vacuo and purification by flash 
chromatography eluting with petrol/EtOAc (1/1) gave an impure product. Further 
purification was needed by flash chromatography eluting with CHCl3/Et2O (3:1) which 
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gave the title compound as an off-white waxy solid (29 mg, 5% yield): 1H NMR (400 
MHz, CDCl3) δ 5.16 (br s, 1H), 4.30-4.20 (m, 1H), 3.91 (br s, 1H), 3.78-3.77 (m, 2H), 
3.72 (s, 3H), 3.64-3.49 (m, 2H), 3.32 (br s, 3H), 3.31-3.27 (m, 2H), 1.85-1.83 (m, 2H), 
1.67-1.63 (m, 2H), 1.47 (s, 9H), 1.45 (s, 9H), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) 
δ 172.8 (s), 156.4 (s), 155.3 (s), 155.3 (s), 143.9 (s), 80.0 (3 x s), 70.8 (t), 58.5 (d), 53.0 
(q), 52.4 (q), 40.8 (t), 40.4 (t), 29.6 (t), 25.8 (t), 28.3 (q), 28.2 (q), 28.1 (q); IR (neat) 
3337, 3055, 2931, 2858, 1702, 1697, 1685, 1655 cm-1; LRMS (ES+) 569 (58%, 
[M+Na]+), 469 (40), 347 (100); HRMS (ES+) calcd for C25H46N4O9Na [M+Na]+ 
569.3162, observed 569.3172. 
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(S)-Benzyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl)guanidino)-2-
(tert-butoxycarbonylamino) pentanoate29 94 
 
N
H
O
O
NHBoc
NBoc
N
Boc
O
 
 
Boc-L-Orn-OH (250 mg, 1.09 mmol) and triethylamine (300 µL, 2.19 mmol) was added 
to a solution of 1,3-bis-(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-isothiourea 
95 (250 mg, 0.73 mmol) in DMF (8 mL). The solution was stirred as a clear solution for 
10 min after which HgCl2 (0.36 g, 1.32 mmol) was added and the reaction mixture 
turned into a milky off-white suspension. The reaction mixture was further stirred for 
120 h. The solvent was evaporated in vacuo and a mixture of the product and starting 
material acid obtained by flash chromatography eluting first with petrol/EtOAc (4/1), 
then with CH2Cl2/MeOH (4/1). The crude product obtained (0.64 g) was dissolved in 
CH2Cl2 (10 mL) with stirring, to which was added triethylamine (430 µL, 3.09 mmol) 
and benzyl bromide (370 µL, 3.09 mmol). The reaction mixture was stirred for 24 h. 
The solvent was evaporated in vacuo and the crude product was purified by flash 
chromatography eluting with petrol/EtOAc (1/1). Further purification by flash 
chromatography eluting with CHCl3/Et2O (3:1) gave the title compound as an off-white 
waxy solid (110 mg, 24% over two steps): 1H NMR (300 MHz, CDCl3) δ 7.38-7.33 (m, 
5H), 5.17 (d, J = 15.6 Hz, 1H), 5.13 (d, J = 15.6 Hz, 1H), 4.35-4.33 (m, 1H), 3.76 (br s, 
2H), 3.48-3.46 (m, 2H), 3.26 (m, 5H), 1.86-1.85 (m, 2H), 1.63-1.53 (m, 2H), 1.47 (s, 
9H), 1.43 (s, 9H), 1.41 (s, 9H); ); 13C NMR (75 MHz, CDCl3) δ 172.2 (s), 155.4 (s), 
153.5 (s) 152.4 (s), 135.3 (s), 128.6 (d), 128.5 (d), 128.3 (d), 83.5 (3 x s), 82.1 (s),  79.9 
(t), 79.2 (t), 70.8 (t), 67.2 (t), 58.4 (d), 53.2 (q), 29.9 (t), 26.0 (t), 28.3 (q), 28.2 (q), 28.1 
(q); IR (neat) 3330, 2980, 2927, 1712, 1623, 1605 cm-1; LRMS (ES+) 645 (90%, 
[M+Na]+), 623 (100%, [M]+),  523 (98), 432 (92). 
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(S)-Methyl 2-amino-5-(N’-(2-methoxyethyl)guanidino)pentanoate hydrochloride29 
24 
N
H
O
O
NH2
NH
N
H
O
.HCl
 
 
A solution of the (S)-methyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl) 
guanidino)-2-(tert-butoxycarbonylamino)pentanoate 93 (29 mg, 0.05 mmol) in 4 M HCl 
in dioxane (3 mL) was stirred for 36 h. The solvent was removed in vacuo, dissolved in 
distilled water (5 mL) and freeze dried for 48 h giving the title compound as a waxy off-
white solid (16 mg, 99% yield): 1H NMR (300 MHz, D2O) δ 4.19 (t, J = 6.5 Hz, 1H), 
3.85 (s, 3H), 3.61 (t, J = 5.0 Hz, 2H), 3.39 (s, 3H), 3.40 (t, J = 5.0 Hz, 2H), 3.27 (t, J = 
6.5 Hz, 2H), 2.03-1.95 (m, 2H), 1.76-1.33 (m, 2H); 13C NMR (75 MHz, D2O) δ  172.7 
(s), 158.6 (s), 72.7 (t), 60.6 (t), 56.0 (d), 54.9 (q), 43.5 (t), 42.7 (t), 29.2 (q), 26.2 (t); 
LRMS (ES+) 246 (17%, [M]+), 201 (24), 178 (100), 130 (22). 
 
 
(S)-Benzyl 2-amino-5-(N’-(2-methoxyethyl)guanidino)pentanoate hydrochloride29 
90 
.HCl
N
H
O
O
NH2
NH
N
H
O
 
 
A solution of (S)-benzyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl) 
guanidino)-2-(tert-butoxycarbonylamino) pentanoate 94 (90 mg, 0.15 mmol) in 4 M 
HCl in dioxane (5 mL) was stirred for 48 h. The solvent was evaporated in vacuo, the 
compound dissolved in distilled water (5 mL) and freeze dried for 48 h to give the title 
compound as a waxy off-white solid (36 mg, 60% yield): 1H NMR (400 MHz, D2O) δ 
7.45-7.48 (m, 5H), 5.39 (d, J = 12 Hz, 1H), 5.26 (d, J = 12 Hz, 1H), 4.23 (t, J = 6.3 Hz, 
1H), 3.55 (t, J = 5.0 Hz, 2H), 3.36 (s, 3H), 3.34 (t, J = 5.0 Hz, 2H), 3.18 (t, J = 6.9 Hz, 
2H), 2.01-1.95 (m, 2H), 1.68-1.64 (m, 1H), 1.55-1.50 (m, 1H); 13C NMR (75 MHz, 
D2O) δ 170.3 (s), 157.0 (s), 135.3 (s), 129.7 (d), 129.5 (d), 129.4 (d), 70.9 (t), 69.2 (t), 
58.8 (d), 53.0 (q), 41.7 (t), 40.8 (t), 27.5 (t), 24.4 (t); IR (neat) 2930, 1746, 1660, 1606 
cm-1; LRMS (ES+) 323 (100%, [M+H]+), 306 (15), 259 (40).  
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(S)-tert-Butyl 5-(N’, N’’-bis(tert-butoxycarbonyl)-3-(N’-methoxyethyl)guanidino)-2-
(tert-butoxycarbonylamino)pentanoate29 107 
 
N
H
O
O
NHBoc
NBoc
N
Boc
O
 
 
Triethylamine (340µ mL, 2.46 mmol), 1,3-bis-(tert-butoxycarbonyl)-1-(2-
methoxyethyl)-S-methyl-isothiourea 95 (430 mg, 1.23 mmol), and 4-
dimethylaminopyridine (18 mg, 0.12 mmol) were added to a stirred solution of Boc-L-
Orn-OtBu (400 mg, 1.23 mmol) in THF (20 mL) under nitrogen for 72 h. The solvent 
was evaporated in vacuo and purification by flash chromatography starting with 
petrol/EtOAc (19/1) gave the title compound as a yellow waxy solid. Further 
purification by freeze drying for 48 h furnished the title compound as a white waxy 
solid (0.52 g, 70 % yield); 1H NMR (300 MHz, CDCl3) δ 5.19-5.12 (m, 1H), 4.20-4.15 
(m, 1H), 3.78 (br s, 2H), 3.62-3.55 (m, 2H), 3.31 (s, 3H), 3.31-3.27 (m, 2H), 1.83-1.79 
(m, 2H), 1.66-1.54 (m, 2H), 1.47 (s, 9H), 1.45 (s, 9H), 1.44 (s, 9H), 1.42 (s, 9H); 13C 
NMR (75 MHz, CDCl3) δ 172.0 (s), 158.0 (s), 155.5 (s), 153.0 (s), 144.0 (s), 82.0 (s), 
81.9 (s), 81.7 (s), 79.6 (s), 70.7 (t), 58.5 (d), 53.01 (q) 42.0 (t), 40.2 (t), 30.3 (t), 29.7 
(q), 28.3 (q), 28.2 (q), 27.9 (q), 26.0 (t); IR (neat) 3335, 2976, 2931, 1711, 1615 cm-1; 
LRMS (FAB) 588 (100%, [M]+), 489 (20), 415 (48), 359 (23), 303 (68); HRMS (FAB) 
calcd for C28H52N4O9 [M]+ 588.3679, observed 588.3660.  
 
 
(S)-tert-Butyl 2-(tert-butoxycarbonylamino)-5-(N’-(2-methoxyethyl)guanidino) 
pentanoate 111 
O
N
H
N
H
NH
O
O
NHBoc  
 
Iodine (7 mg, 0.023 mmol) was added to a stirred solution of (S)-tert-butyl 5-(N’, N’’-
bis(tert-butoxycarbonyl)-3-(N’-methoxyethyl)guanidino)-2-(tert-butoxycarbonylamino) 
pentanoate 107 (55 mg, 0.094 mmol) in water (8 µL) and acetonitrile (1 mL) under 
reflux for 5 h. The reaction mixture was diluted with aqueous Na2S2O3 (1 mL) and 
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extracted with EtOAc (2 x 5 mL). The combined organic layers were dried over 
anhydrous MgSO4 and the solvent evaporated in vacuo. Purification by flash 
chromatography eluting with MeOH/CHCl3 (1/9) gave the title compound as a waxy 
solid (19 mg, 55%): 1H NMR (500 MHz, CDCl3) δ 7.26 (br s, 2H), 5.36 (br s, 1H), 
4.10-4.09 (m, 1H), 3.54-3.24 (m, 7H), 3.38 (s, 3H), 1.80-1.78 (m, 2H), 1.70-1.67 (m, 
2H), 1.46 (s, 9H), 1.42 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 171.5 (s), 158.2 (s), 
156.7 (s), 82.9 (s), 80.6 (s), 73.5 (t), 59.3 (q), 52.5 (d), 43.0 (t), 41.2 (t), 29.4 (t), 28.4 
(q), 28.1 (q), 25.1 (t); IR (neat) 3310, 3188, 3054, 2929, 2855, 1712, 1693, 1660, 1633 
cm-1; LRMS (CI) 389 (100%, [M+H]+); HRMS (CI) calcd. for C18H37N4O9 [M+H]+ 
389.2764, observed 389.2752. 
 
 
(S)-2-Amino-5-(N’-(2-methoxyethyl)guanidino)pentanoic acid hydrochloride29 22 
 
.HCl
N
H
OH
O
NH2
NH
N
H
O
 
 
The (S)-tert-butyl-5-(N’,N’’-bis(tert-butoxycarbonyl)-3-(N’-methoxyethyl)guanidino)-
2-(tert-butoxycarbonylamino)pentanoate 107 (0.52 g, 0.88 mmol) was dissolved in 4 M 
HCl in dioxane (5 mL) and stirred under nitrogen for 24 h. The solvent was evaporated 
in vacuo to give the title compound as a white waxy-solid (0.27 g, 0.88 mmol, >99% 
yield): 1H NMR (300 MHz, D2O) δ 4.01 (t, J = 6.0 Hz, 1H), 3.56 (t, J = 5.0 Hz, 2H), 
3.36 (t, J = 5.0 Hz, 2H), 3.34 (s, 3H), 3.23 (t, J = 6.0 Hz, 2H), 2.01-1.92 (m, 2H), 1.85-
1.70 (m, 2H); 13C NMR (75 MHz, D2O) δ 172.7 (s), 156.6 (s), 70.7 (t), 58.6 (d), 53.2 
(q), 41.5 (t), 40.8 (t), 27.4 (t), 24.2 (t); IR (neat) 3334, 3195, 3053, 2987, 2929, 1645 
cm-1; LRMS (FAB) 233 (100%, [M+H]+), 188 (6),  158 (8); HRMS (FAB) calcd for 
C9H21N4O3 [M+H]+ 233.1613, observed 233.1610.  
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(S)-5-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) 
pentanamide 117a 
FmocHN NH2
O
NHBoc  
 
EDC.HCl (370 mg, 1.93 mmol) was added to a stirred solution of Boc-L-Orn(Fmoc)-
OH (800 mg, 1.76 mmol) and HOBt (260 mg, 1.93 mmol) in CH2Cl2 (15 mL) at 0 °C. 
The reaction was stirred at 21 oC for 30 min. NH3(g) was bubbled through the mixture 
for 3 min after which the solution turned cloudy and precipitates formed. This was 
further stirred at 21 oC for 1 h. The mixture was concentrated in vacuo, dissolved in 
EtOAc (30 mL), washed with water (50 mL) and NaHCO3 (50 mL) and back extracted 
with EtOAc (2 x 50 mL). The organic layers were collected and washed with 0.5M HCl 
(30 mL), brine (50 mL) and then dried over MgSO4, filtered and the solvent evaporated 
in vacuo to leave the crude product as a yellow solid. Purification by flash 
chromatography eluting with petrol/EtOAc (6/4) gave the title compound as a white 
solid (713 mg, 89% yield): m.p. 171-173 °C;  1H NMR (600 MHz, CDCl3): δ 7.78 (d, J 
= 7.5 Hz, 2H), 7.58 (dd, J = 1.3, 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.32 (t, J = 7.5 
Hz, 2H), 6.48 (br s, 1H), 5.61 (br s, 1H), 5.25 (br s, 1H), 5.12 (br s, 1H), 4.44-4.39 (m, 
2H), 4.29 (br s, 1H), 4.21 (t, J = 7.0 Hz, 1H), 3.50 (br s, 1H), 3.18-3.16 (m, 1H), 1.83 
(br s, 1H), 1.64-1.63 (m, 1H), 1.60-1.55 (m, 2H), 1.45 (s, 9H); 13C NMR (150 MHz, 
CDCl3): δ 174.6 (s), 156.9 (s), 155.8 (s), 143.9 (s), 141.3 (s), 127.7 (d), 127.0 (d), 125.0 
(d), 120.0 (d), 80.1 (s), 66.6 (t), 52.7 (d), 47.2 (d), 39.7 (t), 29.9 (t), 28.3 (q), 26.2 (t); IR 
(neat) 3500, 3054, 2986, 1694, 1682,  1660 cm-1;  LRMS (ES+) 476 (63% [M+ Na]+), 
376 (100); HRMS (ES+) calcd for C25H31N3O5Na  [M+Na]+  476.2161, observed 
476.2172. 
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(S)-Dimethyl-5-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-
butoxycarbonylamino) pentanamide 117b 
FmocHN NMe2
O
NHBoc  
 
EDC.HCl (230 mg, 1.20 mmol) was added to a stirred solution of dimethylamine (110 
µL, 2.11 mmol), HOBt (260 mg, 1.94 mmol) and Boc-L-Orn(Fmoc)-OH (0.80 g, 1.76 
mmol) in CH2Cl2 (15 mL) at 0 C. The mixture was stirred at this temperature for 1 h 
after which the reaction mixture was warmed to 21 oC and stirred for 3 h. The mixture 
was concentrated in vacuo, dissolved in EtOAc (30 mL), washed with water (50 mL) 
and NaHCO3 (50 mL) and back extracted with EtOAc (2 x 50 mL). The organic layers 
were collected and washed with 0.5 M HCl (30 mL), brine (50 mL) and then dried over 
MgSO4, filtered and the solvent evaporated in vacuo to leave the crude product as a 
yellow solid. Purification by flash chromatography eluting with petrol/EtOAc (7/3) gave 
the title compound as a white solid (0.40 g, 46% yield): m p: 76-82 °C; IR (neat) 3500, 
3054, 2985, 1713, 1645 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.75 (d, J = 7.0 Hz, 2H), 
7.64-7.56 (m, 2H), 7.34 (t, J = 7.0 Hz, 2H), 7.31-7.25 (m, 2H), 5.52 (d, J = 8.0 Hz, 1H), 
5.27-5.24 (m, 1H), 4.64-4.61 (m, 1H), 4.40-4.29 (m, 2H), 4.19 (t, J = 7.0 Hz, 1H), 3.23-
3.21 (m, 2H), 3.00 (s, 3H), 2.92 (s, 3H), 1.68-1.56 (m, 4H), 1.43 (s, 9H); 13C NMR (75 
MHz, CDCl3): δ 171.9 (s), 156.5 (s), 155.7 (s), 144.0 (s), 141.3 (s), 127.6 (d), 127.0 (d), 
125.1 (d), 119.9 (d), 79.7 (s), 66.6 (t), 49.8 (d), 47.3 (d), 40.8 (t), 37.0 (q), 35.7 (q), 30.9 
(t), 28.4 (q), 25.4 (t); LRMS (ES+) 504 (100%, [M+Na]+), 448 (25), 404 (95); HRMS 
(ES+) calcd for C27H35O5N3Na [M+Na]+ 504.2474, observed 504.2453. 
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 (S)-Benzyl-5-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) 
pentanamide 117c 
FmocHN N
H
O
BocHN  
 
Benzylamine (290 µL, 2.64 mmol) and HOBt (330 mg, 2.42 mmol) were added to a 
solution of Boc-L-Orn(Fmoc)-OH (1.0 g, 2.20 mmol) in CH2Cl2 (15 mL) with stirring. 
The solution was cooled to 0 C, EDC.HCl (460 mg, 2.42 mmol) was added and further 
stirred at 0 C for 1 h after which the reaction mixture was warmed to 21 oC and stirred 
for 3 h. The mixture was concentrated in vacuo, diluted with EtOAc (30 mL), washed 
with water (2 x 30 mL) and back extracted with EtOAc (2 x 50 mL). The organic layers 
were collected and washed with 0.5 M HCl (40 mL), brine (50 mL) and then dried over 
MgSO4, filtered and the solvent evaporated in vacuo to leave the crude product as a 
yellow solid. Purification by flash chromatography eluting with petrol/EtOAc (7/3) gave 
the title compound as an off-white solid (854 mg, 70% yield): 1H NMR (300 MHz, 
CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H), 7.54-7.50 (m, 2H), 7.39 ( t, J = 7.5 Hz, 2H), 7.31-
7.12 (m, 7H), 6.90 (br s, 1H), 5.30-5.27 (m, 1H), 5.08-5.04 (m, 1H), 4.44-4.36 (m, 2H), 
4.32-4.26 (m, 2H), 4.18-4.13 (m, 2H), 3.40-3.34 (m, 1H), 3.16-3.10 (m, 1H), 1.64-1.51 
(m, 4H), 1.42 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 175.5 (s), 155.5 (s), 151.7 (s), 
143.9 (s), 143.8 (s), 141.3 (s), 137.9 (s), 128.6 (d), 127.7 (d), 127.6 (d), 127.4 (d), 127.0 
(d), 124.9 (d), 119.9 (d), 66.9 (d), 66.6 (t), 47.2 (d), 43.5 (t), 39.7 (t), 31.0 (t), 28.3 (q), 
26.3 (t); IR (neat) 3311, 2937, 1683, 1655, 1519 cm-1; LRMS (FAB) 566 (8%, 
[M+Na]+), 475 (100), 329 (25), 154 (35); HRMS (FAB) calcd for C37H37N3O5Na 
[M+Na]+ 566.2631, observed 566.2645.  
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(S)-Methylbenzyl-5-(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-
butoxycarbonylamino) pentanamide 117d 
 
FmocHN N
O
BocHN  
 
N-Methyl-benzylamine (160 mg, 1.32 mmol) and HOBt (160 mg, 1.20 mmol) were 
added to a stirred solution of Boc-L-Orn(Fmoc)-OH (0.5 g, 1.10 mmol) in CH2Cl2 (15 
mL). The solution was cooled to 0 C, EDC.HCl (230 mg, 1.20 mmol) was added and 
further stirred at 0 C for 1 h after which the reaction mixture was warmed to 21 oC and 
stirred for 3 h. The mixture was concentrated in vacuo, diluted with EtOAc (10 mL), 
washed with water (2 x 20 mL) and back extracted with EtOAc (2 x 50 mL). The 
organic layers were combined and washed with 0.5 M HCl (30 mL), brine (50 mL) and 
dried over MgSO4, filtered and the solvent evaporated in vacuo. Purification by flash 
chromatography starting with petrol/EtOAc (7/3) gave the title compound as a white 
solid (0.56 g, 92% yield): 1H NMR (400 MHz, CDCl3, 55 °C) δ 7.75 (d, J = 7.0 Hz, 2H), 
7.58 (d, J = 7.0 Hz, 2H), 7.39 (t, J = 7.0 Hz, 2H), 7.31-7.25 (m, 5H), 7.17-7.09 (m, 2H), 
5.35 (m, 1H), 4.89 (br s, 1H), 4.56-4.50 (m, 3H), 4.39-4.35 (m, 2H), 4.19 (t, J  = 6.5 Hz, 
1H), 3.28-3.30 (m, 2H), 2.96 (s, 3H), 1.68-1.54 (m, 4H), 1.44 (s, 9H); 13C NMR (100 
MHz, CDCl3, 55 °C) δ 172.1 (s), 156.2 (s), 155.5 (s), 143.9 (s), 141.2 (s), 137.0 (s) 
136.6 (s), 128.5 (d), 127.8 (d), 127.4 (d), 127.1 (d), 126.8 (d), 124.8 (d), 119.7 (d), 79.6 
(q), 66.5 (t), 51.2 (d), 49.9 (d), 47.3 (t), 40.7 (t), 30.5 (t), 28.2 (q), 25.4 (t); IR (neat) 
3316, 2931, 1701, 1638 cm-1; LRMS (FAB) 580 (32%, [M+Na]+), 360 (22), 329 (28), 
176 (100), 154 (30); HRMS (FAB) calcd for C33H39N3O5Na [M+Na]+ 580.2787, 
observed 580.2787. 
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(S)-Benzyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl)guanidino)-2-
(tert-butoxycarbonylamino) pentanamide 118c 
 
N
H
N
H
O
BocHN
N
Boc
NBoc
O
 
 
Piperidine (0.74 mL, 7.53 mmol) was added to a solution of (S)-benzyl-5-(((9H-fluoren-
9-yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) pentanamide 117c (0.84 g, 1.54 
mmol) in CH2Cl2 (15 mL) and stirred for 24 h. The solvent was evaporated in vacuo and 
redissolved in dry THF (20mL) with stirring. Triethylamine (0.43 mL, 3.08 mmol), 1,3-
bis-(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-isothiourea 95 (610 mg, 1.54 
mmol) and 4-dimethylaminopyridine (20 mg, 0.15 mmol) were added to this solution 
and stirred under nitrogen for 72 h. The solvent was evaporated in vacuo  and 
purification by flash chromatography eluting with petrol/EtOAc (1/4), and further 
purification by flash chromatography eluting with CHCl3/Et2O (1/4) gave the title 
compound as a white waxy-solid (670 mg, 70 % yield): 1H NMR (300 MHz, CDCl3) δ 
7.33-7.18 (m, 5H), 4.43 (t, J = 6.5 Hz, 1H), 4.45-4.41 (m, 2H), 3.78-3.75 (m, 2H), 3.49-
3.47 (m, 2H), 3.33-3.30 (m, 2H), 3.30 (br s, 3H), 1.92-1.89 (m, 2H), 1.65-1.55 (m, 2H), 
1.45 (s, 9H), 1.43 (s, 9H), 1.41 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 171.9 (s), 156.0 
(s), 152.4 (s), 146.5 (s), 138.0 (s), 128.6 (d), 127.7 (d), 127.4 (d), 119.9 (s), 82.2 (s), 
79.9 (s), 79.4 (s), 70.6 (t), 67.0 (d), 53.6 (q), 43.5 (t), 31.1 (t), 29.5 (t), 28.3 (q), 28.2 (q), 
29.1 (q), 25.3 (t), 20.2 (t); IR (neat) 3430, 3321, 3055, 2981, 2933, 1712, 1674, 1620 
cm-1; LRMS (FAB) 644 (100%, [M+Na]+), 422 (18), 344 (34), 176 (98), 154 (43); 
HRMS (FAB) calcd for C31H51N5O8Na [M+Na]+ 644.3635, observed 644.3626. 
  
117 
 
(S)-Methylbenzyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-ethoxyethyl)guanidino) -
2-(tert-butoxycarbonylamino) pentanamide 118d 
 
N
H
N
ONBoc
N
Boc
O
BocHN  
 
Piperidine (310 µL, 3.43 mmol) was added to a stirred solution (S)-methylbenzyl-5-
(((9H-fluoren-9-yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) pentanamide 117d 
(380 mg, 0.68 mmol) in CH2Cl2 (10 mL) and stirred for 24 h. The solvent was 
evaporated in vacuo and redissolved in dry THF (5 mL) with stirring. Triethylamine 
(190 µL, 1.37 mmol), 1,3-bis-(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-
isothiourea 95 (240 mg, 0.68 mmol) and 4-dimethylaminopyridine (10 mg, 0.07 mmol) 
were added to the reaction mixture under nitrogen for 72 h. The solvent was evaporated 
in vacuo and purification by flash chromatography eluting with petrol/EtOAc (1/4) and 
further purification by flash chromatography eluting with CHCl3/Et2O (1/4) gave the 
title compound as a white waxy-solid (110 mg, 24% yield): 1H NMR (300 MHz, 
CDCl3) δ 7.35-7.23 (m, 3H), 7.20-7.14 (m, 2H), 5.50 (d, J = 8.5 Hz, 1H, major), 5.42 (d, 
J = 8.5 Hz, 1H, minor), 4.67-4.56 (m, 2H), 3.78-3.76 (m, 2H), 3.47-3.45 (m, 2H), 3.28 
(br s, 3H), 3.27-3.25 (m, 2H), 2.97 (s, 3H, major), 2.90 (s, 3H, minor), 1.78-1.63 (m, 
4H), 1.46 (s, 9H, minor), 1.44 (s, 9H, major), 1.43 (s, 9H), 1.42 (s, 9H, major), 1.39 (s, 
9H, minor);  13C NMR (75 MHz, CDCl3, major rotamer ) δ 173.0 (s), 155.6 (s), 152.4 
(s), 137.0 (s), 136.6 (s), 128.9 (d, minor), 128.7 (d, major), 127.8 (d, major), 127.5 (d, 
minor), 126.7 (d), 82.1 (s), 79.7 (2 x s), 79.0 (s), 70.8 (t), 58.0 (d), 56.0 (t), 51.2 (t), 50.0 
(q), 34.6 (q, major), 33.0 (q, minor), 31.0 (t), 30.0 (t), 28.3 (q), 28.2 (q), 28.1 (q), 24.9 
(t); IR (neat) 2970, 2880, 1720, 1650 cm-1; LRMS (FAB) 658 (25 % [M+Na]+), 176 
(100); HRMS (FAB) calcd for C32H53O8N5Na [M+Na]+ 658.3791, observed 658.3802. 
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(S)-Dimethyl-2-amino-5-(N’-(2-methoxyethyl)guanidino)pentanamide 
hydrochloride 119b 
.HCl
N
H
NMe2
O
NH2
N
H
NH
O
 
 
Piperidine (0.26 mL, 2.64 mmol) was added to the (S)-dimethyl-5-(((9H-fluoren-9-
yl)methoxy)carbonyl)-2-(tert-butoxycarbonylamino) pentanamide 117b (255 mg, 0.53 
mmol) in CH2Cl2  (10 mL) and stirred for 1 h. The solvent was evaporated in vacuo and 
redissolved in dry THF (10 mL) under nitrogen. To this solution was added 1,3-bis-
(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-isothiourea 95 (180 mg, 0.53 
mmol), Triethylamine (150 µL, 1.06 mmol) and 4-dimethylaminopyridine (10 g, 0.05 
mmol). The solution was stirred for 72 h. The solvent was evaporated in vacuo and the 
reaction mixture was redissolved in DMF (10 mL) and heated at 130 °C for 2 h and at 
21 oC for 24 h. The solvent was evaporated in vacuo and purification three times by 
flash chromatography eluting with CHCl3/MeOH (30/1) gave an impure product as a 
waxy solid (23 mg, 8 % yield). The product was dissolved 4M HCl in dioxane (2 mL) 
and stirred for 2 h. The solvent was evaporated in vacuo, extracted into water and freeze 
dried twice to give the title compound as a yellow waxy solid (0.43 mg, 3.3 % yield): 
1H NMR (300 MHz, D2O): δ 4.55 (t, J = 6.0 Hz, 1H), 3.61 (t, J = 5.0 Hz, 2H), 3.40 (t, J 
= 5.0 Hz, 2H), 3.39 (s, 3H), 3.29-3.24 (m, 2H), 3.11 (s, 3H), 2.99 (s, 3H), 1.99-1.89 (m, 
2H), 1.73-1.63 (m, 2H); 13C NMR (125 MHz, D2O): δ 170.0 (s), 156.8 (s), 70.9 (t), 58.8 
(q), 50.7 (d), 41.7 (t), 41.0 (t), 37.6 (q), 36.4 (q), 27.8 (t), 23.9 (t); IR (neat) 3390, 2926, 
1639 cm-1; LRMS (ES+) 282 (20%, [M+Na]+), 260 (100, [M+H]+), 243 (45); HRMS 
(ES+) calcd for C11H26O2N5 [M+H]+ 260.2087, observed 260.2093. 
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 (S)-Benzyl-2-amino-5-(N’-(2-methoxyethyl)guanidino)pentanamide hydrochloride 
119c 
.HCl
N
H
N
H
O
NH2
N
H
NH
O
 
 
(S)-Benzyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl)guanidino)-2-(tert-
butoxycarbonylamino) pentanamide 118c (100 mg, 0.32 mmol) was dissolved in 4 M 
HCl in dioxane (2 mL) with stirring for 24 h. The solvent was evaporated in vacuo, 
dissolved in distilled water (3 mL) and freeze dried for 48 h which gave the title 
compound as an off-white hydroscopic solid (41 mg, 62 % yield): 1H NMR (300 MHz, 
D2O ) δ 7.42-7.22 (m, 5H), 4.54 (6, J = 16.0 Hz, 1H), 4.33 (d, J = 16.0 Hz, 1H), 4.04 (t, 
J = 6.0 Hz, 1H), 3.56 (t, J = 7.0 Hz, 2H), 3.36-3.34 (m, 2H), 3.41 (s, 3H), 3.18 (t, J = 7.0 
Hz, 2H), 1.91-1.86 (m, 2H), 1.59-1.43 (m, 2H); 13C NMR (75 MHz, D2O) δ 169.7 (s), 
156.6 (s), 138.1 (s), 129.5 (d), 128.4 (d), 128.3 (d), 70.9 (t), 58.9 (d), 53.5 (q), 43.9 (t), 
41.7 (t), 40.9 (t), 28.6 (t), 24.6 (t); IR (neat) 3363, 3217, 1650 cm-1; LRMS (CI) 322 
(13%, [M+H]+), 215 (18), 203 (15), 115 (40), 91 (100); HRMS (CI) calcd for 
C16H28O2N5 [M+H]+ 322.2242, observed 322.2234. 
 
 
 (S)-Methylbenzyl-2-amino-5-(N’-(2-methoxyethyl)guanidino)pentanamide 
hydrochloride 119d 
.HCl
N
H
N
ONH
N
H
O
NH2  
 
(S)-Methylbenzyl-5-(N',N''-bis(tert-butoxycarbonyl)-3-(N'-methoxyethyl)guanidino)-2-
(tert-butoxycarbonylamino) pentanamide 118d (100 mg, 0.16 mmol) was dissolved in 4 
M HCl in dioxane (2 mL) and stirred for 24 h. The solvent was evaporated in vacuo, 
dissolved in distilled water (3 mL), and freeze drying for 48 h which gave the title 
compound as an off-white hydroscopic solid (0.045g, 71 % yield, mixture of rotamers): 
1H NMR (400 MHz, D2O, 90 °C) δ 7.59-7.38 (m, 3H), 7.35-7.25 (m, 2H), 4.96 (d, J = 
14.0 Hz, 1H, major), 4.85 (br s, 1H, minor), 4.77-4.73 (m, 1H, major), 4.77-4.70 (m, 
2H, minor), 4.59 (d, J = 14.0 Hz, 1H, major), 3.76-3.73 (m, 2H), 3.56-3.54 (m, 2H), 
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3.54 (br s,  3H), 3.41-3.39 (m, 2H), 3.25 (br s, 3H, major), 3.18 (br s, 3H, minor), 2.12-
1.92 (m, 2H), 1.79-1.62 (m, 2H); 13C NMR (100 MHz, D2O, 90 °C) δ 170.4 (s, minor), 
169.8 (s, major), 156.8 (s), 136.7 (s, major), 136.2 (s, minor), 129.8 (d, minor), 129.6 (d, 
major), 128.7 (d, minor), 128.6 (d, major), 127.3 (d), 70.9 (t), 58.9 (d), 53.6 (t, minor), 
52.4 (t, major), 51.2 (q, minor), 51.0 (q, major), 41.8 (t), 41.0 (t), 35.6 (q, major), 35.5 
(q, minor), 28.2 (t, minor), 27.7 (t, major), 24.1 (t); IR (neat) 3363, 3207, 1650 cm-1; 
LRMS (ES+) 336 (100% [M+H]+), 319 (10); HRMS (ES+) calcd for C17H30N5O2 
[M+H]+ 336.2400, observed 336.2415. 
 
 
1,3-Diazepane-2-thione114,115 122 
HN NH
S
 
 
Carbon disulphide (0.68 mL, 11.0 mmol) was added to a stirred solution of 1,4-
diaminobutane (1.0 g, 11.0 mmol) in ethanol (15 mL) and water (10 mL). White 
precipitate immediately formed and the reaction mixture was refluxed overnight at 90 
°C. The next day the reaction was warmed to 21 oC before being put in the fridge 
overnight for crystallization. Filtration and washing with diethyl ether (50 mL) gave the 
title compound as colourless crystals (0.78 g, 53% yield): m.p. 182-184 °C; 1H NMR 
(400 MHz, CDCl3) δ 7.51 (br s, 2H), 3.05 (br s, 4H), 1.58-1.55 (m, 4H); 13C NMR (400 
MHz, CDCl3) δ 193.0 (s), 49.9 (t), 32.3 (t); IR (neat) 3217, 2942, 2920; LRMS (EI) 130 
(100%, [M]+•), 97 (8).  
 
 
Di-tert-butyl 2-thioxo-1,3-diazepane-1,3-dicarboxylate116 123 
 
BocN NBoc
S
 
 
NaH 60% in mineral oil (0.77 g, 19.28 mmol) was added to a stirred solution of 1,3-
diazepane-2-thione  122 (0.56 g, 4.28 mmol, 1 eq.) in dry THF (20 mL) under argon at 
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0 °C. The ice bath was removed after 5 min and the reaction mixture was stirred at 21 oC 
for 10 min. The reaction mixture was cooled to 0 °C, and di-tert-butyl dicarbonate (2.06 
g, 9.43 mmol) was added slowly over 5 min at which the reaction turned bright yellow. 
The ice bath was removed after 30 min of stirring at that temperature and the resulting 
slurry was stirred for 2 h at 21 oC and then quenched with saturated NaHCO3 solution 
(50 mL). The reaction mixture was poured onto water (50 ml) and extracted with ethyl 
acetate (3 x 50 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated in vacuo. Purification by flash chromatography eluting with petrol/Et2O 
(9/1) gave the title compound as a bright yellow solid (1.23 g, 87 % yield): m.p. 103-
106 °C; 1H NMR (400 MHz, CDCl3) δ 3.78-3.75 (m, 4H), 1.58-1.53 (m, 4H), 1.43 (s, 
18H); 13C NMR (400 MHz, CDCl3) δ 186.9 (s), 152.7 (s), 82.6 (s), 49.3 (t), 27.3 (q), 
24.9 (t); IR (neat) 2978, 2942, 1718, 1120 cm-1; LRMS (ES+) 353 (100%, [M+Na]+), 
253 (85),153 (95); HRMS (ES+) calcd for C15H26N2O4SNa [M+Na]+ 353.1512, 
observed 353.1502. 
 
 
(S)-5-(1-(tert-Butoxycarbonyl)-4,5,6,7-tetrahydro-1H-1,3-diazepin-2-ylamino)-2-
(tert-butoxycarbonylamino)pentanoic acid 124) and (S)-5-(1-(tert-Butoxycarbonyl)-
4,5,6,7-tetrahydro-1H-1,3-diazepin-2-ylamino)-2-aminopentanoic acid 125 
 
N
H
OH
O
NHBoc
N
N
Boc NH
OH
O
NH2
N
N
Boc
124                                                 125
+
 
 
MeI (100 µL, 1.73 mmol) was added to a stirred solution of the (E)-tert-butyl 2-
(methylthio)-4,5,6,7-tetrahydro-1,3-diazepine-1-carboxylate 123 (459 mg, 1.39 mmol) 
in MeCN (5 mL) and refluxed for 4 h. The solvent was evaporated in vacuo and the 
compound redissolved in dry THF (5 mL). To this solution was added Boc-L-Orn-OH 
(323 mg, 1.39 mmol), Triethylamine (0.48 mL, 3.47 mmol), and 4-
dimethylaminopyridine (10 mg, 0.08 mmol). The solution was stirred at 21 oC for 72 h. 
The solvent was evaporated in vacuo and redissolved in MeCN (5 mL) and stirred at 21 
oC for 48 h, and then refluxed for 48 h. The solvent was evaporated in vacuo and 
purification by flash chromatography eluting with CHCl3/MeOH (99/1) and freeze 
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drying gave (S)-5-(1-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-1H-1,3-diazepin-2-
ylamino)-2-(tert-butoxycarbonyl)pentanoic acid 124 as a white waxy-solid (25 mg, 11% 
yield) and  (S)-5-(1-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-1H-1,3-diazepin-2-
ylamino)-2-aminopentanoic acid 125 as a white waxy-solid (129 mg, 28% yield). 
 
Data for 124: 1H NMR (400 MHz, CDCl3) δ 3.98-3.97 (m, 1H), 3.39-3.37 (m, 2H), 
3.32-3.39 (m, 4H), 1.84-1.70 (m, 8H), 1.51 (s, 9H), 1.43 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 178.0 (s), 159.3 (s), 157.6 (s), 152.0 (s), 80.2 (s), 79.5 (s), 57.0 (d), 45.7 (t), 
44.0 (t), 31.7 (t), 28.8 (q), 28.3 (q), 27.9 (t), 27.0 (2 x t), 25.0 (t); IR (neat) 3258, 2934, 
1642, 1581 cm-1; LRMS (ES+)  429 (15%, [M+H]+), 329 (100), 60 (64); HRMS (ES+) 
calcd for C20H36N4O6 [M+H]+ 429.2708; observed 429.2707. 
 
Data for 125 (Boc Group tentatively assigned): 1H NMR (400 MHz, CDCl3) δ 10.20 
(br s, 1H), 7.37 (br s, 1H), 5.81 (m, 2H), 3.98 (br s, 1H), 3.40-3.37 (m, 2H), 3.28 (br s, 
1H), 3.20-3.10 (m, 2H), 3.01 (br s, 1H), 1.70-1.63 (m, 8H), 1.39 (s, 9H); 13C NMR (100 
MHz, CDCl3) δ 178.2 (s), 162.4 (s), 156.8 (s), 79.0 (s), 53.9 (d), 44.6 (t), 41.6 (t), 31.9 
(t), 29.7 (t), 28.5 (q), 28.2 (t), (28.0 (t), 26.6 (t); IR (neat) 3315, 2933, 1702, 1657 cm-1; 
LRMS (ES+) 329 (100%, [M+H]+); HRMS (ES+) calcd for C15H29N4O4 [M+H]+ 
329.2183, observed 329.2183.  
 
 
(S)-2-Amino-5-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-ylamino)pentanoic acid 
hydrochloride 120 
N
H
OH
O
NH2
N
N
H
.HCl  
 
A solution of (S)-5-(1-(tert-butoxycarbonyl)-4,5,6,7-tetrahydro-1H-1,3-diazepin-2-
ylamino)-2-aminopentanoic acid 125 (120 mg, 0.36 mmol) in 4 M HCl in dioxane (2 
mL) was stirred under argon for 24 h. The solvent was evaporated in vacuo, extracted 
into D2O and freeze dried to give the title compound as a yellow waxy-solid (38 mg, 
46% yield); 1H NMR (400 MHz, D2O) δ 3.97 (t, J = 6.3 Hz, 1H), 3.17-3.14 (m, 6H), 
2.15-1.89 (m, 2H), 1.77-1.71 (m,1H), 1.67-1.63 (m, 1H), 1.42-1.40 (m, 4H); 13C NMR 
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(100 MHz, D2O) δ 171.7 (s), 160.6 (s), 52.4 (d), 44.2 (2 x t), 41.1 (t), 26.8 (t), 26.7 (2 x 
t), 24.0 (t); LRMS (ES+) 229 (100%, [M+H]+), 184 (85), 158 (35), 114 (90); HRMS 
(ES+) calcd for C10H21N4O2 [M+H]+ 229.1732, observed 229.1732. 
 
 
1-Isothiocyanato-2-methoxyethane117 102 
 
O
N
S
 
 
2-Methoxyethylamine (1.0 g, 13.3 mmol) was added to a solution of K2CO3 (5.52 g, 
39.9 mmol) dissolved in water (25 mL) and CHCl3 (25 mL) and stirred for 5 min. 
Thiophosgene (1.52 mL, 19.97 mmol) was added and stirred vigorously for 3 h after 
which the organic layer was separated from the aqueous layer. The aqueous layer was 
washed with CHCl3 (2 x 50 mL) and the combined organic layers were washed with 
brine (100 mL), dried over anhydrous MgSO4, filtered and evaporated in vacuo. 
Purification by flash chromatography eluting with petrol/Et2O (18/1) gave the title 
compound as a yellow oil (0.94 g, 61 % yield); 1H NMR (300 MHz, CDCl3) δ 3.39 (s, 
3H), 3.65 (t, J  = 5.0 Hz, 2H,), 3.56 (t, J = 5.0 Hz, 2H,); 13C NMR (75 MHz, CDCl3) δ 
131.9 (s), 70.3 (t), 58.8 (q), 45.0 (t); IR (neat) 2931, 2833, 2117, 1124 cm-1; LRMS (CI) 
118 (38%, [M+H]+), 91 (100).  
 
 
tert-Butyl (2-methoxyethyl)carbamothioylcarbamate 103 
 
BocHN N
H
S
O
 
 
NaH (30 mg, 0.94 mmol) was added to a solution of tert-butyl carbamate (100 mg, 0.85 
mmol) in dry THF (3 mL) at 0° C and stirred under argon for 5 min, and then at 21 oC 
for 10 min. The reaction mixture was cooled again to 0° C and 1-isothiocyanato-2-
methoxyethane 102 (100 mg, 0.85 mmol) was added and stirred for 30 min at this 
temperature, and then 4 h at 21 oC. The reaction was quenched with water (20 mL) and 
the organic material was extracted with ethyl acetate (3 x 20 mL). The organic layers 
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were dried over anhydrous MgSO4, filtered and evaporated in vacuo. Purification by 
flash chromatography eluting with petrol/EtOAc (18/1) gave the product as a white 
solid (95 mg, 48% yield): 1H NMR (300 MHz, CDCl3) δ 9.85 (br s, 1H), 8.32 (br s, 1H), 
3.80 (m, 2H), 3.56 (t, J = 5.3 Hz, 2H), 3.34 (s, 3H), 1.43 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 179.8 (s), 151.7 (s), 83.4 (s), 69.8 (t), 58.8 (q), 45.2 (t), 27.9 (q); IR (neat) 
3239, 3191, 2935, 2866, 1718, 1097 cm-1; LRMS (ES+) 235 (100%, [M+H]+); HRMS 
(ES+) calcd for C9H19N2O3S [M+H]+ 235.1111, observed 235.1113. 
 
 
N’-Benzyl-N’’-(2-methoxyethyl)guanidine 104 
N
H
N
NH2
O
 
 
MeI (49 mg, 0.35 mmol) was added to a stirred solution of tert-butyl (2-
methoxyethyl)carbamothioylcarbamate 103 (54 mg, 0.23 mmol) in MeCN (2 mL) and 
refluxed for 4 h. To this mixture was added benzylamine (25 mg, 0.23 mmol), 
triethylamine (64 µL, 0.46 mmol) and stirred at rt for 48 h under argon. The solvent was 
evaporated in vacuo and purification by flash chromatography eluting MeOH/CHCl3 
(1/99), and further freeze drying, gave the title compound as a viscous yellow oil (47 
mg, >99% yield): 1H NMR (300 MHz, CDCl3) δ  7.69 (br s, 1H), 7.34-7.23 (m, 5H), 
6.68 ( br s, 2H), 4.49 (d, J = 5.6 Hz, 2H), 3.47 (t, J = 4.0 Hz, 2H), 3.37-3.34 (m, 2H), 
3.26 (s, 3H); 13C NMR (300 MHz, CDCl3) δ 157.7 (s), 135.1 (s), 129.0 (d), 128.3 (d), 
127.7 (d), 72.8 (t), 59.1 (q), 46.2 (t), 42.9 (t); IR (neat) 3173, 2929, 1626 cm-1; LRMS 
(ES+) 208 (100%, [M+H]+); HRMS (ES+) calcd for C11H18N3O [M+H]+ 208.1444, 
observed 208.1443. 
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(S)-2-(tert-Butoxycarbonylamino)-5-(N’-(tert-butoxycarbonyl)-3-(N’’-
methoxyethyl)guanidino) pentanoic acid 105 
 
O
N
H
N
H
OH
O
NHBoc
NBoc
 
MeI (0.45 mmol, 27 µL) was added to a solution of tert-butyl (2-
methoxyethyl)carbamothioylcarbamate 103 (84 mg, 0.35 mmol) in MeCN (3 mL) and 
EtOAc (1 mL). The reaction mixture was stirred under reflux for 7 h. The solvent was 
evaporated in vacuo and the compound was redissolved in dry THF (4 mL) under argon. 
To this mixture was added Boc-L-Orn-OH (89 mg, 0.38 mmol), triethylamine  (0.1 mL, 
0.72 mmol) and 4-dimethylaminopyridine (cat.) and stirred for 24 h. The solvent was 
evaporated in vacuo, redissolved in MeCN (5 mL) and refluxed for a further 24 h. The 
solvent was evaporated in vacuo and purification by flash chromatography eluting with 
MeOH/CHCl3 (1/99) and further freeze drying gave the title compound as an off-white 
waxy solid (25 mg, 19% yield): 1H NMR (300 MHz, CDCl3) δ 9.98 (br s, 1H), 5.67 (br 
s, 1H), 4.02-4.01 (m, 1H), 3.49-3.48 (m, 2H), 3.34-3.30 (m, 4H)  3.37 (s, 3H), 2.70 (br 
s, 1H), 1.68 (m, 4H), 1.40 (s, 9H), 1.39 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 177.6 
(s), 159.0 (s), 158.4 (s), 155.5(s), 78.9 (s), 73.8 (s), 59.2 (q), 54.5 (d), 42.5 (t), 40.9 (t), 
30.4 (t), 29.8 (t), 28.6 (2 x q), 26.0 (t); IR (neat) 3300, 3200, 2930, 1633, 1578 cm-1; 
LRMS (ES+) 433 (10%, [M+H]+), 333 (15), 277 (100); HRMS (ES+) calcd for 
C19H37O7N4 [M+H]+ 433.2664, observed 433.2662. 
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(S)-tert-Butyl 4-(N’,N’’-bis(tert-butoxycarbonyl)-3-(N’-methoxyethyl)guanidino)-2-
(tert-butoxycarbonylamino)butanoate29 115 
 
O
N
Boc
N
H
O
O
NHBocNBoc
 
 
Boc-Dab-O-tert-Bu (50 mg, 1.60 mmol), triethylamine (450 µL, 3.22 mmol) and 4-
dimethylaminopyridine (18 mg, 0.16 mmol) were added to a stirred solution of 1,3-bis-
(tert-butoxycarbonyl)-1-(2-methoxyethyl)-S-methyl-isothiourea 95 (560 mg, 1.60 
mmol) in MeCN (50 mL). The reaction mixture was stirred for 48 h and the solvent was 
removed in vacuo. Purification by column chromatography eluting with petrol/EtOAc 
(3/1) gave the title compound as a clear viscous liquid (153 mg, 83 % yield). 1H NMR 
(400 MHz, CDCl3) δ 8.10 (br s, 1H), 5.14 (br s, 1H), 4.16 (br s, 1H), 3.74 (t, J = 5.2 Hz, 
2H), 3.51 (t, J = 5.2 Hz, 2H), 3.29 (s, 3H), 3.42-3.30 (m, 2H), 2.11-2.03 (m, 1H), 1.87-
1.78 (m, 1H), 1.46 (s, 9H), 1.45 (s, 18H), 1.43 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
171.0 (2 x s), 155.3 (s), 152.5 (2 x s), 82.1 (s), 81.9 (s), 79.7 (s), 79.0 (s), 70.6 (t), 58.3 
(q), 52.4 (d), 47.3 (t), 39.9 (t), 32.4 (t), 28.2 (q), 28.1 (q), 28.1 (q), 27.9 (q); IR (thin 
film) 3316, 2977, 2933, 1713, 1618 cm-1; LRMS (ES+) 575 (100% [M+H]+), 475 (6); 
HRMS (ES+) calcd for C27H51N4O9 [M+H]+ 575.3651, observed 575.3645.  
 
 
(S)-2-Amino-4-(N’-(2-methoxyethyl)guanidino)butanoic acid hydrochloride29 113 
O
N
H
N
H
OH
O
NH2NH
 
A solution of (S)-tert-butyl-4-(N’,N’’-bis(tert-butoxycarbonyl)-3-(N’-methoxyethyl) 
guanidino)-2-(tert-butoxycarbonylamino)butanoate 115 (150 mg, 0.26 mmol) in 4 M 
HCl in dioxane (2 mL) was stirred for 2 h. The solvent was evaporated in vacuo and the 
product was extracted into water (10 mL) and freeze dried for 18 h to give the title 
compound as a white waxy solid (64 mg, 85 % yield).1H NMR (400 MHz, D2O) δ 3.97 
(t, J = 7.0 Hz, 1H), 3.45 (t, J = 5.0 Hz, 2H), 3.31 (t, J = 7.0 Hz, 2H), 3.25 (t, J = 5.0 Hz, 
2H), 3.22 (s, 3H), 2.15-2.01 (m, 2H); 13C NMR (100 MHz, D2O) δ 171.3 (s), 156.1 (s), 
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70.1 (t), 58.1 (q), 50.2 (d), 41.1 (t), 37.2 (t), 28.8 (t); IR (thin film) 3316, 2977, 2933, 
1713, 1618 cm-1; LRMS (ES+) 219 (100%, [M+H]+), 218 (12); HRMS (ES+) calcd for 
C8H19N4O3 [M+H]+ 219.1452, observed 219.1450.   
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5.2.3  Experimental for Chapter 4 
2,4,6-Trichlorophenyl vinylsulfonate82 254 
SO3TCP  
2,4,6-Trichlorophenol (15 g, 0.07 mol) and triethylamine (23 mL, 167 mmol) in CH2Cl2 
(100 mL) was added dropwise to a solution of 2-chloroethanesulfonyl chloride in 
CH2Cl2 (200 mL) at -78 °C over 1 h. The mixture was then warmed to 21 oC and stirred 
for a further 10 min. The mixture was filtered through a plug of 10% K2CO3/silica. The 
solvent was evaporated in vacuo and purification by column chromatography eluting 
with petrol/Et2O (9/1) gave the title compound as a white solid (16.3 g, 57 mmol, 74% 
yield): m.p. 53-55 °C;  1H NMR (300 MHz, CDCl3) δ 7.38 (s, 2H), 6.93 (dd, J = 9.8, 
16.6 Hz, 1H), 6.54 (dd , J = 0.6, 16.6 Hz, 1H), 6.25 (dd, J = 0.6, 9.8 Hz, 1H); 13C NMR 
(75 MHz, CDCl3) δ 141.9 (s), 133.8 (d), 133.0 (s), 131.4 (t), 130.7 (s), 129.1 (d); IR 
(neat) 3080, 1562 cm-1; LRMS (EI) 286 (17% [M]+•), 195 (100), 97 (74).  
 
 
Pentafluorophenyl vinylsulfonate82 208 
SO3PFP  
Pentafluorophenol (13.2 g, 0.07 mmol) and triethylamine (22 mL, 158 mmol) in DCM 
(50 mL) was added dropwise to a solution of 2-chloroethanesulfonyl chloride in CH2Cl2 
(200 mL) at -78 °C over 1 h. The mixture was then warmed to 21 oC and diluted with 
CH2Cl2 (100 mL) and washed with water, 2 M HCl (50 mL x2) and sat. NaHCO3 (50 
mL x2), dried over MgSO4 and the solvent removed in vacuo. Purification by column 
chromatography eluting with petrol/Et2O (6/1) gave the title compound as a clear oil 
which crystallized upon freezing (17.1 g, 62 mmol, 87% yield): m.p. 24-26 °C; 1H 
NMR (500 MHz, CDCl3) δ 6.79 (dd, J = 9.9, 16.5 Hz, 1H), 6.54 (dd, J = 1.0, 16.5 Hz, 
1H), 6.33 (dd, J = 1.0, 9.9 Hz, 1H); 13C NMR (75 MHz, CDCl3) δ 143.8 (s), 133. 1 (t), 
131.8 (d); IR (thin film) 3080, 1651, 1514 cm1; LRMS (EI) 274 (14% [M]+•), 184 (82), 
91 (100). 
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3-(tert-Butyldiphenylsilyloxy)propan-1-ol118 218 
HO O
Si
Ph
Ph
 
TBDPSCl (4.37 mL, 18.2 mmol) was added dropwise over 5 min to a stirred suspension 
of 1,3-propanediol (6.75 mL, 90.9 mmol) and NEt3 (13.9 mL, 100 mmol) in CH2Cl2 
(100 mL  at 0 °C. Stirring was continued for 24 h at 21 oC after which the reaction 
mixture was washed with 10% HCl, sat. NaHCO3 and brine. The organic layer was 
dried over MgSO4, filtered and the solvent was evaporated in vacuo to give a crude oil. 
Purification by column chromatography eluting with petrol/EtOAc (6/1) gave the 
product as a yellow oil which solidified upon freezing (3.09 g, 54% yield): 1H NMR 
(500 MHz, CDCl3) δ 7.71-7.67 (m, 4H), 7.47-7.38 (m, 6H), 3.87-3.83 (m, 2H), 3.87- 
3.83 (m, 2H), 2.41 (m, 1H), 1.85- 1.79 (m, 2H), 1.06 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 135.6 (d), 135.4 (d), 133.3 (2 x s), 129.8 (d), 129.6 (d), 127.8 (d), 127.7 (d), 
63.3 (t), 62.0 (t), 34.3 (t), 26.9 (q), 19.1 (s); IR (neat) 3340, 2930, 2857 cm-1; LRMS 
(CI) 315 (100%, [M+H]+), 237 (10), 117 (12).  
 
 
3-(tert-Butyldiphenylsilyloxy)propanal118 219 
O O
Si
 
DMSO (2.16 mL, 30.52 mmol) was added dropwise to a stirred solution of oxalyl 
chloride (0.72 mL, 7.63 mmol) at -78 °C. This was followed by dropwise addition of 3-
(tert-butyldiphenylsilyloxy)propan-1-ol 218 (2.0 g, 6.4 mmol) in CH2Cl2 (10 mL) and 
30 min stirring at -78 °C. NEt3 (4.35 mL, 32.49 mmol) was added dropwise and the 
reaction was warmed to 21 oC. The reaction mixture was further stirred for 1 h and the 
solvent was removed in vacuo. The remaining residue was triturated with 4:1 petrol: 
EtOAc (50 mL) before filtering through a small plug of silica. The filtrate was 
concentrated in vacuo and purification by column chromatography eluting with 
petrol/EtOAc (12/1) gave the title compound as a pale-yellow oil which solidified upon 
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freezing (1.98 g, 94 % yield).1H NMR (500 MHz, CDCl3) δ 9.83 (t, J = 2.2 Hz, 1H), 
7.67 (dd, J = 1.5, 7.9 Hz, 4H), 7.47- 7.37 (m, 6H), 4.03 (t, J = 6.0 Hz, 2H), 2.61 (td, J = 
2.2, 6.0 Hz, 2H), 1.04 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 201.9 (d), 135.6 (2 x d), 
133.3 (s x 2), 129.8 (d), 129.7 (d), 127.8 (2 x d), 58.3 (t), 46.4 (t), 26.8 (q), 19.2 (s); IR 
(neat) 2931, 2857, 1727 cm-1; LRMS (CI) 313 (5%, [M+H]+), 94 (100). 
 
 
Tetrahydrofuran-2-ol119 226 
       
O
OH
 
DIBAL (1.0 M solution in toluene) (39 mL, 39 mmol) was added to a stirred solution of 
γ-butyrolactone (2 mL, 26 mmol) in CH2Cl2 (30 mL) at -78 °C. The reaction mixture 
was stirred at that temperature for 5 h after which it was quenched with methanol (3.3 
mL). The mixture was warmed to 0 °C and diluted with water (5 mL). The mixture was 
stirred with MgSO4 (4.4 g) and Celite (4.4 g) for 20 min. the mixture was filtered 
through a pad of Celite, the filtered residue was washed with ether and the filtrate was 
concentrated in vacuo to give the crude product as an oil. Purification by column 
chromatography afforded the product and its aldehyde form in a 1:1 ratio, as a yellow 
oil (87 mg, 4% yield): 1H NMR (300 MHz, CDCl3) δ 9.75 (s, 1H, aldehyde), 5.31-5.28 
(m, 1H, lactol), 5.07-5.05 (m, 1H, lactol), 3.68-3.63 (m, 2H, aldehyde), 3.43-3.33 (m, 
2H, lactol), 2.50-2.45 (m, 2H, aldehyde), 1.95-1.69 (m, 6H, lactol); 13C (75 MHz, 
CDCl3) δ 202.0 (d, aldehyde), 103.8 (d, lactol), 66.9 (t, aldehyde), 66.0 (t, lactol), 41.0 
(t, lactol), 32.3 (t, aldehyde), 23.4 (t, aldehyde), 22.6 (t, lactol); IR (neat) 3415, 2952, 
2876, 1723 cm-1. 
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2-Chlorohexanal120 228 
H
O
Cl  
N-Chlorosuccinimide (7.02 g, 52.5 mmol) was added to a solution of proline (0.25 g, 
2.19 mmol) in CHCl3 (87 mL) at -30 °C. Hexanal (6.18 mL, 43.7 mmol) was then added 
and the resulting mixture was stirred at -30 °C for 21 h. The reaction mixture was 
concentrated in vacuo in an ice cold rotary evaporator. The crude product was purified 
by column chromatography eluting with petrol/Ether (99/1) which afforded the product 
as a clear oil which solidified upon freezing (3.70 g, 63% yield): m.p. 145-148 °C; 1H 
NMR (500 MHz, CDCl3) δ 9.48 (d, J = 2.5 Hz, 1H), 4.15 (ddd, J = 2.5, 5.4. 8.1Hz, 1H), 
2.05-1.95 (m, 1H), 1.89-1.82 (m, 1H), 1.59-1.33 (m, 4H), 0.92 (t,  J = 7.2 Hz, 3H); 13C 
NMR (75 MHz, CDCl3) δ 195.4 (s), 64.0 (d), 31.8 (t), 27.7 (t), 22.1 (t), 13.8 (q); IR 
(neat) 2959, 2932, 2863, 1732 cm-1; [α]D20 +7.9 c = 1.0; LRMS (CI) 135 (26%, 
[M+H]+), 99 (36), 81 (100); HRMS (CI) calcd for C6H12OCl [M+H]+ 135.0576, 
observed 135.0571. 
 
 
2-Iodohexanal121 229 
H
O
I  
NaI (2.77 g, 18.5 mmol) was added to a solution of  2-chlorohexanal 228 (2.5 g, 18.5 
mmol) in acetone (10 mL)  at 0 °C and stirred for 1 h. The solvent was evaporated in 
vacuo. The crude product was redissolved in diethyl ether (5 mL) and filtered through a 
short pad of silica. Further purification by flash chromatography eluting with 
petrol/Et2O (4/1) gave the product as a brown oil (1.49 g, 37% yield): 1H NMR (500 
MHz, CDCl3) δ 9.52 (d, J = 3.2 Hz, 1H), 4.47-4.43 (m, 1H), 2.04-1.85 (m, 2H), 1.39-
1.31 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 191.9 (s), 36.8 
(d), 31.9 (t), 31.5 (t), 22.0 (t), 13.8 (q) ; IR (neat) 2957, 2929, 2859, 1720 cm-1; LRMS 
(EI) 225 (100%, [M]+•), 115 (66%); HRMS (EI) calcd for C6H10OI [M]+•  224.9771, 
observed 224.9782. 
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Pentafluorophenyl 3-oxooctane-1-sulfonate 230 
O
SO3PFP  
Hexanal (705 µL, 5 mmol) was added to a solution of pentafluorophenyl vinylsulfonate 
208(274 mg, 1 mmol) in dioxane (1 mL) and stirred for 6 h. The solvent was evaporated 
in vacuo and purification by flash chromatography eluting with petrol/CH2Cl2 (4/1) 
gave the title compound as a white solid (388 mg, 74% yield): m.p. 53-56 °C;  1H NMR 
(300 MHz, CDCl3) δ 3.73 (t, J = 7.2, 7.7 Hz, 2H), 3.14 (t, J = 7.2, 7.7 Hz, 2H), 2.50 (t, J 
= 7.4 Hz, 2H), 1.62 (quintet, J = 7.4 Hz, 2H), 1.29-1.25 (m, 4H), 0.88 (t, J = 7.0 Hz, 
3H);  13C  NMR (75 MHz, CDCl3) δ 205.1 (s), 46.9 (t), 42.7 (t), 35.8 (t), 31.2 (t), 23.3 
(t), 22.3 (t), 13.8 (q); IR (neat) 2953, 2871, 1709, 1531, 1377 cm-1; LRMS (FAB) 397 
(100%, [M+Na]+), 375 (30), 176 (23); HRMS (FAB) calcd for C14H15F5NaO4S 
[M+Na]+ 397.0508, observed 397.0500.                     
 
 
Pentafluorophenyl 9-hydroxy-5,9-dimethyl-3-oxodecane-1-sulfonate 232 
O
SO3PFPHO  
7-Hydrocycitronellal (936 µL, 5 mmol) was added to a solution of pentafluorophenyl 
vinylsulfonate 208 (274 mg, 1 mmol) in dioxane (1 mL) and stirred for 16 h. The 
reaction mixture was washed with sodium bisulphite (5 mL x 5), dried with anhydrous 
MgSO4, filtered and the solvent evaporated in vacuo. Purification by flash 
chromatography eluting with petrol/EtOAc (4/1) gave the title compound as a pale 
yellow oil  (335 mg, 78% yield): 1H NMR (400 MHz, CDCl3) δ 3.79-3.75 (m, 2H), 
3.15-3.11 (m, 2H), 2.53 (dd, J = 16.0, 6.0 Hz, 1H), 2.35 (dd, J = 16.0, 8.0 Hz, 1H), 2.11-
2.04 (m, 1H), 1.50-1.19 (m, 13H), 0.93 (d, J = 6.5 Hz, 3H); 13C NMR (150 MHz, 
CDCl3) δ 204.9 (s), 71.0 (s), 50.1 (t), 46.9 (t), 43.8 (t), 37.2 (t), 36.5 (t), 29.4 (q), 29.3 
(q), 29.2 (d), 21.6 (t), 19.8 (q); IR (neat) 3417, 2968, 1718, 1518, 1383 cm-1; LRMS 
(FAB) 469 (85%, [M+Na]+), 176 (100); HRMS (FAB) calcd for C18H23F5NaO5S 
[M+Na]+ 469.1084, observed 469.1090.  
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Pentafluorophenyl 3-oxohexane-1-sulfonate82 205 
SO3PFP
O
 
Butaraldehyde (445 µL, 5 mmol) was added to a solution of pentafluorophenyl 
vinylsulfonate 208 (288 mg, 1 mmol) in dioxane (1 mL) and stirred for 3 h. The solvent 
was evaporated in vacuo and purification by flash chromatography eluting with 
petrol/CH2Cl2 (4/1) gave the title compound as a white solid (273 mg, 79% yield): m.p. 
53-55 °C); 1H NMR (500 MHz, CDCl3) δ 3.75 (t, J = 7.3 Hz, 2H), 3.13 (t, J = 7.3 Hz, 
2H), 2.50 (t, J = 7.3 Hz, 2H), 1.68-1.64 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H); 13C NMR (75 
MHz, CDCl3) δ 205.0 (s), 47.0 (t), 44.7 (t), 35.9 (t), 17.2 (t), 13.6 (q); IR (thin film) 
2960, 2936, 1713 cm-1; LRMS (FAB+) 369 (35% [M+Na]+), 329 (18), 176 (100). 
 
 
2-Iodo-1-isopropyl-4-methylcyclohexane91  
I
 
Imidazole (1.96 g, 28.8 mmol) and iodine (7.3 g. 28.8 mmol) were added to a 
suspension of PPh3 (7.55 g, 28.8 mmol) in CHCl3 (60 mL) at 0 °C and stirred for 30 
min. A solution of L-menthol (3.0 g, 19.0 mmol) in CH2Cl2 (40 mL) was added and 
stirring continued for a further 30 min at 0 °C. The reaction mixture was allowed to 
warm to 21 oC and stirred for a further 2 h. The reaction was quenched with water (30 
mL) and the aqueous layer was extracted with CH2Cl2 (3 x 50 mL). The combined 
organic layers were washed with sat. aqueous sodium thiosulphate (2 x 50 mL) dried 
over MgSO4, filtered and concentrated in vacuo. Purification twice by flash 
chromatography eluting with petrol/EtOAc (4/1) gave the title compound as a brown oil 
(2.91 g, 57% yield): 1H NMR (400 MHz, CDCl3) δ 4.82 – 4.74 (m, 1H), 2.22 (ddd, J = 
3.2, 5.7, 14.4 Hz, 1H), 2.07 – 1.9 (m, 1H), 1.83 – 1.71 (m, 2H), 1.43 – 1.18 (m, 4H), 
0.96 (d, J = 6.6 Hz, 3H), 0.92 (d, J = 6.6 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H), -0.15 (ddt, J 
= 2.9, 9.2, 11.8 Hz, 1H); 13C NMR (75 MHz,CDCl3) δ 49.3 (d), 46.7 (d), 45.3 (t), 34.8 
(t), 33.8 (d), 28.6 (d), 26.7 (t), 21.6 (q), 20.4 (q), 20.0 (q); IR (thin film) 2948, 2922, 
2867 cm-1; LRMS (EI) 266 (60%, [M]+•), 139 (100).  
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General procedure for decarbonylation reactions: 
Trimethylacetaldehyde (543 µL, 5 mmol) was added to a solution of alkene acceptor (1 
mmol) in 1,4-dioxane (1 mL)  at 100 °C  and stirred until complete consumption of 
alkene (TLC). The solvent was evaporated in vacuo and purification as described below 
afforded the desired sulfonate ester. 
 
 
Pentafluorophenyl 3,3-dimethylbutane-1-sulfonate 255  and pentafluorophenyl 4,4-
dimethyl-3-oxopentane-1-sulfonate82 256 
SO3PFP
O
255                          256
SO3PFP
 
Reaction was complete after 3 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave pentafluorophenyl 3,3-dimethylbutane-1-sulfonate 255 as a 
clear oil (221 mg, 67 %) and pentafluorophenyl 4,4-dimethyl-3-oxopentane-1-sulfonate 
256 as a clear oil (7 mg, 2% yield). 
Data for 255: 1H NMR (500 MHz, CDCl3) δ 3.34-3.30 (m, 2H), 1.85-1.80 (m, 2H), 
0.89 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 49.6 (t), 36.5 (t), 31.3 (s), 28.7 (q) ; IR 
(thin film) 2972, 2948 cm-1; LRMS (CI) 333 (100%, [M+H]+); HRMS (CI) calc. For 
C12H13F5O3S 333.0583 [M+H]+, observed 333.0587.    
Data for 256: 1H NMR (125 MHz, CDCl3) δ 3.74-3.71 (m, 2H), 3.23-3.20 (m, 2H), 
1.19 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 210.5 (s), 47.5 (t), 44.2 (s), 30.7 (t), 26.3 
(q); IR (thin film) 2967, 1707, 1561 cm-1; LRMS (CI) 361 (100% [M+H]+), 177 (41), 
113 (42). 
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2,4,6-Trichlorophenyl 3,3-dimethylbutane-1-sulfonate82 207 
SO3TCP  
Reaction was complete after 6 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a white solid (220 mg, 64%): 1H NMR 
(300 MHz, CDCl3) δ 7.40 (s, 2H), 3.55-3.51 (m, 2H), 2.09-2.01 (m, 2H), 1.99 (s, 9H); 
13C NMR (75 MHz,CDCl3) δ 142.0 (s), 133.9 (s), 130.6 (s), 129.1 (d), 51.2 (t), 36.6 (t), 
30.3 (s), 28.9 (q); IR (thin film) 3079, 2957, 2866, 1718, 1557 cm-1; LRMS (CI) 347 
(100%, [M+H]+), 197 (20).   
 
 
Phenyl 3,3-dimethylbutane-1-sulfonate122 259 
SO3Ph  
Reaction was complete after 2 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a cloudy oil (186 mg, 76%): 1H NMR 
(600 MHz, CDCl3) δ 7.44-7.41 (m, 2H), 7.33 (t, J = 7.4 Hz, 1H), 7.30-7.27 (m, 2H), 
3.25 – 3.22 (m, 2H), 1.91-1.88 (m, 2H), 0.97 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 
149.2 (s), 130.0 (d), 127.2 (d), 122.1 (d), 47.2 (t), 36.6 (t), 30.2 (s), 28.9 (q); IR (thin 
film) 2957, 2870 cm-1; LRMS (EI) 242 (42% [M]+•), 94 (100); HRMS (EI) calcd for 
C12H18O3S [M]+• 242.0971, observed 242.0976. 
 
 
Ethyl 3,3-dimethylbutane-1-sulfonate122 260 
S
O
OO  
 
Reaction was complete after 6 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a pale yellow oil (104 mg, 54%): 1H 
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NMR (500 MHz, CDCl3) δ 4.28 (q, J = 7.1 Hz, 2H), 3.08 – 3.02 (m, 2H), 1.76 – 1.70 
(m, 2H), 1.40 (t, J = 7.1 Hz, 3H), 0.93 (s, 9H); 13C NMR (125 MHz,CDCl3) δ 65.8 (t), 
47.1 (t), 36.5 (t), 30.0 (s), 28.8 (q), 15.1 (q); IR (thin film) 2956, 2871 cm-1; LRMS (CI) 
212 (100%, [M+NH4]+). 
 
 
1-(Ethylsulfonyl)-3,3-dimethylbutane122 261 
S
OO  
Reaction was complete after 40 min. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a clear oil (94 mg, 53%): 1H NMR (400 
MHz, CDCl3) δ 2.99 (q, J = 7.5 Hz, 2H), 2.95-2.89 (m, 2H), 1.75-1.68 (m, 2H), 1.40 (t, 
J = 7.5 Hz, 3H), 0.95 (s, 9H); 13C NMR (125 MHz,CDCl3) δ 48.5 (t), 47.0 (t), 35.1 (t), 
30.1 (s), 29.0 (q), 6.7 (q); IR (thin film) 2955, 2869 cm-1; LRMS (CI) 179 (100%, 
[M+H]+), 111 (8).  
 
 
Dimethyl 2-tert-butylsuccinate 164 
O
O
O
O  
Reaction was complete after 6 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a pale yellow oil (126 mg, 63%): 1H 
NMR (400 MHz, CDCl3) δ 3.70 (s, 3H), 3.67 (s, 3H), 2.80 (dd, J = 11.8, 16.5 Hz, 1H), 
2.65 (dd, J = 11.8 Hz, 3.0, 1H), 2.49 (dd, J = 3.0, 16.5 Hz, 1H), 0.97 (s, 9H); 13C NMR 
(125 MHz,CDCl3) δ 174.7 (s), 173.2 (s), 51.8  (q), 51.4 (d), 51.1 (q), 32.6 (t), 32.6 (s), 
27.9 (q); IR (thin film) 2954, 1731 cm-1; LRMS (ES+) 203 (100%, [M+H]+), 171 (64), 
143 (4); HRMS (ES+) calcd for C10H19O4 [M+H]+ 203.1283, observed 203.1283.    
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Diethyl 2-tert-butylsuccinate123,124 262 
O
O
O
O  
Reaction was complete after 7 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a clear oil (126 mg, 55%): 1H NMR 
(400 MHz, CDCl3) δ 4.22-4.07 (m, 4H), 2.77 (dd, J = 11.8, 16.4 Hz, 1H), 2.61 (dd, J = 
3.0, 11.8 Hz, 1H), 2.45 (dd, J = 3.0, 16.4 Hz, 1H), 1.29-1.21 (m, 6H), 0.96 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ174.1 (s), 172.7 (s), 60.5 (t), 60.2 (t), 51.3 (d), 32.9 (t), 32.6 
(s), 27.8 (q), 14.3 (q), 14.1 (q); IR (thin film) 2965, 1727 cm-1; LRMS (FAB) 253 (25%, 
[M+Na]+), 185 (100), 176 (30); HRMS (FAB) calcd for C12H22O4Na [M+Na]+ 
253.1415, observed 253.1409.    
 
 
Dimethyl 2-(3,3-dimethylbutan-2-yl)malonate 263 
O
O
O
O
 
Reaction was complete after 96 h at 100 °C and then 24 h at 120 °C. Purification by 
flash chromatography eluting with petrol/CH2Cl2 (6/1) gave the title compound as a 
pale yellow oil (21 mg, 10%): 1H NMR (300 MHz, CDCl3) δ 3.72 (s, 3H), 3.70 (s, 3H), 
3.56 (d, J = 5.4, 1H), 2.31-2.17 (m, 1H), 0.99 (d, J = 7.2, 3H), 0.88 (s, 9H); 13C NMR 
(150 MHz, CDCl3) δ 170.6 (s), 169.9 (s), 53.0 (q), 52.5 (d), 52.0 (q), 42.8 (q), 33.5 (s), 
27.5 (q), 14.0 (d); IR (neat) 2955, 1740, 1750 cm-1;  LRMS (ES+) 234 (62% 
[M+NH4]+), 217 (100, [M+H]+), 185 (8); HRMS (ES+) calc. For C11H21O4 217.1434 
[M+H]+, observed 217.1430.    
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Dimethyl 3,3-dimethylbutylphosphonate 264 
P
O
O
O  
Reaction was complete after 4 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave the title compound as a pale yellow oil (96 mg, 50%): 1H 
NMR (500 MHz, CDCl3) δ 3.71 (s, 3H), 3.69 (s, 3H), 1.70-1.63 (m, 2H), 1.46-1.42 (m, 
2H), 0.85 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 52.3 (dq, JC-P = 25 Hz), 35.7 (dt, JC-P 
= 21 Hz), 30.3 (ds, JC-P = 70 Hz), 28.7 (s), 20.1 (dt, JC-P = 561 Hz); IR (neat) 2954, 2867 
cm-1;  LRMS (CI) 195 (100%, [M+H]+), 179 (23), 138 (19); HRMS (CI) calcd for 
C8H20O3P [M+H]+ 195.1150, observed 195.1156. 
 
 
Pentafluorophenyl 4-ethyl-3-oxooctane-1-sulfonate82 (270-A) and 
Pentafluorophenyl 3-ethylheptane-1-sulfonate (270-B) 
SO3PFP
SO3PFP
O
270-A                                            270-B  
Reaction was stopped after 3 h. Purification by flash chromatography eluting with 
petrol/CH2Cl2 (6/1) gave pentafluorophenyl 4-ethyl-3-oxooctane-1-sulfonate 270-A as a 
colourless oil (96 mg, 50% yield) and pentafluorophenyl 3-ethylheptane-1-sulfonate 
270-B as a colourless oil (45 mg, 12% yield). 
Data for 270-A: 1H NMR (600 MHz, CDCl3) δ 3.77-3.74 (m, 2H), 3.16-3.14 (m, 2H), 
2.51-2.47 (m, 1H), 1.71-1.60 (m, 2H), 1.59-1.44 (m, 2H), 1.37-1.27 (m, 2H), 1.26-1.17 
(m, 2H), 0.90 (t, J = 7.3 Hz, 3H), 0.89 (t, J = 7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) 
δ 208.9 (s), 53.9 (d), 46.9 (t), 35.5 (t), 30.9 (t), 29.9 (t), 24.6 (t), 22.7 (t), 13.9 (q), 11.7 
(q); IR (neat) 2961, 2876, 1708, 1519, 1387 cm-1; LRMS (CI) 403 (15%, [M+H]+), 145 
(10), 127 (100); HRMS (CI) calc. For C16H20F5O4S  403.1002 [M+H]+, found 403.1012. 
Data for 270-B: 1H NMR (500 MHz, CDCl3) δ 3.45-3.38 (m, 2H), 2.04-1.96 (m, 2H), 
1.46 (m, 1H), 1.42 – 1.23 (m, 8H), 0.93 – 0.88 (m, 6H); 13C NMR (125 MHz, CDCl3) δ 
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50.9 (t), 37.9 (d), 32.3 (t), 28.6 (t), 26.6 (t), 25.4 (t), 22.9 (t), 14.0 (q), 10.6 (q); IR (thin 
film) 2962, 2876 cm-1; LRMS (CI) 375 (34% [M+H]+), 297 (100), 142 (86); HRMS 
(CI) calcd for C15H20 F5O3S [M+H]+ 375.1053, observed 375.1053. 
 
 
1-(Hexylthio)hexan-3-one83 243 
O
S  
Hexanethiol (52 µL, 0.37 mmol) was added to a solution of pentafluorophenyl 3-
oxohexane-1-sulfonate 205 (100 mg, 0.28 mmol) and DBU (86 µL, 0.57 mmol) in 
CH2Cl2 (1 mL) and stirred for 45 min. The solvent was evaporated in vacuo and 
purification by flash chromatography eluting with petrol/CH2Cl2 (3/1) gave the title 
compound as a yellow oil (62 mg, quantitative yield): 1H NMR (400 MHz, CDCl3) δ 
2.75-2.67 (m, 4H), 2.52 (t, J = 6.0 Hz , 2H), 2.42 (t, J = 6.0 Hz, 2H), 1.67-1.54 (m, 4H), 
1.41-1.23 (m, 6H), 0.94-0.86 (6H); 13C NMR (125 MHz, CDCl3) δ 209.8 (s), 45.0 (t), 
42.8 (t), 32.5 (t), 31.4 (t), 29.6 (t), 28.6 (t), 25.9 (t), 22.6 (t), 17.2 (t), 14.0 (q), 13.7 (q); 
IR (neat) 2958, 2927, 2857, 1713 cm-1; LRMS (ES+)  217 (100%, [M+H]+); HRMS 
(ES+) calcd for C12H25OS [M+H]+  217.1621, observed 217.1622. 
 
 
1-Morpholinohexan-3-one127 246 
O
N
O  
Pentafluorophenyl 3-oxohexane-1-sulfonate 205 (200 mg, 0.55 mmol) and DBU (173 
µL, 1.09 mmol) in CH2Cl2 (1 mL) were stirred at for 20 mins, to which was added 
morpholine (56 µL, 0.63 mmol) and stirred for 3 h. The solvent was evaporated in 
vacuo and purification three times by flash chromatography eluting with petrol/EtOAc 
(2/1) gave the title compound as a yellow oil (81 mg, 80% yield): 1H NMR (600 MHz, 
CDCl3) δ 3.72 (t, J = 4.3 Hz, 4H), 2.70-2.62 (m, 4H), 2.47 (br s, 4H), 2.42 (t, J = 7.4 Hz, 
2H), 1.62 (sextet J = 7.4 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H): 13C NMR (150 MHz, CDCl3) 
δ 209.8 (s), 66.7 (t), 53.5 (t), 53.0 (t), 45.0 (t), 39.9 (t), 17.1 (t), 13.7 (q); IR (neat) 2959, 
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2854, 2808, 1709 cm-1; LRMS (CI) 186 (100% [M+H]+), 88 (43); HRMS (CI) calcd for 
C10H20NO2 [M+H]+ 186.1489, observed 186.1492. 
 
 
Diethyl 3-oxohexylphosphonate125 239 
O
P
O
O
O
 
Triethylphosphite (99 µL, 0.57 mmol) was added to a solution of pentafluorophenyl 3-
oxohexane-1-sulfonate 205 (100 mg, 0.28 mmol) and DBU (86 µL, 0.57 mmol) in 
EtOH (1 mL) in a microwave tube. The tube was sealed and heated at 100 °C (MW) for 
1 h. The reaction was washed with NaHCO3 (2 x 5 mL), water (5 mL). The organic 
layers were collected and dried with MgSO4, filetered, and concentrated in vacuo. 
Purification by flash chromatography eluting with CH2Cl2/MeOH (30/1) gave the title 
compound as a yellow oil (123 mg, 90% yield): 1H NMR (600 MHz, CDCl3) 4.15-4.05 
(m, 4H), 2.74 – 2.69 (m, 2H), 2.42 (t, J = 7.4 Hz, 2H), 2.05 – 1.99 (m, 2H), 1.63 (sextet, 
J = 7.4 Hz, 2H), 1.34 (t, 6H), 0.92 (t, J = 7.4 Hz, 3H ); 13C NMR (150 MHz, CDCl3) δ 
208.3 (d, JC-P = 15 Hz), 61.7 (dt, JC-P = 6 Hz), 44.5 (t), 35.4 (dt, JC-P = 4.5 Hz), 19.3 (dt, 
JC-P = 144 Hz), 17.3 (t), 16.4 (dq, JC-P = 6 Hz), 13.7 (q); IR (neat) 2963, 2933, 1716 cm-
1; LRMS (ES+) 237 (100%, [M+H]+); HRMS (ES+) calcd for C10H22O4P [M+H]+ 
237.1250, observed 237.1250. 
 
 
Dimethyl 2-(3-oxohexyl)malonate126 244 
O
O
O
OO  
NaBH4 (0.5 g, 13.21 mmol) was refluxed in MeOH (25 mL) for 40 min. The solvent 
was evaporated in vacuo to give NaB(OMe)4 as a white solid (1.28 g, 8.1 mmol). 
NaB(OMe)4 (5 mg,  0.03 mmol) and dimethyl malonate (66 µL, 0.57 mmol) was added 
to a solution of pentafluorophenyl 3-oxohexane-1-sulfonate 205 and DBU (173 µL, 1.14 
mmol) in acetonitrile (1.5 mL) under argon and stirred for 48 h. Purification by flash 
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chromatography eluting with petrol/EtOAc (9/1) gave the product as a clear oil (81 mg, 
63% yield): 1H NMR (400 MHz, CDCl3) δ 3.74 (s, 6H), 3.44 (t, J = 8.0 Hz, 1H), 2.50 (t, 
J = 8.0 Hz, 2H), 2.37 (t, J = 7.8 Hz, 2H), 2.16 (q, J = 7.8 Hz, 2H), 1.59 (sextet, J = 7.8 
Hz, 2H), 0.90 (t, J = 7.8 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 209.0 (s), 169.6 (s), 
52.6 (q), 50.4 (d), 44.8 (t), 39.4 (t), 22.5 (t), 17.3 (t), 13.7 (q); IR (neat) 2957, 1720, 
1712 cm-1; LRMS (ES+) 248 (48% [M+NH4]+), 231 (100, [M+H]+), 199 (35); HRMS 
(ES+) calcd for C11H19O5 [M+H]+ 231.1227, observed 231.1225. 
 
 
Diethyl 2-(3-oxohexyl)malonate 245 
O
O
O
OO  
Dimethyl malonate (132 µL, 1.15 mmol) was added to a solution of pentafluorophenyl 
3-oxohexane-1-sulfonate 205 (200 mg, 0.77 mmol) and NaOEt (869 µL, 1.84 mmol) in 
ethanol (4 mL) and stirred at for 48 h. The solvent was evaporated in vacuo and 
purification by flash chromatography eluting with petrol/Et2O (6/1) gave the title 
compound as a clear oil (22 mg, 11% yield): 1H NMR (600 MHz, CDCl3) δ 4.26 – 4.16 
(m, 4H), 3.40 (t, J = 7.3 Hz, 1H), 2.52 (t, J = 3.6 Hz, 2H), 2.38 (t, J = 7.3 Hz, 2H), 2.17 
(q, J = 7.3 Hz, 2H), 1.58 (sextet, J = 7.3 Hz, 2H), 1.28 ( t, J = 7.1 Hz, 6H), 0.92 (t, J = 
7.4 Hz, 3H); 13C NMR (150 MHz, CDCl3) δ 209.7 (s), 169.2 (s), 61.4 (t), 50.7 (d), 44.7 
(t), 39.5 (t), 22.4 (t), 17.2 (t), 14.0 (q), 13.7 (q); IR (neat) 2964, 2937, 1750, 1745 cm-1; 
LRMS (EI) 258 (8% [M]+•), 169 (100); HRMS (EI) calcd for C13H22O5 [M]+• 258.1462, 
observed 258.1472. 
 
 
1-(Phenylamino)hexan-3-one127 247 
O
N
H  
DBU (173 µL, 1.14 mmol) was added to a solution of pentafluorophenyl 3-oxohexane-
1-sulfonate 205 (200 mg, 0.57 mmol) in CH2Cl2 (3 mL) and stirred for 20 min. Aniline 
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(53 µL, 0.57 mmol) was added to the reaction mixture and stirred for 24 h. The solvent 
was evaporated in vacuo and purification twice by flash chromatography eluting with 
petrol/EtOAc (19/1) gave the title compound as a white solid (41 mg, 38% yield): m.p. 
60-61 °C; 1H NMR (600 MHz, CDCl3) 7.22 – 7.18 (m, 2H), 6.76 (tt, J = 7.3 Hz, 1.0, 
1H), 6.67 – 6.65 (m, 2H), 3.44 (t, J = 6.2 Hz, 2H), 2.74 (t, J = 6.2 Hz, 2H), 2.41 (t, J = 
7.4 Hz, 2H), 1.61 (sextet, J = 7.3, 2H), 0.92 (t, J = 7.4 Hz, 3 H); 13C NMR (150 MHz, 
CDCl3) δ 210.4 (s), 147.2 (s), 129.3 (d), 118.1 (d), 113.4 (d), 45.1 (t), 41.4 (t), 38.8 (t), 
17.1 (t), 13.7 (q); IR (neat) 3391, 2957, 2871, 1700, 1605 cm-1; LRMS (EI) 191 (43%, 
[M]+•), 106 (100% ); HRMS (EI) calcd for C12H17ON [M]+• 191.1304, observed 
191.1301. 
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